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ABSTRACT 
 
 
The widespread use of Prostate Specific Antigen (PSA) testing has resulted in the over 
detection and over treatment of potentially indolent disease due to the lack of specificity of 
PSA for prostate cancer (PCa). PROTEOMEX, a method of tumour associated antigen 
(TAA) identification, combines the separation of tumour proteins by conventional 
proteomic methods (2-DE and mass spectrometry) with serological screening using serum 
antibodies, to identify immunogenic proteins in cancer. This project aims to identify TAAs 
and/or biomarkers for PCa which on subsequent validation, can be utilised as an improved 
diagnostic screening test. 
In pilot studies, SDS PAGE, 2-DE and OFFGEL electrophoresis were performed to 
identify immunogenic urine TAAs using PCa and healthy control sera. Proteins within the 
serum-reactive spots were either identified by Liquid Chromatography coupled to Matrix-
Assisted Laser Desorption/Ionisation Time-of-Flight mass spectrometry (MALDI-TOF MS) 
or Electrospray Ionisation mass spectrometry (ESI MS). Among the urinary proteins 
separated by SDS PAGE, 2-DE and OFFGEL respectively, exclusive autoreactivity was 
identified in PCa sera to serum albumin and existing PCa biomarkers - human prostatic 
acid phosphatase & zinc-alpha-2 glycoprotein. Differential autoantibody responses were 
also identified to various TAAs in the PC-3 and DU-145 PCa cell lines using PCa and 
healthy sera. The presence of a differential TAA and autoantibody PCa serum response to 
one of the proteins identified by MALDI-TOF, alpha enolase, was further verified in a 
subset of PCa samples using immunohistochemistry, Western blotting and ELISA. 
In a larger sample cohort, the cytoplasmic and nuclear alpha enolase expression in a PCa 
TMA was assessed, where statistical significance was observed between benign controls 
and PCa (p=0.000003 and p=0.003 respectively), although protein expression did not 
correlate with any important clinico-pathological variables. Alpha enolase autoantibody 
expression was statistically significant between PCa and healthy controls (p=0.0038), 
where its expression correlated with D’Amico risk classification, indicating that alpha 
enolase may serve as a potential indicator of biochemical recurrence in PCa. 
PROTEOMEX represents a valuable approach for the identification of tumour biomarkers 
which may have diagnostic and/or prognostic value in PCa. Further work should identifiy 
more TAAs and autoantibodies associated with PCa, alongside a validation of the 
diagnostic utility of the identified biomarkers from this study. 
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1. CHAPTER 1: INTRODUCTION 
 
1.1   Cancer 
1.1.1  Epidemiology 
 
Despite advances in medical research, cancer remains a significant cause of morbidity and 
mortality worldwide. According to the World Health Organisation (WHO), cancer is one 
of the global leading causes of death, accounting for over 8.2 million cancer-related deaths 
and 14 million cases in 2012 alone (WHO, 2015). The WHO expects that annual cancer 
incidences will rise from 14 million in 2012 to 22 million in the next few years. In addition, 
WHO statistics from 2012 show that the most causes of cancer related deaths are from lung 
(1.59 million deaths), liver (745,000 deaths), stomach (723,000 deaths), colorectal 
(694,000 deaths), breast (521,000 deaths), oesophageal (400,000 deaths) and prostate 
cancers (307,000 deaths) (WHO, 2015). 
 
In the UK, cancer is diagnosed every two minutes, where more than 331,000 new cancer 
cases were diagnosed in 2011 alone (Cancer Research UK, 2015a). In 2011, research 
gathered by Cancer Research UK suggests that more than half (54%) of all new cancer 
cases were diagnosed in breast, lung, prostate or bowel cancer; where more than a third 
(36%) of cancers are diagnosed in people aged 75 or over (Cancer Research UK, 2015a) 
(figure 1.1). Cancer Research UK also proposes that 42% of all cancers are preventable, 
while 50% of patients survive cancer for more than 10 years (Cancer Research UK, 2015a). 
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Figure 1.1:  UK cancer incidences by age and gender. 
The incidence rates for most cancers increases with age, where 36% of all cancers in the 
UK are diagnosed in patients aged 75 and above. More cancer cases are diagnosed in men 
(approximately 60,828) than women (57,221). Incidence rates shown occurred between 
2009 and 2011. Source: Cancer Research UK (Cancer Research UK, 2015a). 
1.1.2  The nature of cancer 
 
‘Cancer’ is a broad term given to a group of diseases that involves dynamic changes in the 
genome, resulting in conferring a survival advantage to cells. This eventually leads to 
uncontrolled cell replication and eventually to invasion and tissue metastasis in somatic or 
germinal cells (Pelengaris and Khan, 2009). In a normal multicellular organism, tissue 
mass is tightly regulated by a network of overlapping molecular mechanisms that govern 
the rate of cell proliferation and cell death (by apoptosis) (Bertram, 2000) (figure 1.2). 
Thus, any factor that can alter the balance between cell birth and death, if not controlled 
has the ability to cause disease in a particular organism. 
  CHAPTER 1: Introduction 
3 
 
 
Figure 1.2:  Regulation of tissue mass in multicellular organisms. 
Tissue mass is tightly regulated by the balance of cellular processes which cause cell 
replication and cell death. Any disturbances to these processes results in diseases. When 
cell loss exceeds cell renewal, the result is involution or degeneration, while the opposite 
effect results in hyperplasia, tissue expansion or neoplasia. Adapted from Pelengaris and 
Khan (2009). 
 
 
 Cancer cells must evolve to prevent any limitation on their proliferation potential, in order 
to multiply and allow tumour development (Weinberg, 2014) (figure 1.3). Most cancers 
evolve from a single somatic cell where the initiation and progression of tumourigenesis is 
dependent on the genetic changes that occur to the cell (Pelengaris and Khan (2009) and 
Weinberg (2014). Advanced tumours are monoclonal growths, descending from a single 
normal progenitor that can migrate from their anatomical site of origin to distant sites 
(metastasis), establishing new colonies, where it becomes life threatening (Bertram, 2000).  
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Figure 1.3:  Causes of cancer. 
Cells accumulate mutations which cause the progression from a pre-neoplastic stage, 
where it acquires features required for survival (listed in the ‘progression’ heading). At 
each stage, cancer cells must overcome the features that govern the rate of cell 
proliferation which aim to eliminate mutated cells from the host (listed in the ‘inhibition’ 
heading). Adapted from Bertram (2000). 
 
1.1.3  Carcinogenesis and carcinogens 
 
Carcinogenesis is a multistep process that arises when cells become irresponsive to 
stringent growth control signals; thereby proliferating excessively due to alterations in the 
genes controlling cell proliferation, survival and other traits consistent with the malignant 
phenotype (Bertram, 2000). Most of the mutations (substitutions, frame-shift mutations or 
mutations to stop codons etc.) that give rise to cancer occur spontaneously due to chemical 
damage to DNA, altering the function of crucial genes. Repeated exposure to either 
chemical or physical exogenous agents (such as infection by viruses, radiation and tobacco) 
are generally carcinogenic as they can act as mutagens, responsible for some human 
cancers (Hesketh, 2013).  
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For example, a prolonged infection of the retrovirus, human T cell leukaemia virus type 1 
(HTLV-1), gives a 3-4% risk of developing adult T-cell leukaemia (Uchiyama et al., 1977 
and Poiesz et al., 1980). Studies have shown that HTLV-1 encodes a viral tax gene whose 
products activate the transcription of the growth factors interleukin 2 (IL-2) and 
granulocyte macrophage colony stimulating factor (GM-CSF), inducing proliferation of 
haematopoietic cells, increasing the frequency of neoplastic cell variants (Weinberg, 2014). 
More recently, studies have found that an increased mRNA expression of endogenous 
viruses especially the provirus HERV-K (HML-2) is associated with prostate cancer 
(Wallace et al., 2014). 
 
In addition, UV light is a well-known cause for skin cancers where UVB (with a 
wavelength of 280-320 nm), is well known to form pyrimidine dimers in DNA. Epigenetic 
aberrations (e.g. histone modification, nucleosome remodelling, DNA methylation, 
chromatin remodelling and RNA interference) may also occur, induced by hormones such 
as oestradiol (which is important in the initiation and progression of breast cancer); leading 
to the alteration in chromatin condensation, regulating gene activation and promoting 
malignant behaviour (Pelengaris and Khan, 2009 and Weinberg, 2014). The initiated cell is 
now able to form a tumour although initiation alone is not sufficient enough for tumour 
formation (Hesketh, 2013). 
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1.1.4  Oncogenes and tumour suppressor genes 
 
It is well known that mutations occurring in genes responsible for cell proliferation or 
apoptosis - oncogenes, tumour-suppressor genes and DNA repair enzymes are implicated 
in the tumourigenic process. Such mutations provide cancerous cells the ability to evade 
normal homeostatic mechanisms, further driving carcinogenesis (Bertram, 2000).  
 
Mutations in oncogenes contribute to the malignant process because they acquire a gain of 
function mutation which provides a dominant effect on cell growth due to an enhanced cell 
replication and avoidance of cell death (Hesketh, 2013 and Weinberg, 2014). Genes which 
promote autonomous growth in cancer cells are termed oncogenes while their non-mutated 
counterparts are called proto-oncogenes. Proto-oncogenes function as growth factors or 
receptors, cell cycle components, signal transducers or transcription factors while their 
mutated equivalents also carry out the same function with an additional trait allowing them 
self-sufficiency in growth (Hesketh, 2013). For example, the normal form of the epidermal 
growth factor gene (ERBB1) is overexpressed in 50% of glioblastomas, 80% of squamous 
cell carcinomas and 80-100% of head and neck tumours, contributing to the malignant 
phenotype in the proliferating cell population (Kumar et al., 2007).  
 
While oncogenes drive cell proliferation, tumour suppressor genes control proliferation, 
differentiation or cell death by acting as cell cycle inhibitors, transcription factors, cell 
surface receptors, signal transduction molecules, transcription factors and regulators of cell 
response to DNA damage. One main tumour suppressor gene, p53, the ‘molecular 
policeman’ of the cell, prevents the transformation to neoplasm by triggering apoptosis or 
inducing a permanent or temporary cell cycle arrest (Bertram, 2000 and Hesketh, 2013). 
Homozygous loss to p53 is evident in nearly every cancer – lung, colon and breast, the 
three leading causes of cancer mortality worldwide. Homozygous loss of p53 has been 
identified in prostate cancer (PCa) and has been demonstrated to facilitate the invasion and 
metastasis of PCa cells (Wang et al., 2013). In addition, Ecke et al (2010) has shown that 
p53 mutations in exon 7 and exon 8 are factors of tumour progression, where p53 
mutations were detected in 35.6% of patients with PCa. Tumour suppressor genes have 
also been shown to be hypermethylated in various tumours (e.g. MGMT in colorectal 
cancer and DAPK in bladder cancer), allowing uncontrolled cell division of the malignant 
population (Kumar et al., 2007). 
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1.1.5  The hallmarks of cancer 
 
In 2000, Hanahan and Weinberg outlined six main essential alterations present in cell 
physiology which combine to drive malignant transformation (figure 1.4). These 
‘hallmarks’ are features that enable tumours grow and metastasise and are shared in 
common by most tumours (Hanahan and Weinberg, 2000). Each of these changes are 
acquired during tumour development and signify successful breaching of an anti-cancer 
defence mechanism by the tumour. Hanahan and Weinberg (2000) suggest that most 
cancers have acquired the same set of features during their development, even if via 
various strategies. The 6 hallmarks of cancer (figure 1.4) are described below. 
 
1.  Self-sufficiency in growth signals  
 
Normal cells are dependent on mitogenic growth signals before they can move from a 
quiescent state to an active proliferative state. Diffusible growth factors, extracellular 
matrix components and cell-to-cell adhesion/interaction molecules bind to transmembrane 
receptors and transmit growth signals to healthy cells. Normal cells cannot proliferate in 
absence of these growth signals (Hanahan and Weinberg, 2000). However, oncogenes in 
cancer produce and respond to their own growth, reducing their dependence on growth 
factor stimulation from their normal tissue microenvironment. For example glioblastomas 
and sarcomas produce PGDF (platelet derived growth factor) and TGF α (tumour growth 
factor α) respectively to which they become responsive, creating autocrine stimulation 
(Fedi et al., 1997). 
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Figure 1.4:  The original hallmarks of cancer. 
Hanahan and Weinberg (2000) outline 6 main hallmarks that are acquired by cancer cells. 
They propose that most cancers acquire these functional characteristics during neoplastic 
development, although via various mechanisms. Adapted from Hanahan and Weinberg 
(2000). 
 
2.  Insensitivity to growth inhibitory (antigrowth) signals 
 
To maintain tissue homeostasis, two distinct mechanisms occur to prevent proliferation in 
normal cells. Antigrowth signals may force healthy cells into the quiescent (G0) state from 
an active state or force cells to permanently abandon their proliferative state, entering into 
a postmitotic state (Weinberg, 2014). Hanahan and Weinberg (2000) outline that emerging 
tumour cells must evade anti-proliferative signals in order to drive malignant growth. 
Inactivation of tumour suppressor genes that limit cell growth and proliferation have been 
reported in many human and animal cancers. The retinoblastoma protein (pRb) governed 
by TGFβ and central to the decision-making of anti-proliferative signals is disrupted in 
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various cancers (Fynan and Reiss, 1993) liberating E2F transcription factors, driving cell 
proliferation, thereby rendering cells insensitive to antigrowth signals.  
 
3.  Evasion of programmed cell death (apoptosis) 
 
Tissue growth in normal tissues is maintained by balancing the rate of cell proliferation 
and cell death. Programmed cell death (apoptosis) is triggered in response to a variety of 
physiological signals which trigger regulatory proteins to disrupt the cell membrane, break 
down the cytoplasmic and nuclear skeletons, extrude the cytosol, degrade the 
chromosomes and fragment the nucleus. Mounting evidence indicates that most, if not all 
tumour cells develop an ability to evade apoptosis by down regulating proapoptotic factors, 
(Bax, Bim, Puma), increasing the expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or 
that of survival signals (Igf1/2) (Hanahan and Weinberg, 2000). 
 
4.  Limitless replicative potential  
 
Normal cells have a finite replicative potential and once they have reached a certain 
number of doublings, they lose their ability to divide and stop growing – senescence 
(Hanahan and Weinberg, 2000). An increasing body of evidence has shown that human 
tumours can prevent senescence by inactivating their tumour suppressor proteins (p53 and 
pRb) enabling their uncontrolled cell division and infinite expansion which results in 
tumour formation (Weinberg, 2014).  In addition, most tumour cell types propagated in 
culture, are immortalised, demonstrating that a limitless, replicating potential is essential 
for their malignant growth. Furthermore, a progressive shortening of telomeres by a 50-100 
bp loss of telomeric DNA after each cell cycle is characteristic of normal cells (Counter et 
al., 1992 and Shay and Bacchetti, 1997). Tumour cells preserve their immortality by 
maintaining their telomeres at a length above a certain threshold, permitting unlimited cell 
multiplication. 
 
5.  Sustained angiogenesis 
 
The formation of new blood vessels from pre-existing vessels, (angiogenesis) is an 
essential process in normal cells, as oxygen and nutrients supplied by the vasculature are 
crucial for cell function and survival. After tissue formation, the process of angiogenesis is 
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tightly regulated (Hanahan and Weinberg, 2000). However, tumours activate the 
angiogenic switch by increasing the gene transcription of angiogenic inducers such as 
vascular endothelial growth factors (VEGF) and/or fibroblast growth factors (FGFs) (Fedi 
et al., 1997; Veikkola and Alitalo 1999) or downregulating the expression of endogenous 
angiogenic inhibitors such as thrombospondin-1 or β-interferon (Singh et al., 1995; 
Volpert et al., 1997). 
 
6.  Tissue invasion and metastasis  
 
The capability for tissue invasion and metastasis occurs providing that transformed cells 
possess all the previously aforementioned characteristics. Tissue invasion and metastasis 
after tumour development occurs where cancer cells escape the primary tumour and 
colonise a new area where nutrients and space are abundant in supply, enabling them to 
form new colonies (Hanahan and Weinberg, 2000). This distant settlement is responsible 
for mortality in over 90% of cancer cases (Sporn, 1996). Downregulation and occasional 
mutation of E-cadherin, an important cell-to-cell adhesion molecule, which helps to 
assemble adjacent epithelial cells is another feature of human carcinomas (Christofori and 
Semb, 1999). Furthermore, in some invasive tumours, an upregulation of N-cadherin, an 
adhesion molecule associated with cell migration is observed while genes encoding cell-to-
extracellular matrix adhesion molecules are demonstrably downregulated or mutated in 
highly aggressive carcinomas. 
 
In 2011, Hanahan and Weinberg revisited the original hallmarks and added four new 
concepts which emerged as important for tumour development (Hanahan and Weinberg, 
2011). The new hallmarks are described below: 
 
7.   Genomic instability and mutation 
 
Certain mutant genotypes confer a selective advantage on subclones of cells allowing their 
outgrowth and dominance in a tissue microenvironment. Multistep tumour progression is 
believed be a succession of clonal expansions, each triggered by the acquisition of a 
mutant genotype (Hanahan and Weinberg, 2011). Genome maintenance systems detect and 
resolve any defects in the DNA to ensure that the rate of spontaneous mutations are kept 
low throughout each cell generation. In order to form tumours, cancer cells increase the 
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rates of mutation by increasing the sensitivity to mutagenic agents and/or the breaking 
down one or more of the components of the genomic maintenance machinery (Negrini et al. 
2010, and Salk et al. 2010). Furthermore, Jackson and Bartek (2009), Kastan (2008) and 
Sigal and Rotter (2000) have also reported that surveillance systems that normally monitor 
genomic integrity and force cells into apoptosis or senescence (e.g. p53) have been 
compromised in various cancers. 
 
8.   Tumour promoting inflammation 
 
Most tumours contain cells of the immune system that are present in various amounts from 
subtle infiltrations to gross inflammations (Pages et al., 2010). Inflammation may 
contribute to many of the hallmarks of cancer by supplying growth factors that sustain 
proliferative signals, proangiogenic factors, extracellular matrix-modifying enzymes to 
promote angiogenesis, invasion and metastasis, and survival factors that limit cell death 
(DeNardo et al., 2010, Karnoub and Weinberg 2006, Grivennikov et al., 2010 and Qian 
and Pollard 2010). In many patients, inflammation is evident at early stages in the 
neoplastic transformation and capable of driving the progression of incipient neoplasms 
into full blown cancers. Inflammation may also release reactive oxygen species that induce 
mutations for nearby cancer cells, thus promoting their genetic evolution into malignancy 
(Grivennikov et al., 2010). 
 
9.   Deregulating cellular energetics 
 
Under aerobic conditions, respiring cells convert glucose to pyruvate in the cytosol and 
eventually to carbon dioxide in the mitochondria. While during anaerobic conditions, 
glycolysis is favoured such that little pyruvate is taken up into the mitochondria. Otto 
Warburg (1930) observed that tumour cells reprogram their glucose metabolism (and thus 
energy production) even in the presence of oxygen by limiting their energy metabolism 
mainly to glycolysis, a term described as ‘aerobic glycolysis’. Reprogramming energy 
metabolism is unproductive, as tumour cells must compensate for the  ̴ 18-fold lower ATP 
produced by glycolysis compared to mitochondrial oxidative phosphorylation. This is 
achieved by upregulating glucose transporters (i.e. GLUT-1), increasing the glucose uptake 
into the cell (Hsu and Sabatini, 2008 and DeBerardinis et al., 2008). Marked increases in 
the uptake and utilisation of glucose is documented in many tumour types and visualised 
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using positron emission tomography (PET) using a radiolabelled glucose analogue (18F-
fluorodeoxyglucose, FDG) as a reporter. Increased glycolysis also allows the diversion of 
glycolytic intermediates into various biosynthetic pathways including generating 
nucleosides and amino acids, facilitating the synthesis of macromolecules and organelles 
for assembling new cells (Hanahan and Weinberg, 2011). 
 
10.   Avoiding immune destruction 
 
It is widely accepted that the immune system plays a role in preventing the formation of 
tumours (Dunn et al., 2002). The theory of immune surveillance postulates that the 
immune system constantly monitors cells and tissues in order to eliminate nascent tumours 
(Dunn, Old and Schreiber, 2004). Solid tumours are thereby believed to be formed as a 
result of evading immune detection (Hanahan and Weinberg, 2011). Teng et al., (2008) 
demonstrated that mice genetically engineered to be deficient for various components of 
the immune system, developed more frequent tumours compared to immunocompetent 
controls. In addition, they also showed that mice deficient in the development or function 
of CD8+ cytotoxic T lymphocytes, CD4+ Th1 helper T lymphocytes or natural killer (NK) 
cells resulted in increased rates of tumour incidence, while mice with combined 
immunodeficiencies in both T cells and NK cells were more susceptible to the 
development of tumours, demonstrating the contribution of the immune system to tumour 
eradication. 
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1.1.6  The immune system and cancer 
 
 
It is well-known that the immune system is a barrier to the growth of tumours (Dunn et al., 
2002), where it is well-accepted that the interaction between tumours and immunity is in 
three forms, termed the three ‘E’s of cancer immunity – elimination, equilibrium and 
escape (Dunn, Old and Schreiber, 2004). Cancer arises from an accumulation of genetic 
alterations in cells (Hanahan and Weinberg, 2011). Elimination of cancer consists of three 
stages – elimination, equilibrium and escape (figure 1.5).  
 
During elimination, the adaptive and innate immune systems work together to destroy 
tumours in order to keep the host free of cancer. If this process fails, and a rare variant is 
not eliminated, it may lead to an equilibrium phase where tumour growth is kept in a state 
of dormancy by T cells, IL-12 and IFN-ᵞ. Due to the constant immune selection pressures 
placed on genetically unstable tumours, tumour cell variants may arise that are insensitive 
to adaptive immunity, effector mechanisms or induce an immunosuppressive state within 
the tumour. This may then lead to a final, escape phase where growth of tumour cells is no 
longer inhibited by immunity. These cells are then able to cause clinically apparent disease 
(figure 1.5) (Schreiber, Old and Smyth, 2011). 
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Figure 1.5:  Cancer immunoediting: from immunesurveillance to immune escape 
After cells become transformed from normal cells to cancerous cells, cells of the immune system may eliminate tumour cells 
(elimination/immunesurveillance). When elimination is unsuccessful, the immune system and cancer reach equilibrium where it can keep the cancer in check, 
but cannot eliminate it completely. The immune system also selects/promotes the generation of tumour variants with ability to survive immune attack. This 
may lead to escape where tumour cells expand in an uncontrolled manner in an immunocompetent host. Adapted from Strausberg (2005).
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1.2  Prostate cancer (PCa) 
1.2.1   Prostate anatomy  
 
The prostate gland is a small, walnut shaped gland lying underneath the bladder (figure 1.6) 
and directly below the internal urethral orifice, around the beginning of the urethra. Adult 
prostatic parenchyma is divided into four anatomically and biologically distinct zones: the 
peripheral, central, transitional zones and the region of the anterior fibromuscular stroma 
(Kumar et al., 2007). Histologically, the prostate is made up of glands lined by two layers 
of cells: a basal layer of low cuboidal epithelium covered by a layer of columnar secretory 
cells. Testicular androgens control the growth and survival of prostatic cells. The prostate 
gland is surrounded by the prostatic capsule and secretes an alkaline fluid containing 
prostate-specific antigen (PSA) which forms part of the ejaculate, aiding the nourishment 
and motility of sperm (Spickett and Robertson, 2010). 
 
 
Figure 1.6:  Prostate anatomy. 
The prostate gland lies under the bladder and is made up of two tissue types – the glandular 
or epithelial cells which produce seminal fluid (including prostate-specific antigen; PSA) 
and stromal tissue. The stromal tissue is comprised of smooth muscle and connective tissue 
that contract to release prostatic secretions during sexual activity. The prostate gland is 
divided into 4 anatomical zones – the transitional, central, peripheral and anterior zones. 
Adapted from WholeLifeProstate (2015). 
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1.2.2   Incidence, risk factors, clinical presentation and treatment of 
PCa 
 
Prostate cancer (PCa) is the most common cancer in men above 65 years (Drewa and 
Styczynski, 2008), where three quarters of PCa deaths occur in men above 75 years 
(Cancer Research UK, 2015b) (figure 1.7). In 2011, approximately 41,700 new cases of 
PCa were diagnosed in the UK causing approximately 11,000 deaths in 2012 (Cancer 
Research UK, 2015b). According to the American Cancer Society, approximately 1 in 7 
men will be diagnosed with PCa in their lifetime, where 1 in 38 men will die from PCa in 
their lifetime (American Cancer Society, 2015). PCa incidences at autopsy are high, 
increasing from 20% in 50 year old men to 70% in men between 70 and 80 years. 
 
Figure 1.7:  UK PCa incidences by age at diagnosis. 
The highest incidence rate of PCa occurs in older men between the ages of 65 and 74 
where it occurs in approximately 8,000 per 100,000 men. Source: Cancer Research UK 
(2015b). 
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Risk factors for PCa include advanced age, family history (in the father or brother) and 
race where African American men have the highest risk of developing PCa (Kohli and 
Tindall, 2010 and Hunchareck et al., 2010). According to the American Cancer Society, 
27,130 cases were diagnosed in African American populations, which accounted for 34% 
of all the cancers diagnosed in this population (American Cancer Society, 2015). In 
addition, men from African American decent are generally diagnosed with more advanced 
disease at an earlier age compared to men from Caucasian or Asian populations (Odedina 
et al., 2009). PCa can be eradicated or treated effectively if detected at early stages. As a 
result, methods of detecting PCa at earlier stages of the disease are of prime importance for 
cancer patient management (Madu & Lu, 2010 and Kumar et al., 2007). 
 
PCa is generally asymptomatic in early stages of disease, however it may exhibit a wide 
range of clinical behaviours, ranging from incidentally discovered, clinically insignificant 
cancers to more aggressive lethal tumours (Roth-Kauffman, 2011). Lower urinary tract 
symptoms may be present such as weak stream, frequency, urgency, hesistancy, straining, 
incomplete emptying, nocturia, intermittency and various degrees of incontinence. Men 
with advanced PCa may present with pain in the hips, back and pelvis as a result of 
metastatic disease (Litman et al., 2007). 
 
Tumours originating in glandular, prostatic epithelia are referred to as ‘adenocarcinomas’ 
which account for more than 95% of PCa cases. Of these, 70% occur in the peripheral zone, 
15-20% in the central zone while 10-15% occur in the transitional zone (Bostwick et al., 
2004). PCa tumours metastasise through the bloodstream and lymphatic system, forming 
secondary tumours mainly in the bones and lymph nodes. As a result, a dramatic decline in 
the cure rates occurs in metastatic tumours (Thalmann et al., 1994). 
 
When PCa is confined to the prostate gland, curative treatment options include various 
forms of radiation therapy (external beam and/or brachytherapy), radical prostatectomy, 
and active surveillance (Roth-Kauffman, 2011). In advanced stages, where the tumour has 
metastasised beyond the prostatic capsule, the chances of cure are decreased. Treatment 
options for metastatic PCa include local therapy combined with adjuvant radiation therapy 
or androgen deprivation therapy (Widmark et al., 2009). Survival rates for men with early 
stage PCa is prolonged. Studies have reported up to 60-90% occurrence of 10 year survival 
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rates after radical prostatectomy or radiation therapy (Inmann et al., 2008 and Sanda and 
Kaplan, 2009). 
1.2.3   Diagnosing PCa  
 
PCa is asymptomatic until it becomes advanced or metastatic disease, thus, patient 
screening to aid early PCa diagnosis is mandatory (Smith et al., 2003). PCa screening is 
carried out in order to detect tumours before symptoms have developed. In early stages of 
PCa, screening is achieved through PSA blood test, digital rectal examination (DRE) and 
transrectal ultrasound of the prostate (TRUS) (Mettlin et al., 1991 and Catalona et al., 1991) 
while diagnosis is achieved by a histological examination of prostate tissue obtained from 
a prostate needle biopsy, carried out using a transrectal ultrasound of the prostate (TRUS). 
 
1.2.3.1 Prostate specific antigen (PSA) 
 
PSA is the most important biomarker for PCa detection, staging and monitoring (Catalona 
et al., 1991). PSA, a serine protease of approximately 30 kDa, is produced in normal 
prostatic epithelium and secreted into the semen to cleave and liquefy seminal coagulum 
after ejaculation (Spickett and Robertson, 2010). Normal serum levels of PSA range from 
0 – 4.0 ng/mL, where elevated levels are frequently observed in localised and advanced 
PCa (Roth-Kauffman, 2011). A PSA value of >4.0 ng/mL may require follow up 
depending on age, ethnicity and family history of PCa. 
 
Although PSA can increase the detection rate in men with no symptoms (Catalona et al., 
1993 and Mettlin et al., 1991), and men at an early age and stage (Balducci et al., 1997), 
PSA has resulted PCa overdiagnosis. PSA lacks specificity and sensitivity for PCa as it is 
raised in other non-malignant conditions such as Benign Prostatic Hyperplasia (BPH), 
prostatitis, or regular processes such as ejaculation, while reduced PSA levels can be 
observed in castration, surgery to the prostate or radiation therapy (Dimakakos et al., 2014). 
In addition, only 25% of men who display elevated PSA are associated with PCa (Andriole, 
2012, Barry, 2001 and Schroder, 2009). These false positive rates, resulted in the use of 
invasive procedures leading to over diagnosis and overtreatment of potentially indolent 
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disease, or delayed treatments for more advanced, aggressive and life threatening tumours 
(Oh et al., 2003). 
 
Recently, variations of PSA have been introduced to increase the sensitivity and specificity 
of PSA for PCa, such as free vs. total PSA (Stenman, 1995), age of patient (Carter et al., 
1992), PSA velocity and doubling time, pro-PSA (Mikolajczyk et al., 2003), and PSA 
density of the transition zone. In 1991, a study by Stenman et al demonstrated that free 
PSA may be better at detecting BPH while bound PSA could more accurately detect PCa. 
 
Although each of these variations have shown some added diagnostic value to PCa, serum 
PSA alone cannot accurately predict pathological stage as it varies with tumour volume, 
grade and tumour site of origin (Partin et al., 1990 and Partin et al., 1993). In addition, 
studies have shown that for each patient benefitting from PSA diagnosis-initiated treatment, 
unnecessary biopsy and treatment is carried out on 47 patients due to false positive PSA 
results (Andriole et al., 2009). Furthermore, over diagnosis rates of up to 29% for Whites 
and 44% for Blacks have been reported (Oh et al., 2003), suggesting the need for more 
accurate biomarkers for PCa. 
 
1.2.3.2 Digital rectal examination (DRE) 
 
A DRE involves feeling the prostate through the rectum for irregularities in prostate size, 
shape and texture. DRE is a routine screening method for PCa, which can detect cancer in 
men with small, well differentiated tumours, and cancers missed by other tests (Basler and 
Thompson, 1998). It has 59% accuracy and 94% specificity in detecting PCa (Hoogendam 
et al., 1999) and is relatively well tolerated by patients and inexpensive to perform. DRE is 
useful for the detection of other abnormal prostate conditions such as BPH (Yedema et al., 
1993). 
 
On the other hand, a DRE is invasive, subjective and cannot detect tumours that are non-
palpable (usually early stage tumours) or tumours located in regions of the gland that are 
distant and obscure from digital palpitation (Mahon, 2005). Furthermore, studies have 
showed that DRE is more accurate in combination with other diagnostic indicators such as 
PSA (Harris and Lohr, 2002). Despite its limited sensitivity, a DRE along with elevated 
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PSA levels are the primary indicators for a prostate biopsy, although both markers still 
result in overdiagnosis (Gomella et al., 2011). This highlights the need for novel 
biomarkers which can detect PCa particularly aggressive from indolent diseases.  
1.2.3.3 Transrectal ultrasonography (TRUS) of the prostate  
 
PSA use in clinics has resulted in an increase in the number of patients undergoing TRUS 
(Punnen et al., 2009). A transrectal ultrasound (TRUS) involves the use of an 
ultrasonograph which sends out high energy sound waves to the rectum of a patient to 
allow the imaging of the entire prostate gland (Keyhole Urology, 2015). Using 
ultrasonography, areas of the prostate with varying morphology produce different images, 
which results in a high sensitivity, paramount for early PCa diagnosis. In addition, TRUS 
can be used to guide a needle biopsy in order to confirm PCa diagnosis after PSA and/or 
DRE (Oh et al., 2003). This involves isolating 10-12 cores of the prostate, which is 
histologically analysed for the morphological assessment of tumour cells and the extent of 
spread. 
 
It is well documented that TRUS should not be utilised alone as a primary screening tool 
due to its low specificity. One study by Catalona et al., (1994) demonstrated that nearly 40% 
of tumours would have been missed if biopsies were performed only in men with 
abnormalities in TRUS. Furthermore, it is not feasible as a screening test in primary care 
clinics, but rather to guide biopsy for diagnostic purposes. In addition, studies have shown 
that TRUS guided biopsy have sensitivities ranging from 39-52% (Norberg et al., 1997), 
PCa detection rate of 25% on initial biopsy (Naughton et al., 2000) and 18-32% detection 
rate on repeated biopsies (Yuasa et al., 2008 and Aganovic et al., 2011).  
 
1.2.3.4 Transperineal template prostate biopsy (TPTPB) 
Unlike TRUS, transperineal template prostate biopsy (TPTPB) is associated with a high 
detection rate for PCa in men who have rising PSA and negative TRUS biopsy. A study by 
Pal et al., (2012) showed a higher PCa detection rate in 40 men who underwent a 
standardised 36-core TPTPB despite two sets of negative TRUS biopsies. It involves using 
a brachytherapy template grid to allow the sampling (every 5 mm of prostate) and isolation 
of 30-50 tissue cores from various parts of the prostate, through the perineum. This allows 
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the detection of small cancers compared to other methods of prostate biopsy (Nafie et al., 
2013). The absence of a sensitive and specific marker for the diagnosis and prognosis of 
PCa creates a demand for new, reliable markers which can be used in a clinical setting.  
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1.2.4   Staging & grading PCa  
 
1.2.4.1 Grading system (Gleason grade) 
 
PCa biopsies are carried out to histologically determine the stage and grade of the prostate 
tumour, as these are the best prognostic indicators for PCa (Fielding et al., 1992). The 
grading of PCa refers to the microscopic description of the glandular patterns of 
differentiation (aggressiveness of PCa) and is achieved using the Gleason scoring system, 
outlined by Donald Gleason et al., 1966 and refined in 1974 and 1977 (Gleason 1966 and 
Gleason and Mellinger, 1974). The Gleason scoring system classifies PCa into one of five 
grades - grade one represents well differentiated tumours, where the neoplastic glands are 
round in appearance, uniform, and packed into well-defined nodules (figure 1.8). Grade 5 
tumours have no glandular differentiation and tumour cells infiltrate the stroma in forms of 
cords sheets and nests (Gleason et al., 1974). 
 
 
Figure 1.8:  Gleason pattern scale. 
Gleason scoring system grades tissues collected at biopsy, where pathologists determine the two 
most common tissue patterns giving them a score of 1 (well differentiated) to 5 poorly 
differentiated) tumours. The Gleason sum is a sum of both most common patterns observed under 
the microscope. Adapted from Prostate Health Organisation (Prostate Health Organisation, 2015).  
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Tumours may contain more than one pattern where a primary grade is assigned to the most 
dominant pattern, and a secondary grade to the second most dominant pattern (Kumar et al., 
2007). The numeric values of both patterns are added up to make a Gleason score or sum. 
Gleason scores with a similar biological behaviour are classified into groups. Grades 2 – 4 
are classified as well differentiated tumours, while 5 – 6 are regarded as intermediate 
tumours. Gleason grades 7 tumours are termed moderate to poorly differentiated cancers 
while 8 -10 are high grade tumours (Dunn and Kazar, 2011) and figure 1.7. 
 
1.2.4.2 Staging system (TNM staging) 
 
The stage and grade classification of PCa indicates the tumour size, extent of spread, depth 
of penetration, organ of metastasis and effect on organ in relation to stage (Yano et al., 
2007). The pathologic staging system used for PCa is the TNM system based on the grade 
and extent of the tumour size (T), lymph node involvement (N) and possible metastasis (M) 
(American Joint Committee on Cancer, 1997). Staging is established on a scale of 0 to IV 
(cancer is staged as progressing from Stage 0 to Stage IV), where each stage is subdivided 
into more specific alphanumeric categories based on the primary tumour, regional nodes 
and distant metastasis (Bostwick et al., 1994). The extent of the tumour involvement is 
divided into T1-T4, where higher T values indicate more prostate involvement (figure 1.9). 
Although PCa staging is essential, it cannot be carried out independently. Staging of PCa is 
carried out alongside knowledge of the PSA level, DNA ploidy, nuclear morphometry as 
well as cellular, molecular and genetic factors (Montie et al., 1995). 
 
Incorrect staging of PCa may result in overdiagnosis, overtreatment and a reduction in a 
patient’s survival chances (Yano et al., 2007). As staging is based on results from a DRE, 
PSA and TRUS, this highlights the need to utilise accurate markers for PCa screening and 
diagnosis. Nevertheless, other clinical tests such as CT scans, X-rays, bone scans and 
MRIs can be used to further determine the stage of PCa and/or detect localised tumours 
beyond the prostate. 
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Figure 1.9:  Staging prostate cancer – the ‘T’ system. 
The figure above shows the pathological staging of PCa depicting the extent of the tumour 
size at various stages. 
 
1.2.4.3 D’Amico risk classification system  
 
In 1998, D’Amico et al. stratified patients into groups with low, intermediate or high risk 
of biochemical recurrence after radical prostatectomy, based on their stage, Gleason grade 
and PSA level (table 1.1) (Hernandez et al., 2007). 
 
Table 1.1: D’Amico risk classification system 
 Gleason score Clinical stage Serum PSA (ng/mL) 
Low risk ≤6 T1 or T2a <10 
Intermediate risk ≤ 6 - 7 T1 or T2a or b 10 – 20 
High risk ≤ 7 
8 - 10 
T1 or T2a, b or c 
T1 or T2a, b or c 
>20 
Any PSA 
 
D’Amico risk classification system to determine patients with a low, intermediate or high risk of 
biochemical recurrence of PCa after radical prostatectomy. Risk system is based on clinical stage, 
Gleason score and serum PSA. Adapted from: D’Amico et al., 1998.  
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1.3  Cancer biomarkers and biomarker discovery 
 
Epidemiologic and intervention studies have shown that early detection decreases the 
incidence of cancer morbidity and mortality (Brooks, 2012). Thus, tremendous effort is 
currently placed on cancer detection in early, curable stages in order to decrease the rates 
of cancer mortality, worldwide. Consequently, identifying serum biomarkers which 
manifest prior to the onset of cancer is the Holy Grail for biomarker discovery (Tan et al., 
2009). 
 
1.3.1   Biomarkers 
 
According to the National Cancer Institute, a biomarker is: 
 
‘Any biological molecule found in blood, or other body fluids, or tissues 
that is a sign of a normal or abnormal process or of a condition of disease.’ 
          - (National Cancer Institute, 2015). 
 
Cancer biomarkers are biochemical indicators of the presence of a tumour in a patient 
(Goedegebuure et al., 2004). They are produced by or present in tumours or produced by a 
host in response to a tumour, and used to differentiate the presence of a tumour via 
measurements of the analytes in serum, tissue or urine (Diamandis 2002 and Sokoll and 
Chan, 2004). Biomarkers may be altered qualitatively or quantitatively in precancerous or 
cancerous conditions, making them detectable by an assay (Schrohl et al., 2003). 
According to the National Cancer Institute, the ideal cancer screening and detection 
biomarker should be present in an easily available sample source (e.g. serum or urine) 
(Madu and Lu, 2010). 
 
In symptomatic patients, cancer biomarkers (tumour markers) may be useful in 
determining tumour stage, grade and response to therapy (Ludwig and John, 2005) as well 
as for screening for early signs of malignancy in asymptomatic patients (table 1.2). After 
diagnosis, and treatment, cancer biomarkers may be used in assessing patient prognosis, 
therapy prediction, postoperative surveillance and response to systemic therapy (Duffy, 
2001 and Duffy, 2007). 
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Table 1.2: Biomarker types based on their clinical application 
Type of biomarker Biomarker application 
Screening/detection 
Predict the potential occurrence of disease in a asymptomatic 
patients or those with non-disease specific symptoms 
Diagnostic 
Make predictions for patients suspected of having a disease. 
Required to have high sensitivity and specificity. 
Prognostic 
Predict the overall outcome of a patient, including recurrence and 
aggressiveness, regardless of therapy. 
Predictive 
Used to identify patient subpopulations that are most likely to 
respond to therapy. May also be used as a target for therapy. 
Common uses of some tumour markers. Adapted from (Rigau et al., 2013). 
 
1.3.2   The ideal PCa biomarker 
 
Pin et al. (2013) suggest that PCa biomarkers should ideally originate from the stromal or 
epithelial cells in the tumour and correlate to the tumour microenvironment (Pin et al., 
2013). Furthermore, they outline that levels of the tumour marker should be present at 
detectable levels in healthy controls, but significantly increased in cancer where its 
concentration reflects tumour burden. The ideal PCa biomarker should also be specific to 
PCa, yielding a high diagnostic sensitivity and specificity (Kulasingam and Diamandis, 
2008). It should also have a short half-life which enables frequent serial measurement and 
correlate with tumour burden, indicating tumour progression. The clinical value of such a 
biomarker must be validated in a large patient cohort, where assays of tumour markers 
should be standardised, reproducible, cheap and simple to perform. They must also have 
clearly defined reference ranges to allow screening in a large population cohort (Duffy, 
2013). 
 
Despite advances in medical research, the ideal biomarker does not exist and only a few 
FDA approved serum biomarkers are currently available in clinical settings for example 
CA125 (for ovarian cancer), PSA (for prostate cancer), carcinoembryonic antigen (for 
colon cancer) and HER2/neu (for breast cancer). However, of these markers, PSA is the 
only serological marker utilised in cancer screening; having a sensitivity of 90% and 
specificity of 21% for prostate cancer making its use as a screening tool controversial 
(Pedersen and Wandall, 2011). Although these screening methods are available, they all 
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pose issues with sensitivity and specificity, indicating the need for more sensitive, accurate 
biomarkers for PCa detection. 
1.3.3  Sample choices for PCa biomarker discovery (sources of PCa 
biomarkers) 
 
Biomarker discovery is challenged by the necessity to use large sample numbers in order to 
obtain statistically significant data; which is essential for the robustness of the identified 
biomarkers (Rabilloud and Triboulet, 2013). The other main difficulty lies in electing the 
most appropriate sample source for biomarker discovery studies (Alvarez-Chaver et al., 
2014). Samples which can be utilised for biomarker identification include clinical samples 
such as patient serum, tissue and urine or other biological samples such as PCa cell lines 
(Fliser et al., 2007). This section discusses the types of biological sample sources for 
biomarker discovery. A summary of diagnostic PCa biomarkers is outlined in table 1.3.  
1.3.3.1  Serum and plasma 
 
The most commonly used biological fluid for biomarker research is human blood as it is 
obtained via a minimally invasive procedure, is abundantly available, and changes in the 
blood, serum and plasma reflect diverse pathological states (Even-Desrumeaux et al., 
2011). However, serum and plasma have a heterogeneous mixture of proteins which are 
derived from various tissues, making it difficult to attribute differentially expressed 
proteins in cancer biomarker discovery studies to tissue specific tumours (Alvarez-Chaver 
et al., 2014). 
 
One of the PCa biomarkers identified in serum is urokinase plasminogen activator (uPA). 
The inactive precursor of the serine protease urokinase plasminogen activator (uPA), binds 
to a cell surface receptor (uPA receptor [uPAR]) and promotes the conversion of 
plasminogen to plasmin, which degrades the extracellular matrix proteins by activating 
proteases (Otero et al., 2014). Various forms of uPA have been measured in patients to 
improve PCa detection, including serum cleaved uPAR domain I (uPAR [I]) and uPAR [II-
III]) which are increased in PCa patients compared to benign controls. Furthermore, 
Piironen et al. (2006) showed that in patients with a total PSA of 2-10 ng/mL, combining 
the percentage of free PSA with uPAR (I)/uPAR (I-III) ratio increased specificity (0.73 
ROC score) for PCa than using a free PSA alone (0.68). In addition, immunohistochemical 
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studies by Gupta et al. (2009) showed that overexpression of uPA, its inhibitor (PAI-1) and 
uPAR were associated with aggressive PCa reoccurrence in patients who had a radical 
prostatectomy, while Kumano et al. (2008) also found the same correlation with poor 
pathological features, including stage, Gleason grade, lymph node metastasis, surgical 
margin status and lymphatic invasion. 
 
1.3.3.2  Urine 
 
The formation of human urine occurs in the kidney, via processes resulting in ultrafiltration 
of plasma proteins and proteins of the urinary tract, selective reabsorption of water, 
glucose, sodium, and nitrogenous wastes, tubular secretion of urea, uric acid, drugs and 
creatinine, and the concentration of water (Kumar et al., 2009). The normal urinary 
proteome contains a significant amount of proteins and peptides consisting of the soluble 
proteins and solid components of urine (figure 1.9) (Pisitkun et al., 2006). As urine 
eliminates bodily waste products and maintains homeostasis, it is widely accepted that 
urine may contain information on urogenital and systemic diseases (Gonzalez-Buitrago and 
Ferreira, 2007). Thus, medical evaluation of renal function and the pathophysiology of the 
kidney and other distant organs rely on urinary analysis. Urinary biomarkers identified for 
PCa include DNA based markers e.g. Glutathione-S-Transferase P1 (GSTP-1), RNA based 
α-methylacyl coenzyme-A (AMACR) or protein based such as telomerase, calgranulin, 
and AMACR (Ludwig and Weinstein, 2005). 
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Figure 1.10:  Sources of urinary proteins. 
Urinary proteins include soluble proteins from glomerular filtration and membrane bound 
proteins, solid phase components such as epithelial cells and casts. Adapted from Pisitkun 
et al. (2006). 
 
 
Exosomes may also serve as biomarkers from urine. The formation of exosomes occurs in 
multivesicular bodies by almost all tissues and utilises an inward budding mechanism that 
encapsulates cytoplasmic components to create small (50-150 nm), secreted membranous 
vesicles (Rigau et al., 2013). Exosomes represent their tissue of origin and are present in 
most body fluids – urine, serum and ascites and in some cell lines, where they have a role 
in inter-cellular communication (Duijvesz et al., 2013). Tumour derived exosomes are 
essential in growth and tumour progression and an increase in exosomal release has been 
shown to facilitate the communication between the tumour microenvironment and the 
tumour cell (Roberson et al., 2013).  
 
Urinary exosomes have been described as a treasure chest of information and potential 
source of new biomarkers for PCa, because purification of prostate derived exosomes will 
allow the identification of new biomarkers for the early diagnosis of PCa (Duijvesz et al., 
2011). Duijvesz et al. (2013) identified PDCD6IP, fatty acid synthase, exportin and alpha 
enolase as new candidate biomarkers for cancer where a higher abundance of fatty acid 
synthase, exportin and PDCD6IP was observed in PCa exosomes.  
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1.3.3.3  Tumour tissues 
 
The analysis of biopsy-obtained tissue samples from cancer patients allows the comparison 
of protein profiles between adjacent healthy tissues and tumour tissue for the identification 
of cancer biomarkers (Alvarez-Chaver et al., 2007). Tumour tissues are ideal for biomarker 
discovery studies because not all proteins altered in tumours, and therefore tumour marker 
candidates are secreted from the tumour cells into the blood or urine (Alvarez-Chaver et al., 
2014). Furthermore, because altered proteins originate in the tumours themselves, in theory 
tumour tissue samples have the richest concentration of tumour proteins, providing a more 
accurate representation of the tumour microenvironment, making them the ideal source for 
cancer biomarkers (Chen and Yates, 2007 and Even-Desrumeaux et al., 2011).  
 
Using tissue samples for cancer biomarker discovery has many limitations. Firstly, tumour 
tissue samples are obtained via an invasive biopsy procedure. Furthermore, it is difficult to 
obtain sufficient sample quantities, especially adjacent normal counterparts for comparison 
with tumour tissue for biomarker discovery (Even-Desrumeaux et al., 2011). Tumours are 
also complex by nature and heterogeneously composed of stromal cells and surrounding 
neoplastic cells, therefore using them for cancer biomarker identification studies involves 
overcoming the challenges with tissue heterogeneity and cellular diversity (Pin et al., 
2013). One of the methods to overcome this has been the use of Laser Capture Micro-
dissection (LCM) which isolates histologically pure cancer cells from surrounding a 
complex heterogeneous tissue microenvironment using laser-assisted micro-dissection 
(Hussain et al., 2013). However, protein yield from LCM are low, limiting its use prior to 
biomarker discovery. A summary of tissue biomarkers can be found in table 1.3. 
1.3.3.4  Immortalised PCa cell lines 
 
Cell lines used in cancer biomarker discovery are isolated from primary tumours or tumour 
metastasis (e.g. pleural effusion or aspirates), while those derived from metastatic cancers 
may not always represent tumour diversity, thus using cell lines in translational studies 
may introduce bias (Hussain et al., 2013). However, cell lines obtained from tumours are 
useful in biomarker research because they provide information on tumour biology and 
molecular characteristics such as cell-matrix and cell-cell interactions and gene expression 
(Lacroix and Leclercq, 2004). They offer an advantage over clinical samples due to their 
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ease of availability and homogeneous populations and the fact that they can be rapidly 
propagated in vitro and independently validated (Johnson et al., 2014). Furthermore, it is 
also easy to obtain subcellular fractions such as plasma membrane, nucleus, secretome and 
exosomal fractions from cell cultures, reducing the sample complexity which aids the 
identification of cancer biomarkers (Alvarez-Chaver et al., 2014). 
 
Using cell lines for PCa biomarker research has some drawbacks.  Most of the PCa cell 
lines were derived from prostate tumours, whereas cell lines from normal epithelia do not 
exist, limiting the study of the malignant transformation in PCa. In addition, each cell line 
represents only one tumour, and their cells may have been subjected to clonal drift and in 
vitro selection (Even-Desrumeaux et al., 2011). Furthermore, it is difficult to mimic the 
tumour microenvironment in cell lines as cell cultures lack features of an in situ tumour 
such as the interaction with other tumour cells, stromal cells and the cells of the immune 
system, thus making them a poor representation of the tumour in vivo. For this reason, it 
has been argued that it may be difficult to extrapolate candidate biomarkers found in cell 
lines to clinical samples. As a result, it is of prime importance that candidate biomarkers 
identified in cell lines are validated in clinical samples from cancer patients (Alvarez-
Chaver et al., 2014).  
 
Most studies investigating the identification of cancer biomarkers using PCa cell lines have 
been limited to the use a single cell line in isolation, rather than a panel of cell lines, which 
makes the validation of identified biomarkers difficult because these candidate markers 
may not be expressed by other PCa cells, in order to establish biomarker reproducibility or 
have the ability to distinguish between PCa and non-malignant cells (Johnson et al., 2014). 
Johnson et al. (2014) compared multiple PCa cell lines (22RVI and LNCaP) with benign 
PNT1a and PNT2) and found a high expression of the lysosomal protein LIMP-2 protein 
and gene expression in PCa cell lines in comparison to benign controls, highlighting the 
significance of analysing more than one PCa cell line for biomarker discovery. 
 
Conditioned media (secretome) also serves as a source of PCa biomarkers. Secreted 
proteins from cultured tumour cells into the cell supernatant media are thought to mimic 
the proteins released by tumours into the microenvironment where they can reach proximal 
fluids and circulation (Pin et al., 2013). Conditioned media from tumour cells are an 
attractive source for biomarkers because proteins which are specific for and directly linked 
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to tumour cells are easily obtained from this simple matrix which is easier to analyse 
compared to serum. 
 
Chen et al., (2011) analysed the conditioned media of the androgen sensitive PCa cell line 
(LNCaP) compared to BPH cells (BPH-1) by two-dimensional electrophoresis and 
MALDI-TOF MS. They identified differential expression of eleven proteins (6 up 
regulated including: creatine kinase brain (CKB), triosephosphate isomerase 1 (TPI1), 
isocitrate dehydrogenase 2 (IDH2) and 5 down regulated proteins including: glutathione S-
transferase pi (GST-pi) some of which were verified using real time polymerase chain 
reaction. They also found a similar expression pattern between mRNA levels of the 
conditioned media levels of CKB, TPI1, IDH2 and GST-pi in BPH and LNCaP. 
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Table 1.3: Diagnostic PCa biomarkers  
 
The table outlines a list of diagnostic PCa biomarkers identified from various biological sample sources. Although these biomarkers have been identified, none of them have 
been shown to accurately detect PCa. In addition, PCa is a heterogeneous malignancy such that a panel of markers would be more realistic than a single marker to indicate the 
presence of PCa (Downes et al., 2006).  Adapted from Madu and Lu (2010). 
S/N Biomarker Source Biological Function Reference 
1 Prostate specific antigen (PSA) Serum 
Secreted protein that hydrolyses semenogelin-1 thus leading to the liquefaction of the 
seminal coagulum. Ferro et al., (1987) 
2 Prostate membrane-specific antigen (PMSA) Serum 
Possesses folate hydrolase function. Cell stress reaction, signal transduction, cell 
migration, nutrient uptake. May possess questionable receptor function. Rigau et al., (2011) 
3 Zinc alpha-2-glycoprotein (ZA2G) Serum 
Induces lipid decline in adipocytes and therefore implicated as possibly acting in 
cachexia Katafigiotis et al., (2012) 
4 Human kallikrein 2 (KLK2) Serum Secreted serine protease. Splits pro-PSA to create PSA Recker et al., (2000) 
5 Early prostate cell antigen-1, -2 Serum & tissue 
May be involved in early prostate carcinogenesis; however, has uncertain contribution 
to nuclear morphology Gu et al., (2000) 
6 α-Methylacyl-CoA racemase (AMACR) 
Serum, urine & 
tissue 
Engaged in bile acid synthesis, stereoisomerization, and β-oxidation of branched-chain 
fatty acids Jiang et al., (2001) 
7 Thymosine β-15 Urine Regulation of actin polymerization and immune response, key role in facilitating tumour metastasis and angiogenesis. Huchinson et al., (2005). 
8 Telomerase Urine Protects  the  linear  ends  of  eukaryotic  chromosomes against degradation and fusion, thus maintaining genome stability Botchkina et al., (2005) 
9 Prostatic inhibin-like peptide (PIP) Urine Suppresses the synthesis and release of follitropin (follicle-stimulating hormone) Tremblay et al., (1987) 
10 Transferrin (Tf) Urine Iron metabolism. Key role in erythropoiesis/active cell division occur. van Dieijen-Visser et al., (1988) 
11 Sarcosine Urine Catalyses the oxidative demethylation of sarcosine to glycine. Sreekumar et al., (2009) 
12 PCA3 (DD-3) Tissue & Urine non-coding RNA De Kok et al., (2002) 
13 Engrailed-2 (EN-2) Urine Developmental protein; transcriptional repressor Morgan et al., (2011) 
14 Glutathione S-transferase P1 (GSTP1) Tissue & urine 
Conjugate reactive substrates with reduced glutathione (GSH) and are involved in 
detoxification 
Köllermann et al. (2003)  
& Goessl  et al., (2001) 
15 Caveolin-1 (Cav-1) PCa tissue & cells May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity Yang et al., (1999) 
16 Transmembrane protease serine 2 (TMPRSS2):ERG Tissue, urine Androgen-regulated, type II transmembrane-bound serine protease Leyten et al., (2012) 
17 Transforming growth factor 
β1 Tissue 
Growth factor involved in cellular differentiation, immune response, angiogenesis and 
proliferation. Shariat et al., (2004) 
18 Spondin-2 (SPON2) Tissue, serum Cell adhesion protein, promotes adhesion & outgrowth of hippocampal embryonic neurons. Essential in initiating innate immune response Qianet al., (2012) 
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1.3.4 Proteomics & mass spectrometry for biomarker discovery 
 
 
Mass spectrometry (MS) is an analytical technique that can provide qualitative (structural) 
and quantitative (concentration or molecular mass) information on analyte molecules after 
their conversion into ions (Ho et al., 2003). Samples for mass spectrometry are ionised in 
the ion source to acquire positive or negative charges. The ions can then travel through the 
mass analyser, arriving at various parts of the detector depending on their mass-to-charge 
(m/z) ratio. Ions that make contact with the detector generate signals recorded by a 
computer system (figure 1.11), which displays these signals as a mass spectrum indicating 
the relative abundance of the detected signals according to their m/z ratio. The various 
components of mass spectrometers will be discussed below. 
 
1.3.4.1  Ion source 
 
Samples are analysed prior to analysis in the source using various ionisation techniques, 
depending on the instrument used. Some ionisation techniques are energetic, causing 
excessive fragmentation while others are softer, only producing ions of the molecular 
species (Hoffman and Stroobant, 2007). Ion sources produce ions by ionising a neutral 
molecule in the gas phase by electron ejection, protonation, deprotonation, adduct 
formation, electron capture or transferring a charged species from a condensed phase onto 
a gas phase. Examples of ion sources used in biomarker discovery include Electrospray 
Ionisation (ESI) or Matrix Assisted Laser Desorption Ionisation (MALDI). 
 
1.3.4.1.1  Electrospray Ionisation (ESI) 
 
Electrospray ionisation (ESI) was first reported in 1984 by Yamashita and Fenn. It is 
achieved when a strong electric field is applied to a liquid passing through a capillary tube 
with weak flux under atmospheric pressure (Ho et al., 2003). At the liquid surface located 
at the end of the capillary, the electric field induces a charge accumulation which breaks to 
form highly charged droplets. At this point, a gas is injected at a low flow rate which 
allows the spray dispersion to be limited in space. The droplets then pass through a curtain 
of heated nitrogen, or via a heated capillary to remove the last solvent molecules (Hoffman 
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and Stroobant, 2007). The solvent contained in the droplets evaporates, causing them to 
shrink, increasing their charge per unit volume. These small, highly charged droplets 
continue to lose solvent such that when the electric field on their surface is large enough, 
desorption of ions from the surface occurs (Kebarle and Tang, 1993). 
 
ESI is different to MALDI as it may produce multiply charged ions, which effectively 
extends the mass range of the analyser (most commonly ion trap and quadrupole 
instruments) in order to accommodate kDa – Mda orders of magnitude commonly 
observed with proteins and polypeptide fragments (Ho et al., 2003). ESI carries out ‘soft 
ionisation’ as little fragmentation occurs. The detection limit of ESI depends on the sample 
analysed (its preparation and purity), the type of instrument used and the skill of the 
operator. ESI is the ion source of choice coupled to liquid chromatography with mass 
spectrometry. 
 
 
1.3.4.1.2  Matrix Assisted Laser Desorption Ionisation (MALDI) 
 
In MALDI, compounds to be analysed are dissolved in a solvent containing small organic 
molecules called a matrix, which has a strong absorption at the laser wavelength. The 
mixture is dried before analysis, creating a ‘solid solution’ deposit of analyte-doped matrix 
crystals. In the source, rapid heating of the matrix molecules by the laser causes 
sublimation of the matrix into the gas phase (Hoffman and Stroobant, 2007). Although the 
origins of ions produced by MALDI isn’t fully understood, the most widely accepted 
pathway suggested for ionisation reactions include proton transfer in the solid phase before 
desorption or gas phase proton transfer from photoionised matrix molecules. 
 
MALDI is a very sensitive laser ionisation technique. The matrix acts to minimise sample 
damage from the laser pulse by absorbing most of its energy. It also allows the desorption 
and ionisation of analytes with high molecular masses >100,000 Da. MALDI has also been 
applied in imaging biological materials to map the distribution of targeted biomolecules, 
allowing the direct study of proteins and peptides on tissue samples. MALDI is also 
characterised by an easy sample preparation method which has a high tolerance to 
contaminants such as salt, buffers and detergents, making it suitable for biomarker 
discovery studies (Chen et al., 1998). 
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1.3.4.2  Mass analysers 
 
After ions have been produced in the gas phase, they are separated according to their mass-
to-charge ratio (m/z). The differences between various types of mass analysers are based 
upon the way magnetic/electric fields are applied to achieve mass separation. The most 
important characteristics for measuring the performance of a mass analyser is its analysis 
speed, mass accuracy, resolution and mass range limit (Hoffman and Stroobant, 2007).  
 
1.3.4.2.1  Time of Flight (TOF) 
 
The Time of Flight (TOF) mass analyser is well suited to the pulsed nature of laser 
desorption ionisation, separating ions according to their velocities as they drift in a free 
field region, known as a flight tube. After expulsion from the source, ions are accelerated 
towards the flight tube by a potential difference applied between electrode and an 
extraction grid (Hoffman and Stroobant, 2007). Mass to charge ratios are then determined 
by measuring how long ions take to move through a region between the source and 
detector, where the lower the mass of the ion, the faster it reaches the detector. The speed 
of a TOF analyser is very fast, generating a spectrum over a broad mass range in micro-
seconds. However, TOF instruments are limited by their mass resolution, which is affected 
by time, space and kinetic energy distribution. The development of TOF analysers has 
paved the way for new applications for biomolecules and synthetic polymers and 
polymer/biomolecule conjugates. 
 
 
1.3.4.1 Liquid Chromatography (LC) 
 
In order to analyse a complex sample mixture, chromatography separation techniques are 
coupled to a mass spectrometer, such that separated products are introduced one after the 
other into the mass spectrometer either in gaseous phase (in gas chromatography, GC) or in 
solution (liquid chromatography, LC). High Performance Liquid Chromatography (HPLC) 
is an analytical technique used to separate, quantify and identify each component in a 
mixture (Hoffman and Stroobant, 2007). Using HPLC, a liquid solvent containing the 
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sample to be separated is passed through a column filled with solid adsorbent material 
(usually silica or polymers about 2-50 µm in size). Due to the different degrees of 
interaction of each component in the sample with the adsorbent material, different flow 
rates are generated for each component resulting in the separation of components as they 
flow through the column. A typical HPLC instrument includes a sampler to carry the 
sample into the mobile phase stream, bringing it into the column, a pump to deliver the 
desired composition and flow of the mobile phase into the column and a detector to 
generate a signal proportional to the amount of sample component. This creates a 
quantitative analysis of each sample component. Some HPLC models are able to mix 
multiple solvents in ratios that change with time in order to generate a composition 
gradient in the mobile phase (Hoffman and Stroobant, 2007). 
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Figure 1.11:  The basic features of a mass spectrometer. Samples are ionised in the ion source under vaccum or atmospheric pressure. 
Examples include Electrospray Ionisation (ESI) or Matrix Assisted Laser Desorption Ionisation (MALDI). Ions generated are then separated 
based on their mass-to-charge (m/z) ratio by the mass analyser, examples of which include quadrupole, ion trap and time of flight mass 
analysers. Detected ions are then used to produce a mass spectrum. 
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1.3.5 Tumour antigens and autoantibodies as biomarkers for 
cancer  
 
It is well documented that immune responses against antigens produced by the tumour 
(tumour associated antigens; TAAs) occur in patients in cancer (Rauch and Gires, 2008). 
Autologous proteins expressed by tumour cells may be mutated, misfolded, over-expressed, 
aberrantly degraded or post-translationally modified in a way that renders them 
immunogenic (Forgber, et al., 2009). TAAs that undergo post-translational modifications 
(e.g. oxidation, glycosylation) may generate neo-epitopes or enhance self-epitope 
presentation to the major histocompatibility complex of T-cell receptors, thus making them 
perceived as foreign by the immune system, consequently activating CD4+ T helper cells 
and plasma B cells (Spiotto et al., 2003 and Spiotto et al., 2002). Furthermore, proteins 
that are aberrantly localised during tumourigenesis may evoke a humoral immune response 
in the host. Suzuki et al (2005) showed that T-cell responses to cyclin B1 occurred when 
cyclin B1 was overexpressed and localised in the cytoplasm rather than the nucleus in 
breast, colon, pancreatic and lung cancer cells. 
 
Although the mechanism by which TAAs induce a humoral immune response is not yet 
fully understood (as most of the TAAs identified so far have been intracellular proteins), 
one of the hypothesised mechanisms by which an immune response is generated to self-
antigens postulates that immune responses are triggered to overexpressed TAAs (nearly 
100 fold overexpression). Zinkernagel et al. (2001) suggests that the overexpression of 
self-antigens and/or the existence of neoantigenic peptides within autoantigens would 
overcome the antigen threshold required to mount an immune response. Consequently, the 
increased presentation of these neoantigenic epitopes and their continuous presentation to 
antigen presentation cells (e.g. dendritic cells, macrophages) leads to the activation of 
CD4+ T lymphocytes and the production of antibodies by plasma (B-cells) (Spiotto et al., 
2003 and Spiotto et al., 2002). Furthermore, Winter et al. (1992) showed that tumours 
contained many different p53 mutations including frameshift mutations, stop codon and 
missense mutations, but it was the missense mutations with p53 overexpression and 
increased protein stability that was positively correlated with autoantibody production in 
lung cancer patients. 
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Another mechanism proposes that repeated exposure to modified intracellular proteins 
released in response to aberrant tumour cell death from defective apoptosis, ineffective 
clearance or necrosis leads to the production of a humoral immune response. Proteases 
released during cell death could also generate cryptic self-epitopes which could generate an 
autoimmune response (Tan et al., 2009). For example, Le Naour et al (2002) showed that 
Crt32, a truncated form of calreticulin elicits a humoral immune response in patients with 
hepatocellular carcinoma (HCC) compared to healthy controls and was found 
overexpressed in HCC tissues compared to healthy liver tissue, showing that TAAs can 
serve as potential biomarkers. It was also demonstrated that, although calreticulin induces a 
humoral response in autoimmune diseases such as systemic lupus erythematosus (SLE), 
the epitope recognised in HCC (C-terminal) is different to the one recognised in SLE 
patients (N-terminal), indicating that various mechanisms exist for autoantibody responses 
in autoimmunity and cancer (Le Naour et al., 2002). 
 
Furthermore, some TAAs have been shown to induce leukocyte migration, especially 
immature dendritic cells to damaged tissues by interacting with chemoattractant G-protein 
receptors in order to alert the immune system of danger signals from invaded and damaged 
tissues to facilitate tissue repair. The interaction with immature dendritic cells makes them 
immunogenic because they are liable to be sequestered and aberrantly presented to the 
cellular immune system (Oppenheim et al., 2005). 
 
In addition to TAAs, cancer patient sera contain autoantibodies to various aberrantly 
expressed cancer-related antigens involved with tumourigenesis (e.g. signal transduction, 
cell cycle progression, cell proliferation and apoptosis), making the serum antibody 
profiles for cancer patients and healthy controls vastly different (Mojtahedi et al., 2011 and 
Zhang et al, 2009). Thus, identifying TAAs and their corresponding autoantibodies may 
provide new insights into the interrelationship between the immune system and cancer and 
into the molecular pathology of tumour cells (Forgber et al., 2009). As a result, 
identification of TAAs and autoantibodies, which serve as ‘reporters’ of tumourigenic 
processes will lead to earlier diagnosis, better prognosis and more efficient therapy for 
cancer (Mojtahedi et al., 2011). 
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The ultimate utility of autoantibodies lies in the early detection of cancer. High titres of 
autoantibodies are identified in patients with early stage cancer and correlate with the 
progression of a malignant transformation, suggesting that the immune response to cancer 
occurs at an early stage during tumourigenesis and as such may serve as an indispensable 
biomarker for cancer. Furthermore, research has shown that autoantibodies can be detected 
in asymptomatic stages of cancer and in some cases, 5 years before the onset of disease 
(Fernandez 2005).  
 
One of the advantages of the humoral response to cancer is that it is persistent. Although 
tumour antigens may only be transient in duration (due to short lived changes in tumours, 
transient shedding, rapid degradation or clearance) the corresponding antibody response is 
persistent and present in high concentrations (Imafuku et al., 2004). In addition, even if the 
concentration of the TAAs is low (i.e. below the detection limit of the diagnostic assays or 
technology used to identify them), the nature of an autoantibody response to a single 
autoantigen is such that the autoantibody concentrations can be ‘amplified’ by the immune 
system, making it the autoantibody an easier biomarker target. Compared to TAAs which 
are subject to rapid degradation and clearance and are also rapidly secreted, this amplified 
response persists for months and years after the onset of disease, facilitating the detection 
of TAAs over a long period (Tan et al., 2009). 
 
Furthermore, obtaining serum samples from patients to determine the levels of an 
autoantibody response to a TAA present in the tumour tissue is less invasive than obtaining 
a biopsy. Antibodies are appealing as biomarkers because they have a stable structure, 
which do not commonly undergo proteolytic cleavage, simplifying sample handling. 
Finally, the biochemical properties of antibodies are well understood, making assay 
development easier. Since the primary antibody is available in the serum, only labelled 
species-specific secondary antibodies are required during the detection procedure with 
diagnostic assays (e.g. anti-human IgG), simplifying their commercial assay development 
(Tan et al., 2009). 
 
However, due to the complex nature of cancer, a single autoantibody assay lacks the 
sensitivity and specificity required for cancer screening such that a multi-marker panels of 
autoantibodies might be a more promising approach for early cancer detection (Werner et 
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al., 2014). Casiano et al (2006) suggests that autoantibodies to TAAs occur in between 10-
30% of the patient population due to the heterogenic nature of cancer. Brichory et al (2001) 
has also shown that nearly 60% of lung adenocarcinoma patient sera have autoantibodies 
to annexin I or II (40% and 37% to respectively) with no positive autoantibody response in 
healthy controls, smokers or patients with non-malignant lung disease. 
 
In addition, some TAAs occur in more than one tumour type making it difficult to 
discriminate between cancer subtypes using autoantibodies and TAAs. Autoantibody 
response is also notoriously induced in other autoimmune and non-malignant conditions, 
such as asthma, rheumatoid arthritis, autoimmune thyroid disease and type 1 diabetes, and 
sometimes in healthy patients, making it difficult to distinguish cancer from non-cancer 
using an autoantibody profile (Tan et al., 2009).  
 
Apart from its diagnostic utility, autoantibodies may also be used to selectively isolate and 
identify their cognate antigen protein. Target identification technologies which employ 
autoantibodies to identify potentially novel tumour antigens are of prime importance in 
immunoproteomics. One of the widely used approaches of TAA identification is the use of 
serum autoantibodies from cancer patients to immunoscreen for tumour antigens in patient 
tissue.  
1.3.6   Serological screening methods for TAA identification  
 
Robert W. Baldwin was the first to demonstrate the presence of an immune response to 
solid tumours. In the 1970’s, Lloyd J. Old was the first to demonstrate the use of 
autoantibodies for the identification of cell surface antigens using autologous typing (Shiku 
et al., 1977). Their method bound autologous serum antibodies to autologous tumour cell 
lines in vitro and the specificity of cancer reactivity was determined by antibody 
absorption analysis, to see whether pre-incubation of sera with other autologous or 
allogeneic cell lines would absorb out serum reactivity (Chen, 2012). After several rounds 
of autologous typing experiments, a panel of tumour antigens were identified including 
p53, the cell surface antigen on B-cell lymphomas, CD20 (Seliger and Gires, 2009).  
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In 1988, Boon et al. developed a method to identify TAA and TSA. They isolated cDNA 
libraries from tumours and recombinantly expressed them in bacteria before screening with 
tumour-specific CD8+ T cells. Their technique was modified by Falk et al. (1991) and 
Maldelboim et al. (1994). Over two decades later, due to the advances in molecular 
biology and genetic engineering, the value of using autoantibodies to identify and isolate 
TAAs is still an attractive one. The aim of this field of cancer biomarker discovery is to 
identify tumour relevant autoantibodies and their cognate TAAs and has been termed 
‘cancer immunomics’ (Seliger and Gires, 2009 and Rauch and Gires, 2008). Currently, two 
proteome based methods can be used to serologically screen TAAs: PROTEOMEX and 
AMIDA. 
 
1.3.6.1  PROTEOMEX 
 
PROTEOMEX (an abbreviation of proteomics and SEREX; another serological screening 
method used to screen cDNA expression libraries in bacteria to identify and isolate TAAs) 
is also known as SERPA (Serological Proteomics Analysis) or SPEAR (Serological and 
Proteomic Evaluation of Antibody Response). For the sake of simplicity, the method will 
be referred to as PROTEOMEX throughout this thesis. It is the first TAA identification 
method that combines proteomics technology in order to separate proteins of interest and 
serological screening using serum antibodies (Rauch and Gires, 2008). 
 
PROTEOMEX uses tumour cell lysates to screen for TAAs. Unlike SEREX, TAAs are 
screened in their ‘natural context’ using non-transformed tissues in their screening 
procedure, rather than after their recombinant expression in prokaryotes, which makes it 
possible for the post translational modification (PTM) of TAAs to be ‘considered’, which 
in some cases qualifies them as TAAs (Gunawardana and Diamandis 2007).  These PTMs 
include sumoylation, acetylation, phosphorylation, glycosylation (Seliger and Gires, 2009). 
 
Using PROTEOMEX, diseased and (adjacent) normal tissues are lysed and separated by 2-
DE. IEF is commonly conducted in precast, immobilised IPG strips (18-24 cm) in pH 
ranging from 3-10 or 4-7, while SDS PAGE is run using large 24 x 24 cm polyacrylamide 
gels (figure 1.12). This separation of proteins over a large area allows a better resolution of 
TAAs compared to SDS PAGE alone (Gunawardana and Diamandis 2007). After 
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separation, proteins are transferred onto nitrocellulose or polyvinylidene fluoride (PVDF) 
membranes before probing with cancer patient sera. TAA candidates are selected by 
comparing immunoblots of tumour and healthy tissue screened with cancer sera. Protein 
spots exclusively identified by cancer serum antibodies in tumour lysates are potential 
TAA candidates to be identified (Mojtahedi et al., 2011). A replica gel which contains 
tumour samples is also run in parallel and stained with a MS compatible stain (usually 
Coomassie blue or silver) in order for proteins of interest to be isolated for MS/MS 
identification (Rauch and Gires, 2008). After their identification, the expression pattern of 
TAAs must be validated in a cohort of normal, pre-malignant and diseased tissues 
alongside the investigation of serum auto-reactivity in multiple patient sera. 
 
 
Figure 1.12:  The PROTEOMEX methodology. 
Protein lysates prepared from tumour cell lines or tissues (used as a source of TAA) are 
separated by 2-DE, transferred onto a membrane and screened either with patient or control 
sera. Proteins exclusively reacting with sera from PCa patients are identified from stained 
replica gels by mass spectrometry as potential TAA candidates. 
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PROTEOMEX is however a robust technique for TAA identification which has been 
successfully implemented in tumour antigen discovery for many cancers including the 
identification of UBL1 in renal cell carcinoma (Lichtenfels et al., 2003) and RS/JD-1 in 
breast cancer (Le Naour et al., 2011). PROTEOMEX has also identified TAAs in other 
cancers such as the metabolic enzyme superoxide dismutase in melanoma (Lichtenfels et 
al., 2003) and the glycolytic enzyme glucose -6-phosphate-dehydrogenase (G6PD) in 
pancreatic adenocarcinoma (Tomaino et al., 2007).  
 
PROTEOMEX is not without its limitations. One of the main drawbacks with 
PROTEOMEX is the use of 2-DE for separation of tumour lysates. Without any pre-
fractionation, 2-DE is limited to identifying abundant proteins due to its limitation in 
sensitivity and sample capacity (Gunawardana and Diamandis 2007). Furthermore, it is 
unable to separate proteins which co-migrate on polyacrylamide gels due to their post-
translational modification, making the identification of spots difficult (Rauch and Gires, 
2008). This problem is futher compounded by the use of wide pH ranges for biomarker 
discovery studies. It is also notoriously challenging to separate cell membrane or very 
acidic or basic proteins using 2-DE due to their insoluble nature in aqueous buffers (Martin 
et al., 2011). Finally, PROTEOMEX is a labour-intensive method due to the inherent lack 
of reproducibility of 2-DE gels and the accurate excision of immunoreactive spots from 
replica gels and identification by MS.  
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1.3.6.2  AMIDA 
 
AMIDA stands for Autoantibody-Mediated IDentification of Antigens and was first 
described in 2004. AMIDA immunoprecipitates TAAs from tumour lysates using serum 
antibodies and these antibody-antigen complexes are further separated by 2-DE (Rauch 
and Gires, 2008). TAAs immunoprecipitated using patient sera are compared to those 
precipitated using healthy sera and selected protein spots are in-gel digested before 
analysis by MS. Like PROTEOMEX, gels are stained with a MS compatible stain, usually 
Coomassie blue or silver nitrate and protein spots exclusively immunoprecipitated out of 
tumour sera are identified as potential TAA candidates by MS (table 1.4). Additional 
controls can be introduced into AMIDA by omitting immunoglobulins during 
immunoprecipitation so that non-specific binding can be excluded from samples to be 
identified by MS (Seliger and Gires, 2009).  
 
One of the advantages of using AMIDA is that immunoprecipitation using serum 
antibodies acts as an ‘immunological filter’ which isolates proteins that are assumed to be 
directly associated with cancer. In contrast, other proteomic and genomic methods have the 
added challenge of determining which of the recovered proteins are of importance in 
cancer. The original technique was performed in an autologous fashion where sera and cell 
lysates were obtained from the same donor. Problems associated with the heterogeneity of 
tumour tissue alongside the amount of protein required for the sufficient representation of 
low-abundant proteins on 2-DE limit the use of autologous tumour lysates for TAA 
identification. Thus, an allogeneic AMIDA method was developed by Rauch et al. in 2004 
using tumour cell lines as a source of TAA in order to overcome the limitation of low 
number of proteins and allow for experiment replication. However, one main drawback of 
this method is that there is a biased protein expression in cultured cell lines compared to 
primary tumour cells, stating the need for a thorough validation of all TAAs identified 
using AMIDA.  
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Table 1.4:  A comparison between PROTEOMEX and AMIDA. 
 
Feature  PROTEOMEX AMIDA 
Protein source Protein lysates from primary tumours or cell lines Protein lysates from primary tumours or cell lines 
Screened proteins Proteins resolved by 2-DE (<3,000) Whole lysate 
Properties of TAA Natural, PTM proteins, immobilised on membrane, 
urea/SDS denatured 
Natural, PTM proteins, native conformation in solution 
Detection 2-DE immunoblot using diluted sera Immunoprecipitation (IP) with immobilised serum 
autoantibodies 
Specificity control 2-DE immunoblot with healthy tissue, 2-DE immunoblot 
screened with healthy sera 
IP using healthy tissue, IP using healthy donor 
immunoglobulins 
Isolation and identification of 
TAAs 
Comparison of immunoblot with 2-DE replica gel, tryptic 
digestion and MS 
Tryptic digestion & MS 
Sensitivity Dependent on the number of copies per protein Limited by stain sensitivity  
 
 
Similarities and differences between PROTEOMEX and AMIDA which use proteome based approaches to identify TAAs using protein lysates. Adapted from Rauch And 
Gires (2008). 
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1.4  Study rationale and aims 
 
Previous studies have demonstrated that TAAs and autoantibodies are present in the sera of 
cancer patients. PROTEOMEX, a method of TAA identification, has successfully been 
utilised in the discovery of TAAs for various cancers such as HSP-60 and RS/DJ-1 in 
breast cancer (Hamrita et al., 2008, Desmetz et al., 2008 and Le Naour et al., 2011), 
cytokeratin 8 and thioredoxin in renal cell carcinoma (Kellner et al., 2002 and Lichtenfels 
et al., 2003), eukaryotic elongation factor, alpha enolase, aldolase, glyceraldehyde-3-
phosphate dehydrogenase and heterogeneous nuclear ribonucleoproteins A2B1 and 
galectin-3 in melanoma (Suzuki et al., 2010 and Forgber et al., 2009) and alpha enolase in 
pancreatic adenocarcinoma (Tomaino et al., 2007). Till date, no study has identified PCa 
TAAs using the PROTEOMEX methodology. 
 
It is well known that urine obtained after a DRE may contain prostatic secretions and cells 
originating from the prostate tumour, which may serve as early PCa biomarkers (Downes et 
al., 2006). Thus, an analysis of the urinary proteome of patients with PCa may yield 
potential diagnostic or prognostic biomarker targets. 
 
Thus, the aim of this project was to utilise the PROTEOMEX technique to identify TAAs 
from urine and PCa cell lines that elicit autoantibody responses, which following addional 
validation may serve as potential PCa biomarkers. The objectives of this study are as 
follows: 
 
1. Optimise a reproducible protein preparation method for urine and PCa cell lines 
analysis prior 2-DE. 
2. Optimise conditions for PROTEOMEX and antigen discovery (e.g. sera dilution, 
serum titre, protein concentration). 
3. Screen and identify TAAs associated with PCa using an optimised PROTEOMEX 
method. 
4. Verify and validate all biomarkers identified in a separate cohort of samples from 
PCa, benign and normal patient samples, using Western blotting, ELISA and 
immunohistochemistry. 
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2. CHAPTER 2: IDENTIFICATION OF TUMOUR 
ANTIGENS IN URINE AS BIOMARKERS FOR 
PROSTATE CANCER 
2.1   INTRODUCTION 
 
Despite advances in medical research, PCa is still the most common form of cancer in 
males above 60 years (Johnson et al., 2014). Current methods of PCa cancer diagnosis are 
limited in specificity and sensitivity - unable to accurately discriminate patients with a 
more favourable from a less favourable prognosis. In addition, PSA cannot distinguish 
aggressive from non-aggressive PCa, resulting in over diagnosis, unnecessary treatments 
and increased clinical costs (Dijkstra et al., 2014). Consequently, there is a pressing need 
to identify more accurate biomarkers which can be used in addition to, or in place of the 
current PCa biomarkers. 
 
Urine is an excellent source for biomarker discovery for PCa due to the proximity of the 
bladder to the prostate gland (Hessels and Schalken, 2013). During ejaculation, prostatic 
fluid combines with seminal vesicle derived fluid to promote the activation and function of 
the male sperm (Drake et al., 2009). In patients who have PCa, the gentle massage of both 
sides of the prostate gland during DRE, stimulates the release of prostatic fluids and 
detached epithelial cells (expressed prostate secretions) into the urethra. As a result, urine 
obtained after DRE in patients with PCa may contain prostatic secretions and cells 
originating from the prostate tumour, which could serve as early biomarkers for PCa 
(Downes et al., 2006) and figure 2.1. A summary of urine biomarkers for PCa can be found 
in table 1.3. 
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Figure 2.1:  PCa TAA production and secretion into the urine and serum inducing 
autoantibody responses. 
After a prostatic massage, expressed prostate secretions are released into the urine which is 
believed to contain prostate fluids and detached epithelial cells from the prostate tumour. 
Simultaneously, these TAAs are also released from the prostate tumour into the 
bloodstream where they induce an immune response, which results in the production of 
serum autoantibodies against the TAA. Image adapted from Hospital Vita (2015). 
 
 
The analysis of urine for PCa biomarkers is not without its challenges – urine has a low 
overall protein content compared to serum (1000 fold lower than in plasma, typically <0.1 
mg/mL), high intra-and inter-individual variability and contains high salt and cell debris 
which interfere with proteomic research (Kiprijanovska et al., 2014). In spite of this, the 
use of proteomic technologies to identify potential urinary biomarkers for cancer in recent 
years has been on the rise. As a result, many attempts have been made to identify cancer 
biomarkers in urine for diagnostic or prognostic use due to the non-invasive nature and 
ease of collection of urine (from most patients) (Hessels and Schalken, 2013). 
 
In 1979, the first proteomic profiling of urine was carried out on healthy controls by 
Anderson et al. (1979), in order to determine differences and similarities in 2-DE spot 
patterns of urine. Since then, many studies have been attempted to characterise the urinary 
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proteome, employing an array of techniques such as 1-DE SDS PAGE and 2-DE or LC 
coupled to high resolution mass spectrometry, facilitating the identification of between 
1300 (Adachi et al., 2006) to 1800 proteins in normal human urine (Marimuthu et al., 
2011). From these studies, it is evident that we do not yet have a comprehensive view of 
the urinary proteome. In addition, the identification of all proteins present in the urinary 
proteome will greatly aid the discovery of biomarkers for various cancers. A number of 
studies have been carried out in urine to identify biomarkers for many urological related 
disorders and malignancies such as diabetic nephropathy (Rossing et al., 2008 and Sharma 
et al., 2005), prostate (Okamoto et al., 2009), colon (Ward et al., 2008) and bladder 
cancers (Gkialas et al., 2008). 
 
To date, candidate PCa urine biomarkers identified include Engrailed-2 (Morgan et al., 
2011), semenogelin and uromodulin (M’Koma et al., 2007), calgranulin/MRP-14 (Rehman 
et al., 2004), annexin A3 (Schostak et al., 2009), CD90 (True et al., 2010) and inter-alpha-
trypsin inhibitor heavy chain 4 (Jayapalan et al., 2013). These proteins have been identified 
using various proteomic techniques in independent studies, where the utility of these 
markers are yet to be validated in a larger, independent sample cohort. In addition, PCa is a 
heterogeneous malignancy in that, from a diagnostic perspective, it is unlikely that a single 
marker will have enough specificity and sensitivity for accurate cancer detection 
(Davalieva et al., 2015). Thus, it is well accepted that a panel of markers may be more 
likely to diagnose cancers (Coronell et al., 2012). For example, O’Rouke et al (2012) 
identified that a panel of autoantibodies consisting of TLN1, TARDBP, LEDGF, CALD1 
and PARK7 were better able to distinguish PCa from BPH, increasing the sensitivity from 
12.2% using PSA alone to 95% and 80% specificity for the panel. The aforementioned 
study thus highlights the necessity of carrying out more extensive analysis into well-
defined samples to identify a reliable diagnostic PCa biomarker or biomarker panel. 
 
In addition to urine proteins serving as biomarkers, the existence of neoantigenic peptides 
within a prostate tumour and the overexpression of TAAs, induces immune responses in 
patients, resulting in the production of specific autoantibodies (figure 2.1) and a selection 
of cytotoxic and Th (T helper) cells (Rauch and Gires 2008). These autoantibodies have a 
high affinity and specificity for their cognate antigenic protein and are present even when 
the TAA concentration is low, making them more suitable for use as early cancer 
biomarkers (Massoner et al., 2012). More recently, autoantibodies against alpha 2-HS 
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glycoprotein (Yi et al., 2009), NY-ESO-1 (Fujiwara et al., 2013), HSP60 (He et al., 2007) 
and AMACR (Sreekumar et al., 2004), have been identified in breast, gastric, colorectal 
and prostate cancer. Although many candidate markers have been identified, efforts are 
still made to discover new biomarkers for PCa. The identification of specific 
autoantibodies to tumour markers shed in the urine may aid in sensitive, early disease 
detection and therefore improved prognosis. 
 
PROTEOMEX, a method of tumour antigen identification, which combines serological 
screening using serum autoantibodies with proteomic identification by mass spectrometry, 
has been successfully utilised in the discovery of many TAAs (Lichtenfels et al., 2003; Le 
Naour et al., 201 and Tomaino et al., 2007 (section 1.3.7). In most of these studies 
however, the source of tumour antigens has been tumour tissue lysates and tumour cell line 
extracts (Rauch and Gires, 2008). To date, only one study by Yi et al. (2009) has screened 
sera from breast cancer patients for autoantibodies that may serve as biomarkers to urinary 
proteins. Due to the increased likelihood that urinary TAAs may be present in PCa, this 
chapter aimed to screen urinary proteins with autologous or allogeneic sera containing 
autoantibodies, for the identification of novel PCa associated TAAs. Autoantibodies 
reacting exclusively to proteins in urine are potential candidates which require further 
validation. To our knowledge, this is the first attempt to identify urinary TAAs in PCa 
using the PROTEOMEX approach.  
2.1.1   Aims & objectives 
 
The aim of this chapter is to identify urinary TAAs which can serve as potential PCa 
biomarkers following subsequent validation. This will be carried out by: 
1. Confirming that urine, a sample readily obtained from most PCa patients, contains 
PCa associated TAAs that react with PCa associated serum autoantibodies. 
2. Confirming that these PCa associated autoantibodies can be used to isolate their 
cognate antigenic protein using the PROTEOMEX method. 
3. Developing and optimising reproducible protein preparation, separation and 
immunoblotting conditions for PROTEOMEX. 
4. Identifying TAAs and autoantibodies associated with PCa using an optimised 
PROTEOMEX method. 
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2.2  METHODS 
 
 
Figure 2.2:  Method outline for urinary TAA identification. 
A flowchart summary of the methods used for the identification of urinary TAAs in this 
chapter. All equipments used throughout this study are listed in appendix I. 
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2.2.1  Prostate cancer serum and urine 
 
Matched serum and urine samples from PCa patients were collected and banked at the 
Urology Centre, Nottingham City Hospital, Nottingham, UK after obtaining ethical 
approval from the National Research Ethics Service Committee (NREC #09/H0S04/6). 
Males (n=26) aged 46-83 years, referred by their GP for high PSA levels (>4 ng/mL) and 
attending the urology clinic, were recruited after informed consent forms had been signed. 
Control serum and urine from matched patients were also provided by healthy volunteers 
(above 35 years) with no known history of PCa after ethical approval from Nottingham 
Trent University (Ethical number 165) and informed consent forms had been signed. 
 
In each case, 4 yellow top Vacutainer (Becton Dickinson, Oxford, UK) tubes containing a 
silicone clotting activator were filled with whole blood from PCa patients or healthy 
volunteers. Whole blood was thoroughly mixed in the Vacutainer tubes by inverting the 
tube 5 times and serum was obtained by allowing whole blood to coagulate at room 
temperature for 30 min. Clotted blood was removed by centrifugation at 300 g for 15 min 
at room temperature and 1 mL of each serum sample was aliquoted into sterile 1.5 mL 
Eppendorf tubes using a Pasteur pipette. Each sample was assigned a unique identification 
number, sent to the laboratory on dry ice, stored at -80˚C and thawed only prior to 
processing.  
 
First flow urine from PCa and healthy donors was collected into sterile 25 mL tubes and 
aliquoted into 1 mL aliquots. Each sample was assigned a unique identification number, 
stored at -80˚C and thawed only prior to processing. 
2.2.2  Urinary protein isolation and quantitation  
 
2.2.2.1 Urinary TAA identification in SDS PAGE 
 
Prior to protein harvesting from urine, urine samples were centrifuged at 500 g for 3 min at 
4ºC, to remove debris. 
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2.2.2.1.1 Protein harvesting from urine: Acetone precipitation 
 
Acetone precipitation of urinary proteins was performed in order to further concentrate and 
purify low volumes of urine samples which may still contain some contaminants such as 
salts, into a protein pellet which could be resuspended in a small volume of a solution 
compatible for downstream analysis. 
 
Prior to acetone precipitation, 200 mL of HPLC grade acetone was left at -20ºC overnight 
to ensure that the buffer was cold. 4 volumes of cold acetone were then mixed with 1 
volume of ultrafiltrated urine sample, and vortexed for 20 s. The mixture was chilled at -
80ºC for 10 min and then at -20˚C for 1 h. Precipitated proteins were isolated by 
centrifugation at 3000 g for 10 minutes at 4˚C. The supernatants were carefully aspirated 
and the pellet was allowed to air dry for 20 min at room temperature. Protein pellets were 
resuspended in 40 µL of PBS before protein concentration determination using the mini-
Bradford Assay.  
 
2.2.2.1.2 Urinary protein quantitation: Nanodrop mini Bradford 
protein assay (TECAN Ultra) 
 
Proteins from urine samples were quantified using a mini Bradford protein assay using the 
Nanodrop 8000 (Nanodrop 8000, Thermo Scientific). The mini Bradford assay has a linear 
range of 15-100 µg/mL making it ideal to quantify proteins in urine, which have a low 
protein concentration.  
 
To generate a linear standard curve, a 1:1 protein standard to dye ratio was prepared by 
diluting the BSA standard of 2 mg/mL in ddH2O to generate a serial dilution of protein 
standards of 100 µg/mL, 50 µg/mL, 25 µg/mL, 12.5 µg/mL, 6.125 µg/mL and 0 µg/mL 
(blank). 10µL of dye reagent and 10 µL of sample or standard was added into PCR 96 well 
plates and vortexed before incubating for 5 min at room temperature for colour 
development. The Nanodrop 8000 was calibrated by pipetting a 2.5 µL of ddH2O to 
initialise the Nanodrop machine. Standard curves and samples were then measured by 
pipetting 2.5 µL of the appropriate samples onto the sample pedestal before measuring 
absorbance at 595 nm. A blank sample was also assayed containing ddH2O and dye 
reagent, which was subtracted from each sample to generate a corrected absorbance at 595 
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nm. Each sample and standard was assayed in triplicate to obtain an average absorbance 
reading. Only R2 values greater than 0.98 were considered acceptable for protein 
estimation. 
 
2.2.2.2 Urinary TAA identification in 2-DE & OFFGEL/SDS  PAGE 
 
2.2.2.2.1 Protein harvesting from urine: Diafiltrate columns 
 
In order to isolate and concentrate proteins from urine, urine samples were processed using 
a combination of Vivaspin 20 protein concentrators and acetone precipitation. First, 
proteins from urine were isolated using Vivaspin 20 columns (2,000 MWCO, Sartorious 
Stedim, UK). Vivaspin concentrators use membrane ultrafiltration techniques and 
centrifugal force to concentrate and purify biological samples through a semi-permeable 
membrane. Proteins are concentrated using membrane pores which retain proteins greater 
than the molecular weight cut off (MWCO) of the concentrator, while water and salts pass 
through the membrane. As urine has a high salt (chloride 1.87 g/L; sodium 1.17 g/L), low 
protein (<0.1 mg/mL) and high water content (95% urine composition), ultrafiltration by 
membrane centrifugation was chosen to concentrate urinary proteins.  
 
Typically, 10 mL of PBS was pipetted onto a Vivaspin 20 columns and centrifuged at 3000 
g at 4ºC until all the PBS had passed through the membrane in the permeate. Urine samples 
were diluted 1:4 in PBS and 20 mL of this solution was loaded onto the Vivaspin column 
and centrifuged as before until 200 µL of urine was left in the column. This procedure was 
repeated until all the diluted urine samples had been filtered through the columns and the 
retentate was approximately 200 µL. The retentate was then pipetted out of the membrane 
concentrator into 1.5 mL Eppendorf tubes for further concentration by acetone 
precipitation. 
 
2.2.2.2.2 Urinary protein quantitation: Bradford protein assay 
 
Protein concentration of cell lysates was performed using the Bio-Rad Bradford protein 
assay according to the manufacturer’s instructions. This Coomassie based method is based 
on the colour change that occurs to proteins in the presence of the Coomassie dye. A 2 
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mg/mL BSA protein standard solution (Pierce, UK) was diluted to a 0.5 mg/mL working 
concentration and used to plot a standard curve with concentrations ranging from 0.05 - 
0.5mg/mL (diluted according to table 2.1). 
10 µL of BSA standard solution or protein sample was added into a flat bottom 96 well 
plate and mixed with 200 µL of Bio-Rad dye reagent (diluted 1 in 4 with ddH2O). After a 
5 min incubation at room temperature, the absorbance of the plates were measured at 
570 nm using a Tecan Ultra spectrophotometer (Tecan Group Ltd, UK). The calibration 
curve constructed with the BSA standard curve was used to determine the concentration of 
the unknown protein samples. Each sample and standard was assayed in triplicate. 
 
Table 2.1: BSA protein standards for Bio-Rad protein assay 
BSA concentration 
(mg/mL) 
ddH2O  
(µL) 
0.5 mg/mL BSA 
solution (µL) 
0.5 0 40 
0.4 8 32 
0.3 16 24 
0.2 24 16 
0.1 32 8 
0.5 38 2 
0  40 0 
 
A standard curve was plotted using the above dilutions of BSA and was used to 
determine the protein concentration of the unknown samples. R2 values greater 
than 0.98 were considered acceptable for protein estimation. 
 
2.2.3  Gel based protein separation 
 
2.2.3.1 SDS PAGE 
 
In all cases, 10% SDS PAGE gels were prepared as outlined in table 2.2 and cast using the 
mini gel system (Bio-Rad, UK). The solution was mixed in the order shown. First, 5 mL of 
the gel solution was poured into the casting frame and covered with a layer of 2-propanol 
to prevent dehydration and provide the gel with a flat surface. Gels were allowed to 
polymerise for 30 min at room temperature before the upper surface was rinsed with 
distilled water. 1 mL of the stacking gel solution was poured above the resolving gel and 
added with the 10 well comb (for 1-D SDS PAGE) or without combs (for 2-DE). Gels 
were left to polymerise for 30 min at room temperature. For 2-DE, a layer of isopropanol 
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was added to the top of the stacking gel to provide a flat surface for the IPG strips, instead 
of the addition of a 10 well comb. 
 
Table 2.2: The composition of 10% SDS PAGE resolving and stacking gels 
Solution Resolving gel Volume (mL) 
Stacking gel 
Volume (mL) 
Distilled H2O 6.0 2.44 
Protogel 30% Acrylamide solution (cat: EC-890) 4.94 0.52 
1.5 mM Tris-HCl 0.4% SDS pH 8.8 (cat: EC-892) 3.74 - 
0.5 mM Tris-HCl 0.4% SDS pH 6.8 (cat: EC-893) - 1.0 
10% (w/v) ammonium persulphate (cat: EC-504) 0.150 0.02 
TEMED (cat: EC-503) 0.015 0.004 
 
All solutions are electrophoresis grade and purchased from Geneflow National Diagnostics, UK. This solution can be 
used to prepare 2 resolving gels (approximately 15 mL) and 2 stacking gels (approximately 3 mL) for the Bio-Rad mini 
gel system. 
 
 
Glass plates were placed into the running tank containing 1x running buffer and the combs 
were removed. Protein lysates were prepared by mixing 20 µg of urinary proteins (or 50 µg 
of PCa cell lysate) with approximately 10-20 µL of sample reducing buffer, in a 3:1 
volume ratio, making a final volume of 25 µL to load onto each well of the polyacrylamide 
gel. The solution was left to denature at 95ºC for approximately 5 min, before loading into 
the wells of the polymerised SDS PAGE gels. 5 µL Precision Plus Protein molecular 
weight standards were also loaded into one well of each gel. To run the gels, gel tanks 
were filled with 1 L of 1 x running buffer (Geneflow National Diagnostics, UK) (diluted 1 
in 10 as per manufacturer’s instructions) and the sample was run for approximately 50 min 
at 200 V until the sample dye front reached the anodic side of the gel. 
 
2.2.3.2 2-DE 
 
To separate proteins by 2-DE, 20 µg of protein (urinary proteins or cell lysate) was mixed 
with sample rehydration buffer (Bio-Rad, UK) by aspirating and dispensing the solution 6 
times using a pipette. The lysates were vortexed for 5 min and subsequently pipetted along 
the length of the mini IPG chamber (Bio-Rad, UK). One 7 cm 3-10L IPG strip (Bio-Rad, 
UK) per experiment was placed gel face down over the sample and allowed to passively 
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rehydrate for 1 h at room temperature. After the incubation, each strip was overlaid with 
1.5 mL of mineral oil to prevent the strip from dehydration and urea crystallisation before 
placing it on the PROTEAN IEF cell chamber (Bio-Rad, UK). 
 
Strips were actively hydrated for 13 h 40 min at 20ºC at 50 µA/strip using a PROTEAN 
IEF cell followed by focussing at 250 V for 20 min (linear), 4,000 V for 2 h (linear), 
4,000 V for 10,000 V/h (rapid) and 500 V for 25 h (rapid). IPG strips were then transferred 
onto an equilibration tray where they were incubated for 15 min in equilibration buffer I 
(6 M urea, 2% (w/v) SDS, 20% (v/v) glycerol, 50 mM Tris pH 8.8 in nanopure water and 2% 
DTT) (Bio-Rad, UK), and a further 15 min in the same buffer replacing DTT for 
iodoacetamide (2.5% w/v) (Bio-Rad, UK). 
 
Next, the surface of the gels and IPG strips were rinsed in distilled water and 1 x running 
buffer respectively. 5 µL of precision plus protein molecular weight standards (Bio-Rad, 
UK) was pipetted onto a 50 mm x 50 mm Whatmann filter paper (SLS, Nottingham UK) 
and left to dry for 5 min before inserting in between the glass plates (above the 
polymerised gels). 100 µL of melted agarose (Bio-Rad, UK) was overlaid on the gels and 
the strips were inserted in between the glass plates. 300 µL of the melted agarose solution 
was then added above the IPG strip and left to set for 10 min before being mounted onto 
the Bio-Rad mini gel running tank and filled with 1 x running buffer and run as outlined in 
section 2.2.3.1. 
 
2.2.3.3 OFFGEL electrophoresis 
 
Sample fractionation prior to protein identification by mass spectrometry is essential for 
biomarker discovery studies. OFFGEL electrophoresis utilises immobilised pH gradient 
based isoelectric focussing (IPG IEF) and recovers separated proteins in liquid phase. 
Fractionated proteins can be digested and analysed by LC/MS or separated by SDS PAGE 
for protein identification. 
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Figure 2.3:  The principles of OFFGEL fractionation. 
Samples are separated and retrieved in liquid phase, where high voltage is applied to 
proteins allowing them to migrate until they reach a point where the pH equals the pI of the 
molecule. hv; high voltage. A: At the start, micro-wells are filled with sample and diluted 
in buffer. B: during the run, peptides/proteins migrate until they reach their isoelectric 
point. C: after the run, separated proteins remain in solution and can be removed using a 
pipette. 
 
OFFGEL fractionation was performed using an OFFGEL fractionator kit (Agilent 
Technologies cat: 5188-6425) according to the manufacturer’s instructions with minor 
modifications (Agilent 3100 OFFGEL Fractionator, Agilent Technologies, Cheshire, UK). 
Typically, OFFGEL stock solution was prepared by mixing the urea, thiourea, DTT and 
OFFGEL buffers provided with 50 mL ddH2O. This stock solution was used to prepare a 
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3-10 L IPG strip (Agilent Technologies cat: 5188-6431) rehydration and sample solution 
depending on the strip length as indicated below: 
Table 2.3: Preparing an OFFGEL protein IPG strip rehydration solution 
 24 cm strip 12 cm strip 
Protein OFFGEL stock solution 0.96 mL 0.56 mL 
ddH2O 0.24 mL 0.14 mL 
Total solution  1.2 mL 0.7 mL 
 
The OFFGEL stock solution was mixed in ddH2O to make a rehydration buffer for the 
IPG strips. 
 
Table 2.4: Preparing an OFFGEL sample solution 
 24 cm strip 12 cm strip 
Protein OFFGEL stock solution 2.88 mL 1.44 mL 
Sample 0.72 mL 0.36 mL 
 
The OFFGEL stock solution was mixed in sample an OFFGEL sample solution to aid 
separation by IEF focussing. 
 
For urine, 7 mg of protein (typically from 100 mL urine; or 5 mg from cell lysates) was 
prepared into pellets. Depending on the strip length, each pellet was resuspended in the 
appropriate volume of OFFGEL sample solution and left to vortex for 5 min at room 
temperature. Each 12 or 24 cm 3-10 (low resolution) IPG strip (Agilent Technologies, 
Cheshire, UK) was placed gel side up on an OFFGEL tray underneath a 12 or 24 well 
sample frame. 2 electrode pads were wet with rehydration solution and placed on each 
protruding end of the IPG strip. 40 µL of the rehydration solution was added into each well 
and the IPG strips were allowed to passively rehydrate for 15 min at room temperature. 
After the incubation, cover seals were applied onto the 12 or 24 well frames and 200 µL of 
mineral oil (Agilent Technologies, Cheshire, UK) was applied onto the anode ends of the 
gel and 400 µL to the cathode end (24 cm strip) or 200 µL and 200 µL (12 cm strip) to 
prevent the samples from drying up.  
 
After a min incubation, 200 µL of mineral oil was applied to both anodic and cathodic ends 
(12 and 24 cm strip) and after 3 min, 200 µL of mineral oil was pipetted onto the anodic 
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end (24 cm strip only) before allowing the samples to run using a manufacturer’s 
predefined method (table 2.5 below). The upper electrode pads were replaced with fresh 
pads wetted with deionised water every 24 h, and protein fractionation was performed until 
the samples had reached their isoelectric point; indicated by a flashing light on the 
OFFGEL fractionator. 
 
Table 2.5: Method for performing a 24 fraction OFFGEL strip 
 Volt Hours Volts Current Power Time 
Focussing 64.0 kVh 4500 V 50 µA 200 mW 100 h 
Hold - 500 V 20 µA 50 mW - 
 
OFFGEL fractionation using high resolution protein separation (pH 3-10, 24 cm strip) was run 
using the manufacturer’s default methods on the Agilent 3100 OFFGEL fractionator as 
described above. 
.  
Table 2.6: Method for performing a 12 fraction OFFGEL strip 
 Volt Hours Volts Current Power Time 
Focussing 20.0 kVh 4500 V 50 µA 200 mW 100 h 
Hold - 500 V 20 µA 50 mW - 
 
OFFGEL fractionation using low resolution protein separation (pH 3-10, 12 cm strip) was 
run using the manufacturer’s default methods on the Agilent 3100 OFFGEL fractionator as 
described above. 
 
 
After OFFGEL fractionation, the cover seals were removed and each liquid fraction was 
carefully removed from the chamber using a pipette and transferred into a 1.5 mL 
Eppendorf tube. Samples were stored at -20ºC until their analysis by SDS PAGE 
(described in section 2.2.3.1). 
2.2.4  Western blotting 
 
Separated proteins were transferred electrophoretically onto a nitrocellulose membrane 
(Amersham, UK) using a wet transfer method as follows. For each gel, a 9 x 6 cm square 
of nitrocellulose membrane and four pieces of 9 x 6 cm filter cards (SLS, Nottingham UK) 
were pre-soaked in transfer buffer (Geneflow National Diagnostics, UK) before 
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assembling the transfer stack in the following order: transfer sponge pad, 2 x filter paper, 
polyacrylamide gel, nitrocellulose membrane, 2 x filter paper and transfer sponge pad (as 
shown in figure 2.3).  
 
 
Figure 2.4:  Assembling the transfer stack. 
Western blots were arranged in the order shown with the nitrocellulose and SDS PAGE gel 
sandwiched in between 2 filter paper cards. 
 
 
Before the transfer procedure, the transfer sponge was submerged in transfer buffer in an 
appropriately sized glass container and gels were removed from the running tank before 
rinsing once in distilled water to remove excess running buffer and then once in transfer 
buffer. The ‘transfer sandwich’ was assembled as described above and air bubbles were 
eliminated from the ‘transfer sandwich’ by rolling an empty glass pipette over the 
nitrocellulose membrane. The transfer sandwich was placed into the transfer tank with cold 
transfer buffer solution and transferred electrophoretically at a constant voltage of 100 V 
for 60 min. Following transfer, the blotting efficiency was assessed by staining the 
nitrocellulose membrane with a ponceau S solution prior to immunoprobing. 
2.2.5  Ponceau S membrane staining 
 
After proteins had been transferred onto nitrocellulose membranes, they were visualised 
using a Ponceau S solution (Sigma, UK). To do this, nitrocellulose membranes were rinsed 
once in distilled water to remove excess transfer buffer before placing them into a plastic 
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tray containing 10 mL of Ponceau S solution. Membranes were allowed to incubate with 
the stain at room temperature for 5 min on a rocker before rinsing 4 times with 10 mL of 
distilled water until excess background stain was removed.  
To visualise the proteins, membranes were placed on a white laminated paper and 
visualised using a CCD camera (Fujifilm intelligent dark box, UK). After visualising 
stained bands or spots (1-DE or 2-DE respectively), each membrane was further destained 
by rinsing the membranes using distilled water until the bands were no longer visible.  
2.2.6  Coomassie blue staining 
 
In order to visualise stained proteins on polyacrylamide gels, gels were stained with a 
Coomassie brilliant blue solution (R-250, Phi-Bio, UK).  First, polyacrylamide gels were 
removed from the Bio-Rad running tanks and rinsed once with distilled water to remove 
excess running buffer. Each gel was placed in an appropriately sized plastic tray and 
incubated with 10 mL Coomassie blue solution and left rocking on an orbital plate shaker 
(VWR, Leicestershire, UK) overnight at room temperature.  
 
The following day, the stain was removed by pouring off excess Coomassie stain and the 
gel was rinsed 3 times in distilled water. Stained polyacrylamide gels were placed in a 
Coomassie destain solution and incubated again at room temperature for 1 h on a rocker. 
After this, gels were rinsed in distilled water and further incubated in fresh destaining 
solution. This procedure was repeated 3 times until the excess Coomassie blue had been 
eliminated and gel spots/bands were distinguishable from the background.  
2.2.7  Immunoprobing 
 
After proteins had been electrophoretically transferred onto nitrocellulose membranes, 
each membrane was incubated in a 3% blocking solution (3% Marvel milk powder in TBS 
0.1% Tween-20, Premier Brands, UK) to minimise non-specific binding of antibodies. 
Membranes were blocked for 1 h at room temperature on an orbital plate shaker and the 
blocking solution was subsequently discarded. To probe membranes with antibodies or 
sera for biomarker discovery, each blocked membrane was incubated in a pre-optimised 
antibody concentration (as stated in table 2.4), prepared in a fresh blocking solution 
containing 3% milk in TBS-0.1% Tween solution and left shaking at 4ºC overnight.  
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Table 2.7:  Optimised dilutions of primary antibody solutions for biomarker 
discovery 
Primary antibody Antibody dilution 
 SDS PAGE 2-DE & OFFGEL 
Patient sera 1:8 1:80 
Monoclonal anti-alpha enolase antibody (L-27) 1:1000 1:1000 
 
Antibody dilutions used in Western blotting for biomarker discovery using SDS PAGE, 2-DE & 
OFFGEL experiments. These dilutions were used for urinary proteins and PCa cell lines.  
 
Following immunoprobing, nitrocellulose membranes were rinsed twice in a TBST wash 
solution (TBS-0.1% Tween-20) to remove excess antibody solution. After this, membranes 
were washed 5 times for 10 min each by incubating them in the wash solution whilst being 
agitated on a rocker at room temperature, to remove unbound primary antibodies. To detect 
primary antibodies bound to proteins of interest, each membrane was incubated for 1 h in a 
HRP conjugated secondary antibody solution (1:1000 Dako polyclonal goat anti-mouse 
IgG for alpha enolase, or Dako polyclonal 1:1000 rabbit anti-human IgG for human sera). 
A 1:5000 dilution of Precision Plus molecular weight reference standard (Bio-Rad, UK) 
was also added to detect binding of the molecular weight ladder. Immunoprobed 
membranes were rinsed and washed as before to remove unbound secondary antibodies.  
 
After immunoprobing, nitrocellulose membranes were sprayed with a chemiluminescent 
substrate reagent spray (Calbiochem, UK) to detect the presence of horseradish peroxidase 
on probed immunoblots. Detection of chemiluminescent images was performed using a 
CCD camera (Fujifilm intelligent dark box, UK).  
2.2.8  Gel to membrane alignment: initial attempts 
 
Gel to membrane alignments were initially attempted using the Progenesis Samespot 
software (Nonlinear Dynamics, Newcastle, UK), which automates the image alignment of 
2D gels with any type of staining including DIGE and secondary staining. However, after 
numerous attempts, this software was unable to align an immunoprobed membrane to a 
stained gel. This meant that manual alignments of gel to membranes had to be performed. 
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2.2.8.1 Gel to membrane alignment: 2-DE 
 
In order to match potential tumour antigen spots on nitrocellulose membranes to their 
corresponding spots on the Coomassie stained gels, probed membranes were stained with 
Ponceau S solution and images were taken using a CCD camera. Before spot comparison, 
it was ensured that the images of the probed membrane and the stained gels membrane 
were identical in size and that the molecular weight ladders on both the polyacrylamide gel 
and nitrocellulose membranes were aligned to each other. Following ladder alignment, the 
most intense 2-DE spots (marker spots) on the membrane were matched to their 
corresponding spots on the stained polyacrylamide gel by comparing the spot to the nearest 
molecular weight standards. To do this, the vertical distance (distance a, figure 2.4) from 
the spot of interest to the nearest molecular weight standard was calculated and recorded 
along with the horizontal distance (distance b, figure 2.4) from the spot of interest to the 
nearest molecular weight standard.  
 
 
Figure 2.5:  Gel to membrane alignment. 
Alignment of 2-DE spots of interest on nitrocellulose membranes with polyacrylamide gels 
to facilitate TAA identification.  
 
Following alignment, the spot pattern of the membrane and the Coomassie stained gel were 
matched. This was achieved by comparing the size and shape of the protein spots on the 
stained gel image to the corresponding spot on the membrane. The spots were only 
considered the same if: 
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a.) The spot size and shape were similar in both the polyacrylamide gel and the stained 
membrane. 
b.) The antigen spot pattern surrounding the antigen spot of interest on the gel was 
matched to the spots on the blots.  
c.) The spot pattern of neighbouring spots resembled those on the immunoblots. 
 
After gel staining, immunoprobing and gel to membrane alignment, spots of interest were 
assigned a unique identification number to aid identification by MS. 
2.2.9   Identification of urinary TAAs 
 
2.2.9.1 Band extraction, spot picking and in-gel digestion 
 
After labelling spots of interest, polyacrylamide gels were rinsed twice in mass 
spectrometry grade water to remove excess Coomassie stain and a pipette tip was used to 
excise relevant spots for mass spectrometry. Each gel spot was cut into small 20 mm pieces 
using a sterile scalpel in order to increase the surface area for enzymatic digestion. Gel 
spots were placed in 1.5 mL Eppendorf tubes and stored at -20ºC until analysis. 
Upon analysis, gels were rinsed twice in mass spectrometry grade water and left agitating 
for 1 h at room temperature to eliminate excess protein stain. To further destain spots, 
200 µL of 200 mM of NH4HCO3 was added to each gel spot and left to shake with the 
spots for a further 15 min at room temperature, and subsequently discarded. In a fume 
hood, a 50:50 ratio of 200 mM NH4HCO3:100% ACN was also added to each Eppendorf 
to aid the destain procedure. The solution was left shaking on a rocker for 15 min and then 
heated for 2 min in a 37ºC incubator, to enhance the destain process. Heated gel spots were 
left to shake for a further 15 min at room temperature and the NH4HCO3:100% ACN 
mixture was then added to the previous sample and left shaking for a further 15 min. 
To allow access of the digestive enzyme (trypsin) to the gel matrix, gel spots were subject 
to a series of hydration and dehydration steps. First, 100 µL 100% ACN was added to the 
Eppendorf tube which was left to shake for 2 min before a further 100 µL NH4HCO3 was 
added and left to shake for a further 5 min. The solution was discarded and a further 
100 µL 100% ACN was added, to completely dehydrate the spots. As before, this was left 
to shake for 2 min, and then all the ACN was removed. To rehydrate the spots, 200 µL of 
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NH4HCO3 was added into Eppendorf tubes and left to shake for 5 min. The same volume 
of 100% ACN was added to the previous mixture and left shaking for 15 min. The liquid 
was discarded and 100% ACN was added to shrink the gel pieces, which was finally 
removed and gel spots were allowed to air dry in a fume hood. 
To allow the identification of potential tumour antigens, enzymatic digestion of proteins 
into peptides was employed using the enzyme trypsin (MS grade trypsin, Promega, UK). 
Trypsin digests proteins by cleaving polypeptide chains at the C terminal end of Lysine (K) 
or Arginine (R) residues except when followed by proline (P). To digest the gel spots, 
100 ng of trypsin diluted in 200 mM NH4HCO3 was added to the gel spots and left at 4ºC 
for 2 h to allow the diffusion of trypsin into the gel matrix. Then, 10 µL of NH4HCO3 was 
added with an additional 6.25 ng of trypsin and then the solution was incubated at 37ºC 
overnight (for a minimum of 15 h). 
 
2.2.9.2 Peptide extraction, Zip-Tip C18 sample clean-up and sample  
 spotting 
 
After sample digestion, peptides were extracted from the gel matrix using several steps. 
First, 7 µL of 1% TFA was added to the digestion mix. The supernatant, containing most 
of the peptides was collected and left on ice and a further 3.5 µL of 0.1% TFA was added 
to the gel spots and vortexed. The supernatant was collected from the gel spots and mixed 
with the previous supernatant to increase the yield of peptides by approximately 5-10%. 
Zip-Tip C18 pipette tips (Millipore, UK) contain a small bed of C18 chromatography media 
at their ends to purify and concentrate proteins and peptide samples before analysis by 
MALDI-TOF MS. Sample clean-up was performed using Zip-Tip C18 reverse phase 
chromatography columns according to the manufacturer’s instructions. First, pipettes were 
set to aspirate and dispense 10 µL solutions and ZipTip columns were wet for 4 cycles in 
80% ACN in 0.1% TFA to hydrate the columns. The columns were then equilibrated for 4 
cycles in 0.1% TFA. For maximum binding of peptides, peptides from the gel spots were 
aspirated and the liquid was expelled back into the sample for 20 cycles before 4 wash 
cycles in 0.1% TFA. Peptides bound to the ZipTip columns were eluted by aspirating and 
dispensing the tips for 20 cycles into a solution of 80% ACN in 0.1% TFA. During the 
binding cycle, air bubbles were avoided by pipetting the solution slowly to maximise 
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binding. The pipette plunger was prevented from fully being released during the elution 
steps. 
Eluted peptides were spotted onto a 384 MALDI ground steel target plate for analysis by 
mixing 1 µL of eluted peptides with the same volume of CHCA matrix (10 mg/mL). 1 µL 
of this mixture was spotted manually onto the MALDI target plate and allowed to air dry at 
room temperature until sample spots had crystallised on the target plate. For calibration 
spots, 1 µL of an external calibrant standard solution (Bruker peptide calibration mix II; 
Bruker Daltonics, Coventry, UK) was mixed with 9 µL of CHCA matrix and 1 µL of this 
mixture was spotted onto one spot of a ground steel target plate (Bruker Daltonics, 
Coventry, UK). 
 
2.2.9.3 Mass spectrometry 
 
2.2.9.3.1 Identification of 2-DE gel spots: MALDI TOF/TOF 
 
Extracted and digested gel spots were analysed on an ultraflextreme MALDI-TOF/TOF 
mass spectrometer (Bruker Daltonics, Coventry, UK) in positive reflectron mode. Matrix 
suppression was carried out in deflection mode, suppressing up to 650 Da at a sample rate 
of 4 GS/s. Data was collected over an m/z range of 800-4000 and calibration was 
performed using external standards of Bruker peptide calibration mix II (Bruker Daltonics, 
Coventry, UK). Monoisotopic peptide masses were recorded. 
Using a flexAnalysis software (Bruker Daltonics, Coventry, UK), MS spectra were passed 
to the BioTools software (Bruker Daltonics, Coventry, UK) where a Mascot PMF search 
(local Mascot Server version 2.2.) was initialised. The BioTools search programme was 
used to search the NCBI database. Typical search parameters were as follows; species: 
Homo sapiens, database: SwissProt, Oct 2012, enzyme: trypsin, variable modifications of 
carbamidomethylation of cysteine residues and oxidation of methionine residues. MS mass 
tolerance of 100 ppm and partials (missed cleavages): 2.  
Monoisotopic peptide peaks were selected in flexAnalysis and passed to flexControl 
software as precursor ions for MSMS. The MALDI-TOF instrument was set to positive 
LIFT mode and fragmentation data was collected for each selected peak. Data was then 
processed in flexAnalysis software to create an m/z and intensity list which was passed to 
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BioTools where a Mascot MSMS ion search was carried out with the following parameters: 
MS mass tolerance of 100 ppm and MSMS tolerance of 0.8 Da. All other parameters were 
the same as previously described.  
 CHAPTER 2: TAA identification in urine 
71 
 
2.3   RESULTS 
 
 
 
 
Figure 2.6:  Overview of the identification of urinary TAAs. 
The identification of urinary TAAs in this chapter is divided into 3 sections - identification 
using SDS PAGE, 2-DE and OFFGEL/SDS PAGE. 
 
2.3.1   Selection of the appropriate urine samples 
 
To date, no studies have demonstrated the presence of urinary TAAs in PCa using the 
PROTEOMEX method. However, this study was carried out with a hypothesis that TAAs 
are present in urine which can be isolated and identified using the PROTEOMEX 
technique. The hypothesis also proposed that urinary TAAs originating from the prostate 
tumour can be investigated as potential PCa biomarkers. To support these hypotheses, 
urine and matched serum from males attending the urology clinic at Nottingham City 
Hospital, were obtained prior to diagnosis. Although urine collected after a gentle prostatic 
massage is known to contain detached epithelial cells and prostatic secretions, making it an 
excellent biomarker source for PROTEOMEX, massaged patient urine was unavailable 
from this patient cohort. Urine samples from healthy volunteers at NTU were also 
collected, which served as a control. 
 
As this was a pilot experiment to establish the presence of PCa specific autoreactivity to 
urinary TAAs, it was important to demonstrate that the PROTEOMEX technology could 
isolate and identify differential urinary TAAs in a small sample cohort. Immunoscreening 
would be carried out using a larger sample cohort if pilot studies were successful. As a 
result, a small number of patients were randomly selected from the samples available. 
Table 2.8 outlines the samples utilised for this study, consisting of PCa (n=3), benign (n=3) 
and healthy control cases (n=3). 
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Table 2.8: Urine samples used for TAA identification by SDS PAGE 
Patient 
category 
Sample 
no. 
Age PSA 
(ng/mL) 
Gleason
1 
Gleason 
2 
Gleason 
grade 
D’Amico 
Risk 
TNM 
staging 
PCa PC01 71 5.4 3 4 7 Intermediate T2N0M0 
PCa PC02 69 7.9 3 4 7 Intermediate T2cN0M0 
PCa PC03 65 178 4 5 9 High T4N1M1b 
Benign BE011 56 4.9 3 4 7 Intermediate - 
Benign BE02 62 8 - - Benign - - 
Benign BE03 67 23.2 - - Benign - - 
Healthy HE01 33 - - - - - - 
Healthy HE02 36 - - - - - - 
Healthy HE03 48 - - - - - - 
 
All urine samples were collected prior to any diagnosis. 1 BE01 was initially diagnosed with BPH when 
samples were collected for this study. Subsequent examination of patient notes after study completion 
showed that BE01 was eventually diagnosed with Gleason 7 PCa. 
 
Before studies were conducted, a series of optimisation experiments were performed to 
determine the optimum conditions for desalting and concentrating urine prior to 
PROTEOMEX, the optimum protein concentration to load on SDS PAGE gels, and the 
serum dilution that showed the lowest background after spot detection. Optimisation 
experiments were also performed to determine stains which could detect proteins on 
replica gels and facilitate protein identification by mass spectrometry. All subsequent 
experiments were carried out using these pre-optimised conditions. 
2.3.2   TAA identification in urine by SDS PAGE 
 
In pilot experiments, urine was separated using 1-DE SDS PAGE and screened with 
allogeneic sera to determine the presence of PCa autoantibody specific reactivity to urinary 
proteins. In brief, 200 µL of urine was collected from each patient: PCa (n=3), benign (n=3) 
and healthy control subject (n=3) and pooled into 3 separate pools, to create a PCa, benign 
and healthy control pool. Each pool was acetone precipitated (section 2.2.2.1.1), and 
quantified using a BCA protein assay using a Nanodrop mini assay method (section 
2.2.2.1.2). 20 µg of total urinary protein from each pool was loaded in duplicate on 10% 
SDS PAGE gels, and run under denaturing conditions before transferring onto a 
nitrocellulose membrane. The transferred membrane was incubated with pooled allogeneic 
PCa sera (n=3) at a 1:8 dilution to detect the presence of PCa serum IgG based 
immunoreactivity to urinary proteins.  
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Figure 2.7A shows the immunoreactivities of PCa sera to allogeneic PCa, benign and 
healthy control urine, where most of the immunoreactivity to urinary proteins occurred in 
the 37-75 kDa molecular weight regions (highlighted in the red rectangle and enlarged in 
figure 2.7B). Figure 2.7A & 2.7B shows that pooled PCa sera detected multiple bands in 
allogeneic urine compared to reactivity in benign and healthy controls. An intense band 
was observed at 50 kDa, and this band was common to PCa, benign and healthy subjects. 
The 50 kDa band was thought to represent normal autoreactivity to PCa serum IgG, 
although this band was more intense in benign urine (figure 2.7A & 2.7B). Two fainter 
bands and a slightly more intense band were detected exclusively to allogeneic PCa urine 
at approximately 40, 44 and 48 kDa. At the same molecular weight (40–50 kDa) these 
bands were absent from benign and healthy urine (figure 2.7A and 2.7B). 
 
This study demonstrated differential reactivity patterns of pooled PCa sera to proteins in 
urine, which may be potentially of interest in PCa. As a result, all immunoreactive bands 
were excised from Coomassie stained replica gels and stored for subsequent identification 
by mass spectrometry. 
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Figure 2.7:  Western blotting showing the screening of PCa serum autoantibodies to 
  urinary proteins by SDS PAGE. 
Urine samples from 3 patients each with PCa, benign disease or healthy controls were 
pooled into 3 distinct pools – a PCa, benign or healthy pool and acetone precipitated. 20 µg 
of total protein from each pool was loaded in duplicate on a 10% polyacrylamide gel and 
immunoscreened for PCa autoantibody specific reactivity to urinary proteins. A 
representative immunoblot is shown in (A), while a cropped blot showing the most 
immunoreactive region 37-75 kDa is depicted in (B). L; molecular weight ladder. 
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It became apparent after inspection of the patient database that the benign samples utilised 
for this investigation and some of the benign patients in our sample database were 
diagnosed ‘benign with a possibility of cancer’. This caused some confusion as to whether 
these samples were truly benign or at a pre-malignant phase. Consequently, these samples 
were omitted from subsequent studies, in order to make the patient categories more 
stringent. 
 
2.3.2.1 Identification of frequency and specificity patterns in 
 autoreactivity 
 
PCa specific reactivity to urine proteins was observed in section 2.3.2, indicating that 
TAAs may be present in urine which can be utilised as potential biomarkers for PCa. 
Before immunoreactive bands were analysed by MALDI-TOF MS, it was important to 
determine the frequency and specificity patterns of serum autoantibody responses to 
urinary TAAs, as pilot experiments utilised pooled patient samples. To this end, two 
separate experiments were performed simultaneously. 
First, urine from each PCa patient and healthy control was separated by 10% SDS PAGE 
and probed with pooled allogeneic PCa sera (n=3) (same samples selected in section 2.3.1) 
(figure 2.8A). Figure 2.8A, shows a band at 50 kDa, present in all PCa and control urine 
samples. As before, this band was thought to represent normal autoreactivity to PCa serum 
IgG, the 50 kDa band was more intense in PC03 urine (Gleason 9). Most of the bands 
identified in figure 2.8A occurred in PC02 urine (Gleason 7; 3+4), where 4 moderately 
intense bands were observed at 50, 47, 43 and 40 kDa, and a much fainter band at 
approximately 39 kDa. A moderately intense band showing immunoreactivity of pooled 
PCa sera occurred at 40 kDa in PC03 urine (Gleason 9), while a less intense band was also 
observed at 39 kDa in urine from the same patient. Similarly, a faint band at 40 kDa was 
identified in PC01 (band observed in the 1st lane). 
Secondly, urine samples were separated as before, and probed with allogeneic PCa sera 
(figure 2.8B). Figure 2.8B shows that immunoblot 1 (PC01 urine screened with allogeneic 
PC01 sera) only detected bands at 50 kDa in both PCa and healthy urine, while 
immunoblot 2 (PC02 urine screened with PC02 sera) detected bands at 66 kDa and 50 kDa 
in both cancer and healthy urine. More intense bands were observed exclusively in PCa 
sera at approximately 46, 43 and 40 kDa, while a strong band was observed at 49 kDa 
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exclusively in healthy urine (HE02). Immunoblot 3 (PC03 urine screened with screened 
with PC03 sera) detected intense bands at 50 kDa in both cancer and control urine, 
moderately intense bands at 75 kDa and fainter bands at 42 and 40 kDa in PCa urine only. 
PC02 and PC03 in figure 2.7B display prominent bands in PCa urine that are not found in 
the healthy control urine or are much stronger than those of the control group. In figure 2.8, 
red arrows to the right of the immunoblots indicate bands that are detected in both PCa and 
healthy urine. Blue arrows indicate proteins in PCa urine reacting exclusively to allogeneic 
sera while green arrows indicate healthy urine proteins which immunoreact exclusively 
with PCa sera.  
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Figure 2.8:  Western blotting showing the allogeneic PCa sera screening of urine proteins to identify patterns and frequencies in 
immunoreactivity.  
Urinary proteins from each PCa and healthy subject was separated on 10% SDS PAGE gels and transferred onto nitrocellulose membranes, 
before probing with pooled PCa sera (1:8 dilution) (figure 2.8A). In figure 2.8B, urinary proteins were separated as before, and probed with 
allogeneic PCa sera (1:8 dilution). Red arrows on the right of the immunoblot indicate shared TAAs identified in PCa and healthy urine, green 
arrows indicate immunoreactivity exclusive to healthy urine, while blue arrows depict TAAs identified in PCa urine alone. A cropped blot at the 
most immunoreactive region (37 – 75 kDa) is shown for each Western blot. 
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2.3.2.2  Identification of TAAs that raise PCa autoantibody
 responses in urine by SDS PAGE 
 
Section 2.3.2.1 documents the reactivity patterns obtained from the allogeneic 
combinations of PCa sera and urine for PROTEOMEX studies, highlighting the 
importance of screening patients individually after a pooled PROTEOMEX study. Figure 
2.8B showed bands at 43 kDa and 40 kDa which were immunoreactive in PC02 and PC03 
urine (both bands were more intense in PC02 than PC03). As these were the most 
frequently observed bands showing exclusive reactivity to PCa sera, they were selected 
first for identification by LC-MS/MS. The PC03 43 kDa band was excised from a 
Coomassie stained replica gel and subject to an overnight in-gel digest with Trypsin. 
Peptides were cleaned up before spotting on an anchorchip target plate for fractionation by 
LC MS/MS. The acquired PMF was searched against the SwissProt database using the 
Mascot search engine to identify potential TAA candidates. Table 2.9 shows a list of 
significant protein hits identified from this band. 
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Table 2.9: Urinary proteins identified from PC03 urine at 43 kDa 
 
 
25 urinary proteins were identified from the immunoreactive 43 kDa band in PC03 urine. Protein hits are arranged in descending order of their Mascot ion score, 
where a Mascot on score >30 = significant. Score; Mascot ion score. SC; sequence coverage, #peptides; number of peptides identified. Proteins in asterisks 
indicate the top 20 abundant serum proteins. 
S/N Protein UniProt Accession Score MW [kDa] pI SC [%] # Peptides 
        
1 Prostatic acid phosphatase PPAP_HUMAN 626.94 44.54 5.81 25.39 14 
2 Ig gamma-1 chain C region * IGHG1_HUMAN 577.32 36.08 9.36 21.82 5 
3 Alpha-1-antitrypsin  * A1AT_HUMAN 515.04 46.71 5.27 23.92 5 
4 Zinc-alpha-2-glycoprotein ZA2G_HUMAN 483.27 34.24 5.66 28.19 7 
5 Ig gamma-4 chain C region * IGHG4_HUMAN 460.01 35.92 7.8 21.71 5 
6 Serum albumin * ALBU_HUMAN 385.78 69.32 5.88 14.61 10 
7 Ig gamma-2 chain C region * IGHG2_HUMAN 373.95 35.88 8.8 11.04 5 
8 Leucine-rich alpha-2-glycoprotein A2GL_HUMAN 308.18 38.15 6.51 23.92 4 
9 Vitamin D-binding protein VTDB_HUMAN 278.07 52.93 5.28 12.03 4 
10 Alpha-1-acid glycoprotein 1 * A1AG1_HUMAN 221.3 23.5 4.79 25.37 4 
11 Fibrinogen beta chain * FIBB_HUMAN 217.52 55.89 9.34 11 3 
12 Alpha-1-acid glycoprotein 2 * A1AG2_HUMAN 199.99 23.59 4.89 11.94 3 
13 Fibrinogen gamma chain * FIBG_HUMAN 187.53 51.48 5.27 7.73 2 
14 Monocyte differentiation antigen CD14 CD14_HUMAN 164.35 40.05 5.82 15.73 4 
15 Haptoglobin * HPT_HUMAN 128.61 45.18 6.13 12.07 3 
16 Gelsolin GELS_HUMAN 124.28 85.64 5.86 3.84 2 
17 Complement C4-A * CO4A_HUMAN 106.35 192.65 6.69 5.79 4 
18 Protein AMBP AMBP_HUMAN 95.21 38.97 5.91 3.41 1 
19 EGF-containing fibulin-like extracellular matrix protein 1 FBLN3_HUMAN 78.65 54.60 4.81 4.67 1 
20 Complement C3 * CO3_HUMAN 78.05 187.03 5.98 4.57 4 
21 Angiotensinogen ANGT_HUMAN 66.53 53.12 5.86 7.01 2 
22 Clusterin CLUS_HUMAN 46.51 52.46 5.86 3.79 1 
23 Ig heavy chain V-III region BRO * HV305_HUMAN 39.01 13.22 7 15.83 1 
24 Ankyrin repeat and SOCS box protein 18 ASB18_HUMAN 32.49 50.77 6.53 4.94 1 
25 Keratin, type I cytoskeletal 9 K1C9_HUMAN 32.11 62.03 5 5.14 1 
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The aim of this chapter was to determine whether urine, a sample easily obtained from 
most PCa patients contained TAAs, which could be utilised as a source of biomarkers for 
PCa following additional investigation. Using PROTEOMEX by SDS PAGE, this study 
demonstrated that differential bands were exclusively present in PCa urine compared to 
healthy (and benign) controls, which warranted their identification by mass spectrometry. 
One of the differential bands subject to MALDI TOF MS yielded 25 significant protein 
identities, making it difficult to determine which of the proteins in the list was responsible 
for the immune response observed. Table 2.9 shows that 52% of the identified proteins are 
high abundant proteins in serum (Millioni et al., 2011); and are likely to be present in urine 
due to the ultrafiltration of plasma proteins which occurs normally in urine, rather than due 
to a neoplastic process. 
 
From the 43 kDa gel band, prostatic acid phosphatase was identified as the protein with the 
most identified peptides (14 peptides) and the protein with the highest Mascot ion score 
(score 626.24 where a score >30 is significant), indicating identity or extensive homology 
to a known protein on the SwissProt database (p<0.05) and the protein with the 2nd highest 
peptide sequence coverage. In addition, the theoretical molecular weight of prostatic acid 
phosphatase is 44.5 kDa, close to the observed molecular weight of the immunoreactive 
band at 43 kDa in PC03. As a result, a conclusion was made that prostatic acid phosphatase 
was likely to be present in the 43 kDa band in PC03 urine. However, due to the limitation 
of the technology utilised in this study, it was not possible to determine whether or not 
prostatic acid phosphatase was responsible for eliciting the immune response in the 
patients studied. Zinc alpha-2-glycoprotein, a well-studied PCa biomarker was also 
identified as the protein with the third highest number of peptides and 4th most significant 
protein identified by MOWSE score (table 2.9). 
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2.3.2.3  Identification of the most significant protein hit (by Mascot 
score) as prostatic acid phosphatase 
 
Prostatic acid phosphatase was identified from 14 peptides (10 of which were considered 
significant) with a MOWSE score of 626.94 (where a score of >30 is significant), 
indicating identity or extensive homology to a known protein on the SwissProt database 
(p<0.05) (table 2.10). Figure 2.9A shows the complete protein sequence of human prostatic 
acid phosphatase where bold letters indicate all matched peptides by mass spectrometry. 
Tandem mass spectrometry of one of fourteen sequenced peptides of prostatic acid 
phosphatase, LSGLHGQDLFGIWSK is also shown in figure 2.9B, where the sequenced 
peptide has a Mascot ion score of 105 where a score of >30 is significant, indicating 
identity or extensive homology to a known protein on the SwissProt database (p<0.05) 
(figure 2.9C). 
 
Table 2.10: Prostatic acid phosphatase peptides identified from PC03 urine by LC 
MS/MS 
Protein  
Mascot 
ion 
score 
Sequence Variable Modifications 
      
Prostatic acid  30.24 FVTLVFR  
phosphatase 76.23 LHPYKDFIATLGK  
 105.08 LSGLHGQDLFGIWSK  
 62.51 RLHPYKDFIATLGK  
 90.93 LQGGVLVNEILNHMK  
 35.36 LQGGVLVNEILNHMK Oxidation (M) 
 83.08 LQGGVLVNEILNHMK Oxidation (M) 
 101.06 ELSELSLLSLYGIHK  
 36.96 LQGGVLVNEILNHMKR  
 27.85 LQGGVLVNEILNHMKR Oxidation (M) 
 108.73 LRELSELSLLSLYGIHK  
 1.69 SRLQGGVLVNEILNHMKR Oxidation (M) 
 13.51 ESSWPQGFGQLTQLGMEQHYELGEYIR  
 10.25 ESSWPQGFGQLTQLGMEQHYELGEYIR Oxidation (M) 
 
Using LC MS/MS, fourteen peptides were identified as prostatic acid phosphatase (where 10 were considered 
significant). The Mascot ion score for each sequenced prostatic acid phosphatase peptide is shown in table 
2.10, alongside any variable modifications. Mascot ion scores >30 indicate identity or extensive homology to 
a known protein on the SwissProt database (p<0.05).  
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Figure 2.9:  Identification of the immunoreactive 43 kDa band as prostatic acid 
phosphatase by LC MS/MS. 
A band at 43 kDa showing exclusive immunoreactivity to PCa sera (patient 03) was 
excised from a Coomassie stained replica gel and subject to identification by LC MS/MS. 
25 significant proteins were identified from this band where the most number of peptides 
and the highest MOWSE score was identified from prostatic acid phosphatase. Panel (A) 
shows the full length protein sequence of prostatic acid phosphatase where bold letters 
indicate all matched peptides by mass spectrometry, while (B) shows the identification for 
one of 14 sequenced peptides for prostatic acid phosphatase, LSGLHGQDLFGIWSK 
with an m/z 1657.9043. Panel (C) shows the Mascot ion score of LSGLHGQDLFGIWSK 
after matching the SwissProt database. The sequenced peptide has a MOWSE score of 105 
where a score >30 is significant, indicating identity or extensive homology to a known 
protein on the SwissProt database (p<0.05). 
 
 CHAPTER 2: TAA identification in urine 
83 
 
This pilot study demonstrated that differential TAA candidates are present in urine, which 
immunoreact with autoantibodies in PCa sera and can be isolated and identified using the 
PROTEOMEX technique in combination with mass spectrometry. However, the study 
highlighted the difficulty in identifying TAAs responsible for immune responses using this 
crude separation technique (SDS PAGE combined with identification by LC MS/MS). As 
a result, no further samples were analysed or identified by mass spectrometry until more 
fractionation was carried out prior to TAA identification. 
 
2.3.2.4 Verification of prostatic acid phosphatase expression in urine 
 
As this was the first attempt at PROTEOMEX in our laboratory, it was important to verify 
the presence of prostatic acid phosphatase in the samples studied. To this end, 20 µg of 
urinary proteins were isolated from samples that made up the discovery pool (n=3 PCa; 
n=3 healthy controls) and separated using 10% SDS PAGE gels. Separated proteins were 
then immunoblotted with a mouse-anti-prostatic acid phosphatase antibody (PASE/4LJ: 
SC-52354, Santa Cruz, UK) by Western blotting.  
 
Figure 2.10 demonstrates an intense band in just one sample (PC03) at 66 kDa while a 
moderately intense band was detected at 50 kDa. A similar expression pattern was 
observed in HE02 where low prostatic acid phosphatase expression was identified at 70 
kDa and a similar expression 50 kDa. No prostatic acid phosphatase expression was found 
in other PCa urine samples (PC01 & PC02) or healthy controls (HE01 & HE03). 
 
 
Figure 2.10:  Verification of prostatic acid phosphatase expression in urine.  
Urinary proteins from PCa patients and healthy controls were separated on 10% SDS 
PAGE gels and immunoblotted with a monoclonal mouse anti-prostatic acid phosphatase 
antibody (PASE/4LJ:SC-52354, Santa Cruz). An intense band at 66 kDa and a moderately 
intense band at 50 kDa was observed in one PCa patient (PC03). A similar expression 
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pattern was observed in HE02, where faint bands were detected at 70 kDa and 50 kDa 
respectively. 
 
 
2.3.3  TAA antigen identification in urine by 2-DE 
 
Section 2.3.2 demonstrates that direct identification of TAAs responsible for eliciting 
immune responses is not possible due to the complexity of protein mixtures which are 
present at every position in the lanes. This is further compounded by the difficulty in 
aligning Western blots to Coomassie stained SDS PAGE gels. As a result of the limitations 
of SDS PAGE, and because pilot studies showed promising results, the next phase of the 
study aimed to determine whether a fractionation step prior to SDS PAGE would offer the 
identification of more TAAs. The study therefore aimed to separate proteins from urine of 
patients with PCa and healthy controls by 2-dimensional electrophoresis (2-DE) using 
mini-gels with a pH gradient of 3 – 10. In theory, 2-DE would offer better separation of 
proteins, allowing a more accurate identification of TAAs that induce an immune response 
in PCa using PROTEOMEX and mass spectrometry. 
 
2.3.3.1 Selection of clinical samples for TAA identification in urine 
 by 2-DE 
 
PCa urine and matched patient sera collected from Nottingham University Hospital and 
Nottingham Trent University were utilised for this investigation. At the time of the study, 
only 3 volunteers had been recruited for our investigation and thus were available for 
biomarker discovery. These control samples could not be age matched to cancer patients 
due to the limited number of volunteers available. In addition, due to sample volume 
restraints, the same patient samples used to screen urinary proteins by SDS PAGE (section 
2.3.1) could not be used for 2-DE screening. Thus, urine from another set of patients 
recruited at the time of diagnosis, were chosen from the available samples collected. 
Patient samples utilised are outlined in table 2.11 - PCa n=26: Gleason 7 (3+4) (n=11), 
Gleason 7 (4+3) (n=10), Gleason 8 (n=2), Gleason 9 (n=3) and healthy controls (n=3). 
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Table 2.11: Patient samples used for TAA identification in urine by 2-DE 
Patient 
category 
Sample 
no. Age 
PSA 
(ng/mL) 
Gleason
1 
Gleason 
2 
Gleason 
grade 
D’Amico 
Risk TNM stage 
PCa PC04 56 4.9 3 4 7 Intermediate - 
PCa PC05 65 8.9 3 4 7 Intermediate - 
PCa PC06 71 5.4 3 4 7 Intermediate T2N0M0 
PCa PC07 69 7.9 3 4 7 Intermediate T2cN0M0 
PCa PC08 58 5.3 3 4 7 High T2cN0M0 
PCa PC09 57 3.6 3 4 7 Intermediate T2aN0M0 
PCa PC10 58 4.3 3 4 7 Intermediate - 
PCa PC11 63 10.5 3 4 7 Intermediate - 
PCa PC12 57 4.6 3 4 7 Intermediate - 
PCa PC13 68 6.8 3 4 7 Intermediate T2cN0M0 
PCa PC14 63 7.0 3 4 7 Intermediate - 
PCa PC15 62 11.3 4 3 7 Intermediate T2cN0M0 
PCa PC16 78 42.1 4 3 7 Mets - 
PCa PC17 68 5.3 4 3 7 High - 
PCa PC18 68 16.2 4 3 7 Intermediate T3bN0M0 
PCa PC19 72 9.3 4 3 7 Intermediate T2cN0M0 
PCa PC201 72 7.3 4 3 7 Intermediate T1/2N0M0 
PCa PC21 64 4.4 4 3 7 Intermediate T2N0M0 
PCa PC22 68 10.5 4 3 7 Intermediate T2cN0M0 
PCa PC23 63 13 4 3 7 Intermediate T1N0M0 
PCa PC242 65 0.05 - - - - - 
PCa PC25 67 7 4 4 8 High  T2aN0M0 
PCa PC26 65 178 4 5 9 Mets T4N1M1b 
PCa PC27 73 8.9 4 5 9 Mets T3aN1M0 
PCa PC28 69 82.5 4 5 9 High T3N0M1 
PCa PC29 68 10.4 4 4 8 High T3a/bN0M0 
Healthy HE01 33 - - - -  - - 
Healthy HE02 36 - - - - - - 
Healthy HE03 48 - - - - - - 
 
Urine samples were collected prior to any diagnosis. To identify autoantibodies to TAAs present in urine of 
PCa patients using 2-DE, patients from the following categories were selected at random and chosen for this 
study. A total of 26 PCa patients were chosen: Gleason 7 (3+4) (n=11), Gleason 7 (4+3) (n=10), Gleason 8 
(n=2), Gleason 9 (n=3) and healthy controls (n=3). 1; post biopsy haemorrhage, 2; prostatectomy sample. 
 
 
2.3.3.2 PCa and healthy sera immunoreactivity to urinary proteins 
 
To screen for TAAs, urinary proteins from a pool of PCa (n=26) or healthy (n=3) controls 
were prepared and separated by 2-DE as described in section 2.2.3.2. In brief, proteins 
were concentrated using molecular weight concentrators and acetone precipitated before 
protein quantification using a Bradford protein assay. 20 µg of pooled urinary proteins 
from PCa or healthy controls were separated by isoelectric focussing in the first dimension 
and SDS PAGE in the second dimension. Resolved proteins were visualised by Coomassie 
brilliant blue for spot picking or transferred onto nitrocellulose membranes for 
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immunoblotting. Membranes were incubated with a 1:80 dilution of pooled allogeneic PCa 
(n=26 patients) or healthy (n=3) sera as a source of primary antibody. 
 
Sera from PCa patients reacted with numerous spots, some of which were observed in the 
control group and thus considered representative of non-specific reactivity (figure 2.11). 
Although a lot of spots were observed from immunoblots, this study aimed to isolate the 
most obvious spots for TAA identification. From both immunoblots, differences in 8 spots 
were observed and circled in red, where 3 out of 8 spots (37%) reacted exclusively with 
PCa sera (spots 6, 7 and 8). One out of 8 spots (circled in red) showed exclusive reactivity 
with healthy sera (spot 1), while 50% of the spots reacted with both PCa and healthy sera 
(spots 2, 3, 4 and 5; figure 2.11). Of the immunoreactive spots occurring in PCa and 
healthy controls, 3 out of 4 spots (75% of the spots) were more intense in PCa (spots 2, 3, 
4), while spot 5 appeared more intense in healthy controls only (figure 2.11). Spots 
identified by both patient groups mainly occurred in the 40-100 kDa molecular weight 
range. 
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Figure 2.11:  Screening PCa serum autoantibodies against 2-DE separated urinary 
proteins.  
Urinary proteins from PCa (n=26) and healthy controls (n=3) were separated by 2-DE, 
transferred to nitrocellulose membranes and immunoblotted with sera from a pool of 
allogeneic PCa patients (Gleason 7, 8 and 9; n=26) or healthy controls (n=3). Immunoblots 
from healthy urine are shown in (A) and from PCa urine in (B) at the most immunoreactive 
region of the probed membrane (40-100 kDa). Circled spots indicate those chosen for mass 
spectrometry. 
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2.3.3.3 Identification of urinary TAAs that raise autoantibody 
 responses in PCa 
 
In order to identify immunoreactive TAAs, all circled spots were aligned to a Coomassie 
stained replica gel (figure 2.12) and corresponding spots were excised from the gel to 
allow identification by MALDI-TOF MS. Proteins were subject to an overnight in-gel 
tryptic digest (methods described in section 2.2.9.1) and peptides were cleaned up and 
spotted on a ground steel target plate. The acquired PMF was searched against the 
SwissProt database using the Mascot search engine to identify potential TAA candidates 
(search criteria described in section 2.2.9.3.1). 
 
 
Figure 2.12:  Gel to membrane alignment for TAA identification by 2-DE.  
Eight protein spots from healthy (A) or PCa urine (B) immunoreactive with pooled 
allogeneic PCa or healthy sera were labelled as shown above and aligned to a Coomassie 
stained replica gel (C). Immunoblots and replica gel shown are cropped around the 
molecular weight where immunoreactivity occurred (40–100 kDa). Each spot was excised 
from the Coomassie stained gel to facilitate protein identification by MALDI TOF MS/MS. 
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Although 8 spots were isolated from the replica gel, only 6 of them were matched to 
proteins on the SwissProt database (table 2.12). Among these, spots 3, 4, 6 and 7 were 
identified as the same protein, serum albumin with high significance (MOWSE score 65, 
119, 82 and 196 respectively; where a MOWSE score >56 is significant, indicating identity 
or extensive homology to a known protein on the SwissProt database (p<0.05) (table 2.12). 
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Table 2.12: Identified urinary TAAs from 2-DE immunoreactive to PCa or healthy sera 
 
Spot 
no. Protein UniProt Accession e. pI t. pI 
e. MW 
(kDa) 
t. MW 
(kDa) 
MOWSE 
Score 
Immunoreactivity with 
sera 
1 Alpha-1-acid glycoprotein 1 A1AG1_HUMAN 3.0 4.97 44 23.50 63/56 Healthy only 
2 Zinc-alpha-2 glycoprotein ZA2G_HUMAN 5.0 5.66 42 34.24 82/56 Healthy & PCa 
3 Serum albumin* ALBU_HUMAN 5.7 5.88 66 69.32 65/56 Healthy & PCa 
4 Serum albumin* ALBU_HUMAN 6.0 5.88 70 69.32 119/56 Healthy & PCa 
5 No protein identified - - - - - - Healthy & PCa 
6 Serum albumin* ALBU_HUMAN 7.0 5.88 55 69.32 82/56 PCa only 
7 Serum albumin* ALBU_HUMAN 9.0 5.88 73 69.32 196/56 PCa only 
8 No protein identified - - - - - - PCa only 
 
 
Identified urinary proteins from 2-DE immunoblots immunoreactive with allogeneic PCa or healthy sera. Only 6 spots were identified out of 8 analysed by PMF using MALDI-
TOF MS/MS.  63/56 = Mascot ion score of 63 where a score of >56 is considered significant. t; theoretical, e; experimental, pI; isoelectric point, MW; molecular weight. Proteins 
in asterisks indicate the most abundant protein in human serum. 
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2.3.3.4 Identification of the 42 kDa tumour antigen as zinc alpha-2- 
glycoprotein by mass spectrometry 
 
The most obvious difference between PCa and control immunoblots occurred in spot 2, 
which separated at 42 kDa and an approximate isoelectric point of 5 from its migration 
distance by 2-DE. Using PMF, spot 2 was identified as zinc alpha 2 glycoprotein with a 
MOWSE score of 82 (where a MOWSE score of >56 is considered significant) (table 2.12). 
Although 6 peaks were identified as zinc-alpha-2 glycoprotein by PMF and chosen for 
sequence analysis, only 4 of them were matched to zinc-alpha-2 glycoprotein by MS/MS 
(table 2.13). Figure 2.13A shows the whole sequence of zinc-alpha-2 glycoprotein, where 
bold letters indicate all four matched peptides by mass spectrometry. B shows the tandem 
mass spectra of one out of 4 peaks sequenced (m/z 2304.2483). The peak at m/z 2304.2483 
was identified as zinc-alpha-2 glycoprotein by the peptide sequence 
HVEDVPAFQALGSLNDLQFFR. Figure 2.13C shows that the fragmented peak yielded 
a MOWSE score of 208 where a score of >29 is significant, indicating identity or extensive 
homology to a known protein on the SwissProt database (p<0.05). 
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Figure 2.13:  Identification of immunoreactive spot 2 as zinc-alpha-2 glycoprotein.  
A single spot (spot 2) showing increased immunoreactivity in PCa sera was excised from a 
Coomassie stained replica gel and subject to identification by PMF using MALDI TOF 
MS/MS. Panel A shows the full length protein sequence of the only identified protein in 
this spot, zinc-alpha-2 glycoprotein, where bold letters indicate all 4 matched peptides by 
mass spectrometry. One of 4 peptides were chosen from PMF and subject to sequence 
analysis by MS/MS. Panel B shows fragmentation spectra of m/z 2304.2483 identified as 
zinc-α-2 glycoprotein by the peptide HVEDVPAFQALGSLNDLQFFR. Panel C shows 
the Mascot ion score of the peptide HVEDVPAFQALGSLNDLQFFR after matching the 
SwissProt database. The sequenced peptide has a MOWSE score of 208 where a score >29 
is significant, indicating identity or extensive homology to a known protein on the 
SwissProt database (p<0.05). 
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Table 2.13: Zinc-α-2 glycoprotein peptides identified from PCa urine by MALDI-TOF MS/MS 
 
Sample & protein m/z peak Mascot ion score SC (%) Peptide 
Spot 2: Zinc-α-2 glycoprotein 2403.2483 208/29 7% K.HVEDVPAFQALGSLNDLQFFR.Y 
 1451.6976 53/30 4% K.AYLEEECPATLR.K 
 1532.8020 71/30 4% K.QKWEAEPVYVQR.A 
 1276.6438 59/29 3% K.WEAEPVYVQR.A 
 2779.8086 - - No significant protein hit 
 804.2823 - - No significant protein hit 
 
Six peaks identified as zinc-α-2 glycoprotein by PMF were subjected to MALDI-TOF MS/MS. Four out of six peaks were matched to the zinc-α-2 glycoprotein 
protein on the SwissProt database. The Mascot ion score for each m/z peak is shown as well as its corresponding sequenced peptide. SC; sequence coverage. 
208/29; indicates a peptide with a MOWSE score of 208, where a score >29 is considered significant. 
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2.3.4  Tumour antigen identification in urine using a combined 
OFFGEL & SDS PAGE approach 
 
In an attempt to identify additional TAAs in urine and combat the issues of low 
reproducibility of 2-DE, another pI based protein separation method was employed using 
OFFGEL fractionation. This method was employed to determine if another method of 
separating proteins prior to PROTOMEX would yield more TAA candidates. 
 
2.3.4.1 ‘Proof of principle’ of the OFFGEL SDS PAGE approach in 
urine 
 
As this was a ‘proof of principle’ experiment to determine if OFFGEL electrophoresis 
could be utilised for PROTEOMEX, it was necessary to carry out pilot experiments to 
determine if urinary proteins could be fractionated by OFFGEL electrophoresis. In brief, 
100 mL of urine from a healthy male (HE03; table 2.8) was centrifuged to remove debris 
and concentrated using molecular weight cut-off columns (section 2.2.2.2.1). Urine was 
precipitated with acetone and quantified before mixing with an OFFGEL sample buffer 
and run as suggested by the manufacturer (pH 3-10, low resolution OFFGEL strips). Each 
fraction was separated using 10% SDS PAGE gels and transferred onto nitrocellulose 
membranes before immunoprobing with a 1:1000 dilution of mouse monoclonal anti-
human alpha enolase antibody (L-27, Santa Cruz, UK). 
 
Figure 2.14 shows intense bands at 47 kDa in fraction 8 while weaker expression was 
identified in fraction 6, 7, 9, 10 and 11. Strong expression of alpha enolase was also 
detected at approximately 66 kDa. Efficient OFFGEL fractionation had also been 
demonstrated using the metastatic PCa cell line, DU-145 (characteristics of this cell line is 
outlined in table 3.1), which was utilised as a control against OFFGEL fractionation in 
urine. The same pattern of expression for alpha enolase was observed in DU-145 using a 
monoclonal mouse anti alpha enolase antibody, where alpha enolase was only detected in 
fractions 7, 8, 9, 10 & 11 and 12 (appendix II).  
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Figure 2.14:  Proof of principle of OFFGEL SDS PAGE methodology in urine.  
100 mL of healthy male urine was concentrated and acetone precipitated before 
fractionation by OFFGEL electrophoresis (pH 3-10, low resolution IPG strips). OFFGEL 
fractions were separated using a 10% SDS PAGE gel and probed with a monoclonal mouse 
anti-alpha enolase antibody. Strong expression of alpha enolase at 47 kDa was observed in 
fraction 8, while weaker expression was identified in fraction 6, 7, 9, 10 and 11 using this 
antibody. Alpha enolase expression was also identified in fraction 6 at 66 kDa. 
 
2.3.4.2 Identification of urinary TAAs and serum autoantibodies 
using OFFGEL and SDS PAGE 
 
‘Proof of principle’ studies using alpha enolase (section 2.3.4.1) demonstrated that 
OFFGEL fractionation can successfully be applied to urine samples, showing the 
separation of urinary proteins into discrete fractions based on their pI. By Western blotting, 
correct expression of alpha enolase at specific fractions (pI 6-9) corresponding to its 
theoretical pI (pI 7.01) and molecular weight (47 kDa) was observed. However, successful 
OFFGEL electrophoresis requires a minimum of 0.5-5 mg total protein (manufacturer’s 
recommendations), typically requiring 5-50 mL of patient urine for a single OFFGEL strip. 
Due to the limited volumes (and as a result, protein concentration) of urine collected for 
this study, it was not feasible to carry out OFFGEL electrophoresis for PROTEOMEX. 
However, an attempt was made to screen sera from PCa and healthy controls for 
autoantibodies, which may serve as potential biomarkers that are immunoreactive towards 
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proteins in urine. To screen for PCa associated TAAs and autoantibodies, a combined 
OFFGEL and SDS PAGE approach was applied. Samples utilised for this study are 
outlined in table 2.14.   
 
Table 2.14: Urine samples used for TAA/autoantibody identification by OFFGEL & 
SDS PAGE 
Patient 
category 
Sample 
no. Age 
PSA 
(ng/mL) 
Gleason 
1 
Gleason 
2 
Gleason 
grade 
D’Amico 
Risk TNM 
PCa PC30 76 20.5 4 5 9 High - 
PCa PC31 71 39.6 4 5 9 High - 
PCa PC32 51 10.9 4 5 9 High T3aN0M0 
PCa PC33 74 8.7 4 5 9 High - 
PCa PC34 59 86.8 4 5 9 High - 
Healthy HE04 38 - - - Healthy  - - 
Healthy HE05 35 - - - Healthy - - 
Healthy HE06 51 - - - Healthy - - 
Healthy HE07 38 - - - Healthy - - 
Healthy HE08 60 - - - Healthy - - 
 
Urine samples were obtained prior to any diagnosis. To identify TAAs and autoantibodies for PCa, patients 
from the following categories were selected at random and chosen for this study. A total of 5 PCa patients 
were chosen: Gleason 9 (n=5) and healthy controls (n=5). 
 
As in the previous section, urinary proteins from healthy controls (n=5) were prepared (as 
described in section 2.2.2) and fractionated using a low resolution IPG strip (pH 3-10). 
Acidic fractions (fractions 1-9) were then separated using 10% SDS PAGE gels and 
immunoprobed with pooled PCa (n=5) or allogeneic healthy sera (n=5). Figure 2.15 shows 
that a similar pattern of reactivity was observed in immunoblots probed with PCa sera 
(figure 2.15A) and healthy sera (figure 2.15B), where bands were detected at 50 kDa in 
PCa and healthy urine (fraction 1 and 2). From figure 2.15A and 2.15B, bands at 45 kDa 
were observed exclusively to PCa sera in both fraction 3 and 4, where no autoreactivity 
was observed towards healthy urine at the same molecular weight and pI. In the 6th, 7th, 8th 
and 9th fraction, the same immunoreactivity pattern was observed towards PCa and healthy 
sera with proteins at 50 kDa, 49 kDa, 48 kDa and 48 kDa respectively, which was thought 
to represent normal autoreactivity to serum IgG. No bands were detected in fraction 5 in 
either immunoblots. 
 From figure 2.15, the most obvious difference between PCa and healthy immunoblots 
occurred in fractions 3 and 4, where a moderately intense band was detected exclusively at 
45 kDa in PCa urine (fraction 3, figure 2.15). Similarly, a less intense band was observed 
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exclusively in fraction 4 from pooled PCa urine. Each immunoreactive band was sub-
divided into two (figure 2.15C) in order to reduce the protein complexity during 
identification. All 4 bands were excised from Coomassie stained replica gels and subject to 
a tryptic overnight in-gel digest. 
 
Figure 2.15:  PROTEOMEX screening of urinary TAAs separated by a combined 
OFFGEL and SDS PAGE approach, using allogeneic PCa and healthy 
sera.  
Urinary proteins from PCa (n=5) and healthy controls (n=5) were separated by low 
resolution OFFGEL (3-10) and then by 1-D SDS PAGE (10% gels). Gels were transferred 
to nitrocellulose membranes and immunoblotted with sera from a pool of PCa sera (A) or 
allogeneic healthy sera (B). C shows highlighted bands chosen for mass spectrometry. 
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2.3.4.3 Identification of urinary TAAs by electrospray LC-MS/MS 
 
ESI MS/MS was the mass spectrometry method chosen to identify potential TAA 
candidates due to the previous issues determining which protein was responsible for the 
immune response. In addition, this was a new instrument acquired by our laboratory and as 
such, this was the first time it was used to demonstrate its compatibility with 
PROTEOMEX. 
After an in-gel digest, samples were cleaned up using a C18 ZipTip column and subjected 
to identification by electrospray coupled to a LC system. As shown in figure 2.14, 2 
immunogenic bands, which separated at approximately 45 kDa in fractions 3 and 4, were 
isolated for TAA identification. Tables 2.15-2.17 show the proteins identified from each 
gel band at the appropriate FDR cut off level, corresponding to bands 1, 2 and 4. No 
proteins were identified from immunogenic band 3. 
 
Table 2.15: Urinary proteins present in the immunogenic 48 kDa band; fraction 3 
(band 1) 
 
Urinary proteins identified from the immunoreactive band at 45 kDa (1). Fifteen proteins and 43 peptides 
were identified by LC ESI-MS at the appropriate 1% FDR cut-off. SC; sequence coverage at a 95% 
confidence interval. #peptides; number of peptides identified. Proteins in double asterisks indicate the most 
abundant protein in human urine. 
 
  
S/N Protein name UniProt Accession MW (kDa) 
SC 
(95%) 
# 
Peptides 
      
1 Actin, cytoplasmic 2 ACTG_HUMAN 41.79 21.87 8 
1 Actin, cytoplasmic 1 ACTB_HUMAN 41.74 21.87 8 
2 Uromodulin ** UROM_HUMAN 69.76 9.06 6 
3 Osteopontin OSTP_HUMAN 35.42 14.97 5 
4 Trypsin-1 TRY1_HUMAN 26.56 17.41 7 
4 Putative trypsin-6 TRY6_HUMAN 26.54 13.36 6 
4 Trypsin-2 TRY2_HUMAN 26.49 9.31 5 
5 Protein AMBP AMBP_HUMAN 39.00 14.49 4 
6 Protein YIPF3 YIPF3_HUMAN 38.25 5.43 3 
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Table 2.16: Urinary proteins present in the immunogenic 48 kDa band; fraction 4 
(band 2) 
 
Urinary proteins identified from the immunoreactive band at 45 kDa (2). 0 proteins and 8 peptides were 
identified by LC ESI-MS at the appropriate 1% FDR cut-off. SC; sequence coverage at a 95% confidence 
interval. #peptides; number of peptides identified.  
 
 
Table 2.17: Urinary proteins present in the immunogenic 43 kDa band; fraction 4 
(band 4) 
 
Urinary proteins identified from the immunoreactive band at 45 kDa (4). 34 proteins and 105 peptides were 
identified by LC ESI-MS at the appropriate 1% FDR cut-off. SC; sequence coverage at a 95% confidence 
interval. #peptides; number of peptides identified. Proteins in asterisks indicate the top 20 most abundant 
proteins in human serum. 
 
In this study, ESI MS/MS identified previously discovered proteins of interest - zinc-alpha 
2 glycoprotein, prostatic acid phosphatase and serum albumin (table 2.17). 
S/N Protein name UniProt Accession MW (kDa) 
SC 
(95%) 
# 
Peptides 
      
1 Actin, cytoplasmic 2 ACTG_HUMAN 41.793 19.73 6 
1 Actin, cytoplasmic 1 ACTB_HUMAN 41.737 19.73 6 
2 Trypsin-1  TRY1_HUMAN 26.558 22.67 5 
S/N Protein name UniProt Accession MW  (kDa) 
SC 
(95%) 
# 
Peptides 
      
1 Serum albumin* ALBU_HUMAN 69.37 22.50 14 
2 Trypsin-1 TRY1_HUMAN 26.56 17.81 13 
3 Prostaglandin-H2 D-isomerase PTGDS_HUMAN 21.03 31.58 7 
4 Zinc-alpha-2-glycoprotein ZA2G_HUMAN 34.26 28.86 6 
5 Prostatic acid phosphatase PPAP_HUMAN 44.57 20.73 6 
6 Gelsolin GELS_HUMAN 85.70 13.17 6 
7 Actin, cytoplasmic 2 ACTG_HUMAN 41.79 18.13 5 
7 Actin, cytoplasmic 1 ACTB_HUMAN 41.74 18.13 5 
8 Vesicular integral-membrane protein VIP36 LMAN2_HUMAN 40.23 14.89 3 
9 Kininogen-1 KNG1_HUMAN 71.96 5.28 3 
10 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4_HUMAN 103.36 6.67 3 
11 Clusterin CLUS_HUMAN 52.50 11.58 3 
12 Beta-glucuronidase BGLR_HUMAN 74.73 4.76 3 
13 Ig alpha-1 chain C region* IGHA1_HUMAN 37.66 5.38 2 
14 Apolipoprotein D APOD_HUMAN 21.28 10.58 2 
15 Protein AMBP AMBP_HUMAN 39.00 7.67 4 
16 Endothelial protein C receptor EPCR_HUMAN 26.67 10.92 2 
17 Cathepsin B CATB_HUMAN 37.82 7.67 2 
18 Ig kappa chain C region* IGKC_HUMAN 11.61 49.06 2 
19 Polymeric immunoglobulin receptor PIGR_HUMAN 83.28 3.53 2 
20 D-3-phosphoglycerate dehydrogenase SERA_HUMAN 56.65 3.94 2 
24 Putative trypsin-6 TRY6_HUMAN 26.54 17.81 12 
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2.4   DISCUSSION 
 
A PROTEOMEX based approach was implemented to identify proteins that elicit a 
humoral immune response in PCa. Using SDS PAGE, 2-DE, OFFGEL and Western 
blotting, urine from PCa, benign and healthy controls were screened with pooled 
allogeneic PCa sera to identify TAAs that react to autoantibodies in PCa. Unlike other 
studies that utilise cell lines and tumour tissues as an antigenic source (Rauch and Gires, 
2008), this study employed urinary proteins to study PCa induced immune responses. 
Although urine collected after a DRE contains prostatic secretions and detached epithelial 
cells, making massaged urine excellent for TAA identification & biomarker discovery 
(Downes et al., 2006), this study was carried out to identify if PCa specific immune 
responses could be observed, allowing the identification of PCa specific TAAs in non-
massaged urine. 
2.4.1  TAA identification by SDS PAGE 
 
Urinary proteins from PCa, benign and healthy controls were screened for seropositivity to 
pooled allogeneic PCa sera. Figure 2.6 demonstrates the presence of differential bands 
exclusive to allogeneic PCa urine at 40, 44 and 48 kDa, which was absent from the control 
groups (figure 2.6A and 2.6B), suggesting the specificity of this immune response to PCa. 
In order to determine the frequency and specificity patterns of the immune responses 
observed, urine from all patients were separated by SDS PAGE (section 2.3.2.1) and 
screened with pooled allogeneic PCa sera (figure 2.7A) or autologous sera (figure 2.7B). 
Figures 2.7A & 2.7B illustrates that most immunoreactivity was detected in PC02 (Gleason 
7 PCa), with a minimum of 2 bands observed per seropositive patient screened (figure 
2.7A). Figure 2.7B shows that apart from the bands that occurred in all patients at 50 kDa, 
no other bands were detected in PC01, while two additional bands were observed in PC03 
and 3 bands in PC02, demonstrating that no two patients displayed the same pattern of 
antigenicity. 
 
Although it would have been of interest to screen urinary proteins with healthy sera to 
determine autoreactivity patterns of urinary proteins to healthy serum IgG, healthy serum 
was not available at the time of the study. Nevertheless, carrying out various combinations 
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of allogeneic screening (figure 2.7A and 2.7B) demonstrated the varying reactivity patterns 
in the allogeneic combination of urine and serum. 
 
A 42 kDa band in PCa urine was exclusively recognised by sera from PC03 (Gleason 9, 
figure 2.7B), and identified by LC MALDI TOF/TOF. Among the 25 significant proteins 
identified by this band using LC-MALDI TOF/TOF, a well-studied PCa biomarker, 
prostatic acid phosphatase was identified (and verified in figure 2.9) with the most number 
of peptides and the highest MOWSE score (table 2.9). Human prostatic acid phosphatase is 
a prostate epithelium-specific differentiation antigen with significantly higher activity in 
PCa patients, especially those with bone metastasis compared to its expression in healthy 
controls (Gutman et al., 1936). This is consistent with findings from this study where 
prostatic acid phosphatase was identified and verified in the only patient with metastasis 
(figure 2.9). In PCa, prostatic acid phosphatase activity correlates with tumour progression 
and may also serve as an indicator of treatment response (Huggins & Hodges, 1941). 
Prostatic acid phosphatase expression has also been shown to serve as an independent 
predictor of biochemical failure and tumour recurrence following radical prostatectomy 
(Veeramani et al., 2005). As a result, prostatic acid phosphatase was the preceding PCa 
biomarker prior to PSA. Prostatic acid phosphatase is secreted glycoprotein enzyme (100 
kDa) synthesised by prostate columnar epithelium secretory cells (Vihko et al., 1978) 
where it may be involved in fertility and the liquefaction of semen (Afzal et al., 2003).  
 
It is tempting to hypothesise that prostatic acid phosphatase could be responsible for the 
immune response observed in this study - it is well documented that prostate cancer is an 
immunogenic tumour and humoral immune responses to prostatic acid phosphatase have 
previously been identified by many researchers, similar to this study (McNeel et al., 2000 
and GuhaThakurta et al., 2015). However, due to the limitation of the technology utilised 
in this study, such conclusions cannot be drawn. What can be concluded is that prostatic 
acid phosphatase is present in the urine of PC03 as identified and verified by mass 
spectrometry and Western blotting (figures 2.9 & 2.10). In order to demonstrate the 
presence of autoantibodies to prostatic acid phosphatase and whether prostatic acid 
phosphatase was responsible for the immune response observed in PC03, it would have 
been beneficial to carry out an ELISA assay using a recombinant prostatic acid 
phosphatase protein screened with PC03 sera. This, in combination with results by mass 
spectrometry would determine whether prostatic acid phosphatase was responsible for the 
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immune response observed at 42 kDa in PC03; as implied by the findings from this study. 
Only then can conclusions be made to whether prostatic acid phosphatase is responsible for 
the immune response observed. Furthermore, in order to determine if prostatic acid 
phosphatase could serve as a potential PCa biomarker, an ELISA assay could be carried 
out to screen a range of PCa patient and healthy urine for differences in the concentration 
of prostatic acid phosphatase protein. 
 
Other proteins identified from this gel band represent the top 20 high abundant serum 
proteins (52% of proteins identified) (high abundant proteins indicated by asterisks in table 
2.9), likely present in urine due to the ultrafiltration of plasma proteins which occurs 
normally in urine, rather than due to a neoplastic process. The identification of diagnostic 
biomarkers in human urine or serum using mass spectrometry based proteomics, is 
hindered by the large dynamic range of serum based proteins and because 22 of the most 
abundant proteins in serum make up approximately 99% of the total serum proteome 
(Prieto et al., 2014). Thus, although immunodepletion of these high abundant proteins (e.g. 
albumin) facilitates the detection of lower abundant biomarkers, high abundant proteins 
serve as a potential source of biomarkers due to the protein fragments or peptides that 
interact with this high abundance group (Dowling et al., 2014). As a result, it is likely that 
these bound, low abundant peptides/fragments may be responsible for eliciting the immune 
response in PC03. However, without an added immunodepletion step to eliminate these 
high abundant proteins, it is not possible to identify the TAA of interest using this 
technology. 
 
Amongst the 25 significant proteins identified, zinc-alpha-2 glycoprotein (identified with 
the 4th highest MOWSE score, 4th highest sequence coverage and 3rd highest number of 
peptides); and this has been established to have diagnostic significance in PCa (Hale et al., 
2001). Hale et al. (2001) identified that high grade tumours expressed significantly less 
tissue zinc-alpha-2 glycoprotein than moderate grade tumours. In addition, they found that 
in men with zinc-alpha-2 glycoprotein positive tumours had higher serum zinc-alpha-2 
glycoprotein levels compared to their race and age matched controls. They also 
demonstrated that tumour produced zinc-alpha-2 glycoprotein contributes to an elevated 
concentration of serum zinc-alpha-2 glycoprotein, by detecting human zinc-alpha-2 
glycoprotein in the serum of mice bearing an hZAG-B16 transfected tumour. Their study 
demonstrates that zinc-alpha-2 glycoprotein production can be useful for diagnostic 
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purposes (Hale et al., 2001). As zinc-alpha-2 glycoprotein was identified by 3 separate MS 
identification methods, it would have been beneficial to determine if zinc-alpha-2 
glycoprotein could serve as a potential PCa biomarker. This could be achieved by 
screening urine samples from a range of PCa and healthy controls for differences in zinc-
alpha-2 glycoprotein protein expression using a quantitative proteomic method such as 
ELISA assay. However, due to time and feasibility constraints, this was not carried out in 
this study. 
 
Overall, TAA identification by SDS PAGE demonstrated that direct identification of 
antigens that elicit an immune response is not possible due to the complexity of protein 
mixtures which are present within every lane on SDS PAGE gels (Forgber et al., 2009). In 
addition, one of the main drawbacks to using pooled samples is that we cannot be sure how 
many patients in the pool have the specific reactivity patterns observed. Due to time, 
feasibility and the limitation in technology utilised, it was not possible to screen each 
patient individually. However, the pilot study has identified PCa relevant biomarkers, 
establishing that these TAAs are present in urine and can be isolated and identified using 
PROTEOMEX in combination with more protein fractionation prior to mass spectrometry. 
2.4.2  Urine TAA identification by 2-DE 
 
The combination of low resolution 2-DE (pH gradient of 3-10) for isoelectric focussing, 
with serum immunoblotting proved to be a suitable technique to reduce the complexity of 
proteins identified after the PROTEOMEX screen. Although 2-DE showed a separation of 
protein bands into spots, which potentially contain a smaller number of proteins compared 
to SDS PAGE, only 8 spots were immunoreactive to PCa or healthy sera from this study 
and thus were shortlisted for identification by mass spectrometry (figure 2.10). Comparing 
both studies; TAA identification by SDS PAGE (section 2.3.2) and using 2-DE (section 
2.3.3), it is evident that more immunoreactivity was observed in the 2-DE than with SDS 
PAGE alone (at molecular weights 37-75 kDa, 4 unique bands were observed in SDS 
PAGE (figure 2.6) and 8 unique spots (figure 2.10) by 2-DE). All 8 spots were aligned to 
protein spots on Coomassie stained gels, where only 6 of them were identified as 3 proteins 
after matching them to the SwissProt database – alpha-1-acid glycoprotein 1 (spot 1), zinc-
alpha-2 glycoprotein (spot 2) and serum albumin (spot 3, 4, 6 & 7) (table 2.12). 
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Interestingly, these same proteins were identified previously in the 1-D SDS PAGE screen 
(proteins #4, #6 and #10, table 2.9) as potential PCa TAAs; though a different set of patient 
samples had been used. Spots 3, 4 (appeared in healthy & PCa urine), 6 and 7 (PCa urine 
only; figure 2.10) were identified using PMF as albumin, the most abundant protein in 
serum, which binds many hormones, proteins, chemicals and drugs and also accounts for 
60% of total serum proteome (Dowling et al., 2014). Many of the albumin bound proteins 
are likely to be released directly from diseased tissues and as such may be responsible for 
eliciting the immune responses observed in this study (Grundy et al., 2007 and Grundy et 
al., 2009 and Camaggi et al., 2010). 
Zinc-alpha-2 glycoprotein demonstrated a more intense differential expression in PCa 
urine, compared to healthy controls (figure 2.10). Zinc-alpha-2 glycoprotein, synthesised in 
the prostate and secreted in various body fluids, is known to stimulate lipolysis by the 
depletion of fatty acids from adipose tissues. Frenette et al. (1987) first identified zinc-
alpha-2 glycoprotein in prostatic tissues. Since then, many studies have suggested that it 
may serve as a potential serum marker for PCa due to its elevation in prostatic 
adenocarcinoma (Gagnon, et al., 1990). Hale et al. (2001) also found that the majority of 
tested PCa cells react with anti-zinc-alpha-2 glycoprotein antibodies, while also 
demonstrating that high grade tumours express minimal zinc-alpha-2 glycoprotein 
compared to moderate grade tumours. These studies alongside Hassan et al (2007), which 
showed an increased expression of zinc-alpha-2 glycoprotein in the seminal fluid of 
prostate cancer patients, indicate that zinc-alpha-2 glycoprotein may serve as a potential 
biomarker for PCa. 
One of the limitations of this study is that mini gels were used for screening, which gives a 
poor resolution and increases the likelihood that excised spots may contain overlapping 
spots. PROTOMEX studies are typically carried out in large-scale gels for IEF (18-24 cm 
length strips) and SDS PAGE (24 x 24 cm gels) to allow better separation of the spots and 
thus a better resolution of proteins (Rauch and Gires, 2007). Also, the global proteome was 
studied using a pH 3-10L IEF strip. It may have been advantageous to use a narrower pH 
range (e.g. pH 4-7 or pH 5-8 IEF strips) as a means of reducing the complexity of the 
samples loaded on the 2-DE gel, in order to increase the visibility of lower abundant 
proteins and increase the loading capacity of the IPG strips (Catsimpoolas, 1976). 
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2.4.3 Urine TAA identification by OFFGEL and SDS PAGE 
 
The next study aimed to determine whether more TAAs could be identified from urine 
using a modified OFFGEL and SDS PAGE approach. To our knowledge, this is the first 
study to utilise OFFGEL and SDS PAGE for the identification of urinary TAAs using 
PROTEOMEX. As a ‘proof of principle’ of this technology, a monoclonal antibody to 
alpha enolase, a well-studied protein utilised for proteomics research, demonstrated the 
presence of alpha enolase in certain fractions corresponding to its theoretical molecular 
weight (47 kDa) and pI (figure 2.13). 
From the PROTEOMEX screen, an obvious differential expression of two bands (fractions 
3 and 4 at 45 kDa) was observed in PCa immunoblots compared to healthy controls. In a 
bid to reduce the complexity of the sample, each immunogenic band was spilt into two. 
Similar to the SDS PAGE study, a list of proteins were identified from each gel band 
where it was not possible to determine which protein(s) were responsible for the immune 
response observed. From this study, the following proteins were present in all 3 bands – 
actin, cytoplasmic 2, actin, cytoplasmic 1, trypsin-1, vimentin, eukaryotic initiation factor 
4A-I, all representing structural proteins involved with cell adhesion, except trypsin, which 
may be present from the digestion mixture. Putative trypsin, protein AMBP and serum 
albumin were present in 2 out of 3 bands identified, while zinc-alpha-2 glycoprotein and 
prostatic acid phosphatase represent proteins which were identified in band 4 (table 2.14), 
but were also identified in previous studies using SDS PAGE or 2-DE.  
From this chapter, the best technology for urinary TAA identification using PROTEOMEX 
appears to be 2-DE in combination with MALDI MS/MS, where single or a smaller 
number of proteins are identified from each gel spot. This does not negate the need 
however, to validate these identified TAAs in a larger sample cohort or repeat the study 
using more fractionation and immunodepletion to determine if these same proteins are 
identified, albeit from the same sample set. Further studies need to carry out more 
fractionation and immunodepletion to the urine before 2-DE to identify more TAAs 
associated with PCa. This study however aimed to determine whether TAAs were present 
in urine and if they could be isolated and identified using PROTEOMEX. The chapter has 
identified prostatic acid phosphatase and zinc-alpha-2-glycoprotein as potential urine TAA 
candidates that require further investigation. Interestingly, both proteins identified are well-
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known PCa markers, which validates the utility of PROTEOMEX as a robust method, 
useful for narrowing down and identifying potentially relevant biomarkers requiring 
further validation. 
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3. CHAPTER 3: IDENTIFICATION OF TUMOUR 
ANTIGENS IN CELL LINES AS BIOMARKERS 
FOR PROSTATE CANCER 
 
3.1  INTRODUCTION 
 
Early detection and diagnosis are essential for the management of PCa. Current diagnosis 
of PCa is based on the identification of raised serum PSA (>4 ng/mL) levels alongside an 
invasive and subjective DRE; where more invasive procedures such as a transrectal 
ultrasonography of the prostate and biopsy are carried out if cancer is suspected (Madu & 
Lu, 2010). However, the lack of specificity of PSA combined with the subjectivity of DRE 
leads to over diagnosis and overtreatment of patients, resulting in increased clinical costs 
and unnecessary patient distress. As a result, more stringent biomarkers are required for 
accurate PCa diagnosis (Larkin et al., 2010). It is therefore necessary to identify 
biomarkers which are more accurate, precise and clinically relevant, which can serve as 
early indicators for PCa. 
 
As outlined in section 1.2.4.1, the grading of PCa uses the Gleason grade system which 
indicates the aggressiveness of tumours. It is well known that within Gleason grade 7, 
Gleason 3+4 tumours (i.e. tumours where pattern 3 is the most prevalent pattern, and 
pattern 4 is the second most prevalent observed under a microscope) have a better 
prognosis than Gleason 4+3 tumours (i.e. tumours where pattern 4 is the most prevalent 
pattern, and pattern 3 is the second most prevalent observed under a microscope) (Stephen 
and Kattan, 2006). In order to identify differences between both Gleason 7 phenotypes, 
clinicians associate Gleason grade with other prognostic factors such as biochemical 
progression (Chan et al., 2000, Rasiah et al., 2003 and Sengupta et al., 2006) or the 
development of tumour metastasis (Lau et al., 2001). Although biochemical recurrence is 
most popularly used in order to determine PCa risk prediction and the efficacy of treatment, 
studies have found that its definition varies (Amling et al., 2001 and Freedland et al., 
2003), making it an imperfect model to discriminate between the two phenotypes. This 
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warrants the identification of more PCa markers that can distinguish between the two 
forms of Gleason 7 PCa. 
 
The previous chapter utilised a PROTEOMEX approach to identify TAAs for PCa using 
urine as a biomarker source. Amongst all the separation methods used in combination with 
mass spectrometry, chapter 2 demonstrated that the best method for TAA identification 
was 2-DE in combination with MALDI-TOF mass spectrometry. The chapter also 
demonstrated that while PCa relevant TAAs could be identified from urine, more 
fractionation is required in order to detect low abundant proteins, which may contain 
potential PCa biomarkers. As a result, the current chapter aims to identify TAAs from 
another biomarker source – immortalised PCa cell lines. 
 
It is not entirely clear how intracellular proteins induce autoimmune responses (Suzuki et 
al., 2010). However, it is well documented that post transcriptional modifications enhance 
protein immunogenicity (Forgber et al., 2009), and that certain foetal antigens are highly 
expressed in tumour cells (Ting et al., 1972). As a result, cancer sera are a valuable source 
of TAAs (Rauch and Gires, 2008). Although there have been a lot of reported TAAs linked 
to the immune response in cancers, the challenge with TAA identification is that it is 
difficult to find TAAs which can be utilised for clinical diagnostic applications (Desmetz 
et al., 2008). As a result, the aim of this study is to identify PCa relevant TAAs that can 
serve as cancer biomarkers using the same PROTEOMEX technology (detailed in section 
1.3.7.1 and successfully utilised in the previous chapter). 
 
Autoantibodies produced in response to TAAs can provide an alternative source of 
biomarkers (Desmetz et al., 2008). During early tumour development, the levels of TAAs 
produced are usually too low to detect using conventional methods. However, the 
autoantibodies produced in response to TAAs are amplified, allowing cancer detection 
long before any clinical diagnosis (Fernandez 2005). Furthermore, high titres of 
autoantibodies are detectable in patients with early stages of cancer (Disis et al., 1997) and 
have been shown to correlate with malignant transformation (Tan et al., 2009). As a result, 
several techniques have been successfully employed to detect TAAs and their 
corresponding autoantibodies for biomarker use. One such method is PROTEOMEX 
which allows the identification of autoantibodies to TAAs as they occur in their natural 
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state, as opposed to SEREX which screens for autoantibodies to proteins expressed in 
bacteria (Rauch & Gires, 2008). 
 
Using proteomic techniques in combination with serological screening, TAAs can be 
identified by matching differential antigen spots on membranes immunoprobed with cancer 
or patient sera against protein spots in stained replica gels. TAAs of interest are then 
excised from these replica gels and identified by PMF or denovo peptide sequencing using 
mass spectrometry (Rauch and Gires, 2008). This approach was employed in this chapter 
to determine the immunogenicity of PCa cell lines and the specificity of the corresponding 
patient autoantibody responses. 
 
While cancer cell lines lack features of an in situ tumour, making them a poor 
representation of the tumour in vivo (Alvarez-Chaver et al., 2014), immortalised cell lines 
can still provide a suitable source of TAAs for identifying autoantibodies associated with 
cancer. Using PROTEOMEX, many studies have identified relevant TAAs and 
autoantibodies for various cancers in tumour cell lines; such as HSP-60 and RS/DJ-1 in 
breast cancer (Hamrita et al., 2008, Desmetz et al., 2008 and Le Naour et al., 2011), 
cytokeratin 8 and thioredoxin in renal cell carcinoma (Kellner et al., 2002 and Lichtenfels 
et al., 2003), eukaryotic elongation factor, alpha enolase, aldolase, glyceraldehyde-3-
phosphate dehydrogenase and heterogeneous nuclear ribonucleoproteins A2B1 and 
galectin-3 in melanoma (Suzuki et al., 2010 and Forgber et al., 2009) and alpha enolase in 
pancreatic adenocarcinoma (Tomaino et al., 2007). These studies have demonstated the 
utility of cancer cell lines as a model to study the interrelationship between cancer and the 
immune system, also showing the value of PROTEOMEX as a means of narrowing down 
and identifying potentially relevant biomarkers requiring further validation. 
 
Despite the utility of this approach, to date, only one study has utilised the PROTEOMEX 
technique to identify TAAs and autoantibodies for PCa using patient tissue lysates as a 
biomarker source (Ummanni et al., 2015). Autoantibody responses to antigens PRDX2, 
PRDX6 and ANXA11 were identified, where a combination of PRDX6 and ANXA11 
autoantibodies yielded a biomarker sensitivity of 90% for PCa and 100% for healthy 
controls. To our knowledge, this will be the first study utilising PCa cell lines as a 
biomarker source to identify TAAs for PCa using PROTEOMEX. Thus, it was important 
to demonstrate the utility of the PROTEOMEX technique in identifying relevant TAAs in 
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PCa using readily available cancer cell lines, before carrying out further validation 
experiments on tumour tissue samples. Table 3.1 outlines the PCa cell lines utilised for this 
investigation alongside their attributes. 
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Table 3.1: Attributes of PCa cell lines utilised for biomarker discovery 
 
General information and characteristics of all PCa cell lines. Words in italics represent markers expressed 
by each cell line. 
 
3.1.1   Aims & objectives 
 
The aim of this chapter is to identify TAAs in PCa cell lines which may serve as potential 
PCa biomarkers, following subsequent validation. This will be carried out by: 
 
1. Identifying PCa TAAs and biomarkers in two well-characterised PCa cell lines 
using PROTEOMEX in combination with MALDI TOF MS. 
2. Identifying biomarkers that can differentiate between the aggressive (4+3) vs. the 
non-aggressive (3+4) phenotype of Gleason grade 7, using PROTEOMEX in 
combination with MALDI TOF MS. 
3. Confirming and verifying the MS identified PCa TAA(s) using 
immunofluorescence, flow cytometry and Western blotting. 
4. Verifying the existence of a differential serum autoantibody response towards the 
identified TAA using ELISA. 
Cell Line Attributes 
PC-3 
Derived from bone metastasis, grade IV prostatic adenocarcinoma 
62 year (male), Caucasian, high tumourigenicity 
Low prostatic acid phosphatase and testosterone-5-alpha reductase 
activities. 
OPCT-1 
Androgen sensitive 
Prostate tumour epithelium (T1cN0M0, Gleason 3+3) 
Patient received no chemotherapy, no radiotherapy and no hormone treatment 
DU145 
Derived from brain metastasis, androgen resistant 
69 year (male), Caucasian, moderate tumourigenicity 
Weakly positive for prostatic acid phosphatase 
Does not express prostate specific antigen 
LNCAP.fcg 
Derived from the left supraclavicular lymph node of a 50 year old patient 
with a confirmed diagnosis of metastatic prostate carcinoma 
Androgen/oestrogen receptors 
Expresses prostatic acid phosphatase, prostate specific antigen positive 
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3.2   METHODS 
 
 
 
Figure 3.1:  Method outline for TAA identification in PCa cell lines. 
This chapter is divided into 3 sections – identification in PC-3 and DU-145 PCa cell lines 
and verification of the identified TAA. The flowchart shows the techniques used for TAA 
identification and verification in this chapter.  
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3.2.1  Selection of the appropriate PCa TAA tissue 
 
3.2.1.1 Prostate cancer sera and urine 
 
Sera and urine samples from PCa patients were collected and banked at the Urology Centre, 
Nottingham City Hospital, Nottingham, UK. Samples were prepared and stored as outlined 
in section 2.2. 
3.2.2 Reactivity of patient and healthy sera with protein extracts 
from PCa cell lines 
 
3.2.2.1 Cell lines and routine cell culture 
 
Two commercially available PCa cell lines were purchased from ATCC and utilised in this 
study as a source of potential TAAs (PC-3 and DU-145). PC-3 were cultivated in Ham’s 
F12K media supplemented with 1% sodium pyruvate, 1% non-essential amino acids and 
10% foetal calf serum (FCS) while DU-145 were grown in DMEM media supplemented 
with 10% FCS and 1% L-glutamine. The attributes of all PCa cell lines utilised in this 
chapter are outlined in table 3.1. 
 
All cell lines were maintained by serial in vitro passage and cultured at 37ºC in an 
incubator containing 5% CO2 and 95% humidified air. When the cultured monolayers had 
reached 80-90% confluence, they were passaged using a combination of trypsin and 
versene (T and V) as described below. 
 
Spent culture media was discarded and adhered cells were rinsed twice with PBS to 
remove traces of culture media during routine cell culture. A 5 mL T and V solution was 
added to the T175 flask and left to incubate at 37ºC for approximately 5 min. After the 
incubation, adherent PCa cells were detached from tissue culture flasks by gently tapping 
the flask 4 times. The dispersion of the adherent cell layer was observed under an inverted 
microscope, after which 10 mL of fresh culture media was added to the flask. The cell 
solution was aspirated by gentle pipetting into a universal tube and centrifuged at 400 g for 
3 min at 20ºC. After centrifugation, 20 mL of fresh culture media was added to new T175 
flasks. The supernatant from the centrifuged cells were discarded and the cell pellet was 
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resuspended in 1 mL routine culture medium. Cells were re-seeded at a 1:20 ratio into 
fresh tissue culture flasks and left to incubate at 37 ºC or left in suspension for protein 
isolation and cell counting. 
 
3.2.2.2 Cell counting 
 
In order to count live (viable) cells for downstream analysis, 10 µL of cell suspension was 
mixed with 90 µL of 0.4% (v/v) trypan blue solution and pipetted onto both chambers of a 
haemocytometer. Cell counting via the trypan blue dye exclusion method is based on the 
principle that non-viable cells take up certain dyes as opposed to viable cells, aiding the 
distinction of cells under a light microscope. Starting with the first chamber of the 
haemocytometer, all the cells in the 1 mm square are counted and an average is taken of all 
four 1 mm squares. The number of cells was calculated using the formula: 
 
Average number of cells/1 mm square x dilution factor x 104 = cell count per mL 
 
The number of cells required for each assay was then calculated from the total number of 
cells and the appropriate volume of cell suspension was collected. 
 
3.2.2.3 Protein isolation from PCa cell lines for biomarker discovery 
 
For proteomic studies, cell lines were harvested at 80-90% confluence and adherent cells 
were rinsed twice with cold PBS to remove spent culture media (as detailed in section 
3.2.2.1). 7 mL of cold PBS was added to the flask and adhered cells were scraped using 
cell a scraper before centrifuging at 400 g for 3 min at 4ºC. After centrifugation, the 
supernatant was discarded and the pellet was resuspended in 1 mL of cold PBS before a 
further centrifugation at 400 g for 3 min at 4ºC to obtain a dry pellet. The supernatant was 
discarded and a dry pellet was stored at -80ºC until use or resuspended in 50 µL of cell 
lysis buffer (9.5 M Urea, 2% DTT, 1% OGP) for proteomic analysis. The solution was 
vortexed for 20 sec, sonicated at 37ºC for 5 min and left on ice for a further 5 min. The 
sonication-ice step was repeated 3 times before centrifugation at 400 g for 3 min to obtain 
a supernatant, which was subsequently collected and stored at -80ºC until the protein 
concentration was determined. 
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3.2.2.4 Protein concentration determination (protein assay) 
 
Protein estimations were performed using a Bradford protein assay as described in section 
2.2.2.2. In brief, serial dilutions of BSA protein standards were prepared and added in 
duplicate into designated wells of a flat bottom 96 well plate. Lysed PCa cells were diluted 
at 1:1000 in lysis buffer before pipetting into the remaining wells of a 96 well plate. 200 
µL of Bio-Rad dye reagent (diluted 1 in 4 with ddH2O) was added to the lysate or BSA 
standard and incubated for 5 min at room temperature. The absorbance was measured at 
570 nm using a Tecan Ultra spectrophotometer (Tecan Group Ltd, UK) and a BSA 
standard curve was constructed using the concentration and absorbance values of the 
standards. 
 
3.2.2.5 2-DE, SDS PAGE and Western blotting 
 
2-DE electrophoresis and SDS PAGE was performed according to the manufacturer’s 
instructions as described in section 2.2.3.1 and 2.2.3.2. In brief, 20 µg of cell lysate was 
mixed with sample dehydration buffer and pipetted along the length of a 7 cm 3-10L IEF 
strip (Bio-Rad, UK), before allowing passive rehydration of the strips for 1 h at room 
temperature. Each strip was run using the manufacturer’s predefined programme for 
approximately 18 h, before loading onto 10% SDS PAGE gels. Each gel was run at 200 V 
until the sample dye front reached the anodic side of the gel. Separated proteins were then 
transferred electrophoretically onto a nitrocellulose membrane using a wet transfer method 
as described in section 2.2.4, or stained with a Coomassie brilliant blue solution. 
Membranes were then immunoprobed with human sera or a monoclonal antibody at a pre-
optimised dilution (stated in table 2.7). 
 
3.2.2.6 Coomassie, Ponceau S stain, gel to membrane alignment 
 
SDS PAGE gels were stained overnight in a Coomassie brilliant blue solution and de-
stained as outlined in section 2.2.6. Electrophoretically transferred membranes were also 
stained using a Ponceau S solution (section 2.2.5) and rinsed in dH2O until stained spots 
were visible on the membrane. In order to carry out TAA identification, gels and 
membranes were manually aligned as described in section 2.2.81 and spots of interest were 
chosen for MS identification. 
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3.3.2.7  Band extraction, In-gel digestion, MS identification 
 
Spots of interest were excised from the Coomassie stained replica gel as described in 
section 2.2.9.1 and digested overnight using trypsin (described in detail in section 2.2.9.1). 
Digested peptides were extracted from the gel matrix and cleaned up using C18 pipette tips 
(Millipore, UK) (section 2.2.9.2). Eluted peptides were spotted onto a 384 MALDI ground 
steel target plate for analysis (section 2.2.9.2) and analysed using an ultraflextreme 
MALDI-TOF/TOF mass spectrometer (search parameters detailed in section 2.2.9.3.1). 
3.2.3   Verification of identified TAAs 
 
3.2.3.1 Immunofluorescence  
 
For examination of protein expression in PCa cell lines, round glass coverslips were dipped 
into methanol, placed into individual wells of a flat-bottomed 24 well plate and allowed to 
air dry in the hood for approximately 15 min. Cells were counted as described in section 
3.2.2.1, diluted accordingly at 5 x 104 cells/well and left to culture at 37ºC in 5% CO2 for 
48 h until the cells had adhered to the coverslips. 
 
To stain the cells, each well was washed twice for 10 min each with PBS on a rocking 
platform to remove the excess culture media. Following washes, 200 µL of cold 4% 
paraformaldehyde was added to each well and left on ice for 15 min to fix the cells. Each 
well was washed twice with PBS for 10 min each and non-specific binding sites were 
blocked using 200 µL of 10% BSA in PBS 0.1% Tween for 1 h at room temperature before 
a wash step for a further 10 min. 
 
To detect protein expression in PCa cell lines, an optimal (1:50) dilution of mouse-anti-
alpha enolase antibody (clone L-27, Santa Cruz, UK), or mouse isotype control  (1:50 
dilution (IgG mouse isotype control, Invitrogen, Paisley, UK) diluted in 2% BSA-PBS was 
added to relevant wells and incubated at room temperature for 1 h. Following incubation, 
unbound primary antibodies were removed by performing three 10 minute washes with 
PBS. An optimised dilution (1:1500 dilution) of a fluorescent Alexa-Fluor antibody (goat 
anti-mouse IgG AlexaFluor 488, Invitrogen, Paisley, UK) was diluted in blocking buffer 
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and allowed to bind to primary antibodies by shaking at room temperature for 1 h and the 
plates were wrapped in foil. 
 
Following incubation, unbound secondary antibodies were removed by washing three 
times in a PBS wash buffer. To visualise the expression of alpha enolase by 
immunofluorescence, a drop of Vectafield containing DAPI mounting media (VectorLabs, 
Peterborough, UK) was placed on a microscope slide and the coverslips were gently 
removed from the wells and inverted onto the DAPI to aid visualisation of the cell nucleus 
during microscopy. The edges of the coverslips were sealed with a clear nail varnish 
(Rimmel 60 seconds nail varnish, UK) to maintain fluorescence. Slides were then wrapped 
in foil until visualisation by fluorescence microscopy using an Olympus BX51 
fluorescence microscope (KeyMed medical & industrial equipment Ltd, Essex, UK). 
 
3.2.3.2  Flow cytometry 
 
To determine whether alpha enolase is expressed in PCa cell lines, cells were trypsinised 
and counted as detailed in section 3.2.2.1. In brief, and 5 x 105 cells were placed into 
FACS tubes for analysis by flow cytometry, to determine cell surface or intracellular 
staining of alpha enolase. 
 
3.2.3.2.1 Cell surface staining 
 
To demonstrate the presence of alpha enolase on the cell surface, 2 mL of FACS buffer 
(PBS 0.05% BSA 0.02% sodium azide) was added to each tube and centrifuged at 400 g 
for 5 min at room temperature to wash off excess culture media. After centrifugation, the 
supernatant was discarded and the pellet was resuspended in an optimised dilution (1:10) 
of a mouse anti-human alpha enolase antibody (clone L-27, Santa Cruz, UK) diluted in 100 
µL FACS buffer. This solution was vortexed for 20 sec and left to incubate in the dark for 
30 min at room temperature to enable antibody binding. 
 
After incubation, cells were washed with 2 mL FACS buffer, centrifuged and incubated 
with an optimised dilution of a secondary antibody (goat-anti-mouse IgG AlexaFluor 488). 
Any unbound secondary antibody was removed by washing twice with FACS buffer, 
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centrifuged and the pellet was resuspended in 500 µL of isoton to aid analysis by flow 
cytometry.  
 
3.2.3.2.2 Intracellular staining 
 
Intracellular alpha enolase was demonstrated by washing cultured cells in 2 mL of cold 
PBS before centrifuging at 400 g for 5 min at 4ºC. Cell pellets were resuspended in 500 µL 
of cold PBS and an equal volume of cold 4% paraformaldehyde was added to each tube to 
fix the cells for 30 min at room temperature. 2 mL of ice-cold PBS was added to wash the 
cells and centrifuged at 400 g at 4ºC for 3 min. 600 µL of permeabilisation buffer was 
added to the cells and mixed before a further incubation at room temperature for 10 min. 
Cells were centrifuged as before and resuspended in permeabilisation buffer containing a 
pre-optimised dilution (1:10 dilution) of mouse anti-human alpha enolase antibody (clone 
L-27, Santa Cruz, UK) or isotype control. Each sample was mixed gently and incubated in 
the dark for 30 minutes at room temperature, after which another wash was performed 
before the addition of secondary antibodies as described in section 3.2.3.2.1). After this, 
cells were resuspended in a BSA/Azide buffer and analysis of cell surface and intracellular 
staining was performed using a Gallios flow cytometer (Beckman Coulter, UK). 
 
3.2.3.3 ELISA 
 
In order to detect autoantibody responses to alpha enolase in PCa and healthy sera, 
recombinant alpha enolase (Fitzgerald, USA) was coated overnight on NUNC 96 well 
plates. Recombinant alpha enolase was diluted to 100 ng/mL in coating buffer and left to 
adsorb overnight at 4ºC onto the bottom of the wells. The next day, any unbound protein 
was washed away three times in a wash solution containing TBS containing 0.05% Tween-
20. Each wash was carried out for 15 min at room temperature and plates were left shaking. 
Using a multichannel pipette, each well was blocked with 4% BSA for 90 min to prevent 
non-specific binding and washed again as described previously. 
 
To determine alpha enolase autoantibody responses in sera, each serum sample was diluted 
1:25 and plated in quadruplicate in 2% BSA in 0.05% Tween or 1:10,000 for mouse anti-
human alpha enolase antibody, which served as a positive control. The solution was left to 
incubate in the wells for 90 min at room temperature to allow maximum binding of 
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antibodies to alpha enolase. Each well was then washed again as described previously to 
remove unbound primary antibodies. 
 
Finally, a 1:3000 dilution of HRP labelled rabbit anti-human (for human sera) or goat anti-
mouse antibody (for alpha enolase) secondary antibody was added to the wells. Secondary 
antibodies were allowed to bind to their respective primary antibodies for 90 min at room 
temperature. A final wash step was performed as described previously and to enable 
visualisation each well was incubated with 50 µL TMB solution for 15 min. The reaction 
was stopped using the same volume of 1 N sulphuric acid before an absorbance reading at 
450nm was measured. 
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3.3 RESULTS 
 
 
Figure 3.2:  Overview of the identification of TAAs in PCa cell lines. 
The identification of TAAs in this chapter is divided into 3 sections - identification using 
PC-3, DU-145 and the verification of identified TAAs. 
 
 
3.3.1 Selection of appropriate PCa samples for biomarker 
discovery 
 
Sera from healthy control male volunteers (above 35 years) at Nottingham Trent 
University (NTU) were collected and stored after ethical approval and informed consent 
forms had been signed (University ethical number 165). Only 3 volunteers had been 
recruited for our investigation at the time of the study and thus were available for 
comparison to patient sera (n=22). In addition, these healthy control samples could not be 
age matched to cancer and benign patients due to the limited number of volunteer sera 
available. 
 
Sera from males aged 46-83 years who had been referred by their GP for high PSA levels 
and attending the urology clinic at the Urology Centre, Nottingham City Hospital, 
Nottingham, UK, were also obtained prior to diagnosis after ethical approval by the 
National Research Ethics Service Committee (NREC #09/H0S04/6). Although matched 
tumour tissue in the form of needle core biopsies were collected from these patients for 
pathological diagnosis and as part of this study, the amount of tissue (and protein) 
available was insufficient for 2-DE (20 µL/IEF strip) and therefore not used as part of this 
experiment. As a result, PCa cell lines were explored as an alternative source of TAAs. 
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One of the sub-aims of this study was to identify serum derived biomarkers that could 
discriminate the so-called aggressive from the non-aggressive (tiger vs. pussycat) 
phenotype of Gleason 7 PCa. As a result, initial experiments aimed to identify biomarkers 
that could differentiate between both phenotypes. Consequently, a small subset of cancer 
and benign patients were chosen randomly from the samples available in the Nottingham 
City Hospital cohort to represent these patient categories (patients summarised in table 3.2). 
 
Table 3.2: Patient serum samples used for TAA identification in PC-3 
Patient 
category 
Sample 
no. Age 
PSA 
(ng/mL) 
Gleason
1 
Gleason 
2 
Gleason 
grade 
D’Amico 
Risk TNM stage 
PCa PC04 56 4.9 3 4 7 Intermediate - 
PCa PC05 65 8.9 3 4 7 Intermediate - 
PCa PC06 71 5.4 3 4 7 Intermediate T2N0M0 
PCa PC07 69 7.9 3 4 7 Intermediate T2cN0M0 
PCa PC08 58 5.3 3 4 7 High T2cN0M0 
PCa PC09 57 3.6 3 4 7 Intermediate T2aN0M0 
PCa PC10 58 4.3 3 4 7 Intermediate - 
PCa PC11 63 10.5 3 4 7 Intermediate - 
PCa PC12 57 4.6 3 4 7 Intermediate - 
PCa PC13 68 6.8 3 4 7 Intermediate T2cN0M0 
PCa PC14 63 7.0 3 4 7 Intermediate - 
PCa PC15 62 11.3 4 3 7 Intermediate T2cN0M0 
PCa PC16 78 42.1 4 3 7 Mets - 
PCa PC17 68 5.3 4 3 7 High - 
PCa PC18 68 16.2 4 3 7 Intermediate T3bN0M0 
PCa PC19 72 9.3 4 3 7 Intermediate T2cN0M0 
PCa PC201 72 7.3 4 3 7 Intermediate T1/2N0M0 
PCa PC21 64 4.4 4 3 7 Intermediate T2N0M0 
PCa PC22 68 10.5 4 3 7 Intermediate T2cN0M0 
PCa PC23 63 13 4 3 7 Intermediate T1N0M0 
PCa PC242 65 0.05 - - - - - 
PCa PC27 73 8.9 4 5 9 Mets T3aN1M0 
Benign BE013 56 4.9 3 4 7 Intermediate - 
Benign BE02 62 8 - - Benign - - 
Benign BE03 67 23.2 - - Benign - - 
Healthy HE01 33 - - - -  - - 
Healthy HE02 36 - - - - - - 
Healthy HE03 48 - - - - - - 
 
Sera was collected prior to diagnosis. To identify TAAs in PC-3, patients from the following categories were 
selected at random and chosen for this study. All patient samples were collected prior to diagnosis. A total of 
21 PCa patients were chosen: Gleason 7 (3+4) (n=11), Gleason 7 (4+3) (n=10), benign (n=3) and healthy 
controls (n=3). 1; post biopsy haemorrhage, 2 prostatectomy sample, 3 BE01 was eventually diagnosed with 
Gleason 7 PCa, after the study was completed.  
 
 
Two ‘classic’ PCa cell lines (DU-145 and PC-3) available in our laboratory were chosen 
for technique optimisation, initial TAA screening and biomarker identification. These were 
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chosen because they represent well characterised PCa cell lines which have been used for 
other biomarker identification studies in the literature (Saraon et al., 2012). Thus, initial 
experiments aimed to identify TAAs in these well-characterised PCa cell lines, that elicit 
antibody responses to PCa patient or healthy sera. Although antibodies produced by an 
organism in response to antigens produced by their own tissues are referred to as 
‘autoantibodies’, they will be referred to as ‘autoantibodies’ throughout this chapter 
regardless of the fact that the patient sera used in this study have not been produced in 
response to TAAs in PCa cell lines. 
 
Before studies were conducted to investigate the presence of sera autoantibodies to PCa 
protein lysates, a series of optimisation experiments were performed to determine the best 
lysis buffer, optimum protein concentration to load on 2-DE, and the ideal serum dilution 
that showed low background after spot detection. Experiments were also performed to 
identify the best stain for detecting proteins on the replica gel which would facilitate spot 
identification by mass spectrometry, alongside the optimum incubation times for each 
experimental procedure. Subsequent experiments were carried out using these pre-
optimised conditions (data not shown). 
 
 CHAPTER 3: TAA identification in PCa cell lines 
123 
   
3.3.2   TAA identification in the PC-3 cell line 
 
3.3.2.1   Reactivity of patient and healthy sera with protein extracts 
from the PC-3 cell line 
 
To investigate the presence of antibodies against PC-3 proteins, the first experiment 
utilised a serological proteome analysis that combines 2-DE and Western blotting. In brief, 
20 µg of total PC-3 protein lysate was separated by IEF in the first dimension and then by 
SDS PAGE in the second dimension. 2-DE separated proteins were transferred onto 
nitrocellulose membranes and probed with diluted sera (1:80 dilution) from either pooled 
healthy (n=3), benign (n=3) or PCa patients: Gleason 7 (3+4; n=10) or Gleason 7 (4+3; 
n=10) sera (figure 3.3). A replica gel was run simultaneously and visualised by Coomassie 
stain (150 µg total proteins) to facilitate spot identification by MALDI-TOF mass 
spectrometry. 
 
As shown in figure 3.3, immunoblots probed with pooled PCa sera reacted with multiple 
spots (two red spots circled in figure 3.3) compared to pooled benign or healthy control 
sera. Both spots migrated at the same molecular weight (approximately 45 kDa) and an 
estimated pI of 6.0 and 6.5, showing strong reactivity to PCa patient sera [Gleason 7 (3+4) 
and Gleason 7 (4+3)] but not with sera from the control groups (benign and healthy 
controls). These spots were excised from the Coomassie stained replica gel, trypsin 
digested for analysis by MALDI-TOF MS. The other spots on the immunoblotted 
membrane in our experience are not spots of interest due to their fine, diffuse spot pattern 
which in our experience is consistent with milk deposits or incomplete washing of the 
nitrocellulose membrane. In addition, as this was the first study identifying TAAs in PCa 
cell lines, the most obvious spots were excised for MALDI-TOF MS analysis. 
 CHAPTER 3: TAA identification in PCa cell lines 
124 
   
 
Figure 3.3:  Immunoblot showing the reactivity of PCa, benign and healthy sera 
with protein extracts from the PC-3 cell line. 
Protein lysates from PC-3 were separated by 2-DE, transferred to nitrocellulose 
membranes and immunoblotted with sera from a pool of Gleason 7 PCa patients, benign or 
healthy controls. An immunoblot probed with pooled Gleason 7 (4+3) sera (n=10) is 
shown in (A), where circled spots represent positive immunoreactivity. The most 
immunoreactive region of (A) is highlighted in the black square and enlarged in B, while 
immunoreactivity at the same regions of membranes probed with Gleason 7 (3+4), benign 
and healthy sera are depicted in (C), (D) and (E) respectively.  
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3.3.2.2 Identification of PC-3 TAAs that elicit antibody responses in 
PCa 
 
To facilitate TAA identification in PC-3, Coomassie stained replica gels were manually 
aligned to the immunoprobed membrane (figure 3.4A & B). Spots corresponding to 
positive immunoreactivity from the immunoblots were excised from the replica gel and 
subjected to an overnight in-gel digest with trypsin. Tryptic peptides were cleaned up using 
C18 ZipTip columns and spotted on a ground steel target plate for identification using 
MALDI-TOF MS. The acquired PMF was searched against the SwissProt human database 
(search criteria outlined in section 2.2.9.3.1) using the Mascot search engine to identify 
potential TAA candidates. 
 
  
Figure 3.4:  Image showing immunoblot to membrane alignment for 
 immunoreactive TAAs identified in PC-3 PCa cell line. 
Two spots showing positive immunoreactivity by Western blotting to PC-3 proteins (A) 
were manually aligned and to Coomassie stained replica gels (B). A is the same 
immunoblot from figure 3.3A. Spots were isolated from the corresponding region on 
replica gels and excised for identification by MALDI-TOF MS. Immunoreactivity to PCa 
Gleason 7 (4+3) sera is depicted in A. 
 
 
After the SwissProt database search, both spots were identified with borderline 
significance as the same protein, alpha enolase (ENOA) by PMF. MOWSE scores of 41 
and 61 were obtained for spot (1) and (2) respectively, where a score of >56 is significant, 
indicating identity or extensive homology to a known protein on the SwissProt database 
(p<0.05). In order to increase the confidence in the protein identified, peptides from each 
sample identified during PMF were fragmented using MALDI-TOF MS. As sample 1 
yielded the lowest score by PMF, 6 peaks identified with low significance from sample 1 
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were subject to sequence analysis using MALDI-TOF/TOF (sequence analysis outlined in 
section 2.2.9.3.1) and are summarised in table 3.3. 
 
Table 3.3:  Identification of alpha enolase peptides from PC-3 by MALDI-TOF  
  MS/MS 
Protein Observed m/z peak 
Mascot 
score SC (%) Peptide 
Alpha enolase 1406.7182 73/31 2% R.GNPTVEVDLFTSK.G 
 
1804.9615 123/31 4% R.AAVPSGASTGIYEALELR.D 
 
1143.6204 42/31 2% R.IGAEVYHNLK.N 
 
1556.7831 60/31 3% K.VVIGMDVAASEFFR.S 
 
1425.7372 101/31 2% R.YISPDQLADLYK.S 
 
1633.8877 127/31 3% K.VNQIGSVTESLQACK.L 
 
Six peaks identified with a low significance as alpha enolase by PMF were subject to sequence analysis by 
MALDI-TOF MS/MS. The Mascot ion score for each observed peak is shown in table 3.3 as well as the 
peptides they correspond to. SC; protein sequence coverage. 127/31; MOWSE score of peptide is 127, where 
a score >31 is considered significant, indicating identity or extensive homology to a known protein on the 
SwissProt database (p<0.05). R. or K. at the start or end of each peptide sequence represents tryptic cleavage 
sites for each peptide. 
 
 
Figure 3.5 shows the full protein sequence of human alpha enolase, where bold peptides 
indicate all 6 matched peptides by MALDI TOF MS/MS. Tandem mass spectrometry of 
one of 6 matched peptides of alpha enolase YISPDQLADLYK, is also depicted in figure 
3.5B, where the sequenced peptides was identified with a Mascot ion score (MOWSE 
score) of 101 (figure 3.5C) where a score of >31 is significant, indicating identity or 
extensive homology to a known protein on the SwissProt database (p<0.05). 
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Figure 3.5:  Identification of alpha enolase as a potential TAA from the PC-3 PCa 
 cell line using MALDI-TOF MS/MS. 
The figure shows the full length sequence of human alpha enolase where peptides in bold 
indicate all six matched peptides by MALDI-TOF MS (A). Panel (B) shows one of six 
sequenced peptides of alpha enolase YISPDQLADLYK with an m/z 1425.7372 by 
MALDI-TOF MS/MS. Panel (C) shows the Mascot ion score of the peptide 
YISPDQLADLYK after matching the SwissProt database. The sequenced peptide has a 
MOWSE score of 101 where a score >31 is significant, indicating identity or extensive 
homology to a known protein on the SwissProt database (p<0.05). 
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3.3.3   TAA Identification in DU-145 
 
3.3.3.1  Selection of appropriate samples for PROTEOMEX 
screening in DU-145 PCa cell lines 
 
Section 3.3.2 demonstrated that autoreactivity towards alpha enolase may occur in some 
PCa patients. The next study aimed to identify TAAs that may serve as biomarkers for PCa 
in DU-145 using the same method. Due to limited sample volumes, the same patient 
samples used to screen the PC-3 cell line could not be used to screen DU-145 lysates. Thus, 
another set of patients recruited at the time of diagnosis were chosen from the PCa sample 
cohort collected at Nottingham University Hospitals. Patients utilised for this study are 
listed in table 2.11 (section 2.3.3.1). This study was carried out at the same time as the 2-
DE urine study (section 2.3.3), where it became apparent that the benign samples collected 
was classed as ‘benign with a possibility of cancer’. Thus, all benign samples were omitted 
from further analysis, in order to make the patient categories more stringent. 
 
3.3.3.2 Reactivity of PCa and healthy sera with protein extracts from 
DU-145 PCa cell lines 
 
To investigate the presence and patterns of serum IgG–based immunoreactivity against 
DU-145 cytosolic proteins, the same approach was used as in the PC-3 study. In brief, 20 
µg of total DU-145 lysate was separated by 2-DE as described in section 3.3.2 and 
transferred onto nitrocellulose membranes to facilitate TAA screening. Serum (1:80 
dilution) from a pool of PCa patients (n=26) or healthy control volunteers (n=3) were used 
for immunoscreening making up the discovery sample set. Figure 3.6 shows the 
immunoblots screened with PCa and healthy control sera, which yielded a larger number of 
spots (16 spots) compared to the PC-3 study.  
 
Figure 3.6A-C demonstrates the immunoreactivity in a heterogeneous combination of sera, 
where six reactive protein spots were observed in control sera (circled in blue) and thus 
were considered to represent proteins expressed in normal patients and therefore not of 
interest. However, pooled PCa sera reacted exclusively and more intensely with twice the 
number of spots detected by healthy controls (circled in red). In addition, in the spots 
identified by both sample groups (circled in blue), spots from PCa sera were more 
prominent in 2 out of 6 spots, equally as reactive in both sample groups in 2 out of 6 spots, 
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and more reactive in healthy sera in 2 out of 6 spots. PCa and healthy sera 
immunoreactivity to DU-145 proteins mainly occurred in the 40 – 90 kDa molecular 
weight range with the strongest PCa detected spots around pI 6 – 7. As this was still a 
preliminary study to identify TAAs in PCa cell lines, only the most obvious spots which 
were clearly distinguishable from the background (circled spots) were chosen for MALDI-
TOF analysis.  
 
 
Figure 3.6: Immunoblots showing the screening of PCa and healthy sera against 
DU-145 PCa cell line proteins.  
Protein lysates from DU-145 were separated by 2-DE, transferred onto a nitrocellulose 
membrane and immunoblotted with sera from a pool of PCa patients (Gleason 7, 8 and 9) 
or healthy controls. An immunoblot probed with pooled PCa sera is shown in (A), where 
the most immunoreactive region of the probed membrane (40 – 90 kDa) is highlighted in 
the black square and enlarged in (B). Immunoreactivity within the same region in healthy 
sera is depicted in (C). Spots identified by both healthy and PCa sera are circled in blue, 
whereas those identified exclusively by PCa patient sera are circled in red. All circled spots 
indicate those chosen for mass spectrometry.  
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3.3.3.3 Identification of TAAs from the DU-145 PCa cell line that 
elicit antibody responses in PCa sera 
 
To facilitate TAA identification by MALDI-TOF MS, DU-145 lysates were separated by 
2-DE and stained using Coomassie brilliant blue as described previously. 18 intense spots 
representing immunoreactivity with PCa or healthy sera were observed from immunoblots 
and circled in red or blue (figure 3.6); although only 16 of them could be assigned to 
protein spots on the Coomassie stained gels (figure 3.7). To identify these potential TAAs, 
the Coomassie stained replica gel and immunoprobed nitrocellulose membranes were 
manually aligned (figure 3.7) and corresponding spots were excised from the replica gel 
before being subjected to an overnight tryptic digest. Tryptic peptides were cleaned up and 
spotted on a ground steel target plate for identification using MALDI-TOF MS and the 
acquired PMF was searched against the SwissProt database using the Mascot search engine 
to identify potential TAA candidates. Identified proteins are summarised in table 3.4. 
 
 
 
Figure 3.7: Image showing immunoblot to membrane alignment to identify 
 immunoreactive TAAs in the DU-145 PCa cell line. 
16 immunoreactive spots identified with pooled PCa (Gleason 7, 8 and 9) sera were 
labelled as shown in (A), and aligned to Coomassie stained replica gels (B) for spot 
picking and TAA identification by MALDI-TOF MS. Immunoblot and membrane shown 
are cropped around the molecular weight and pI where most of the immunoreactivity 
occurred, as shown by the black square in figure 3.6.  
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Table 3.4: DU-145 identified proteins immunoreactive to PCa or healthy sera 
Spot 
no. 
Protein UniProt  
Accession 
e.pI t.pI e. MW 
(kDa) 
t. MW 
(kDa) 
MOWSE 
score  
Immunoreactivity 
with sera 
1 No protein identified - - - - - - PCa sera 
2 Heat Shock Protein 60 CH60_HUMAN 5.0 5.7 57 61 68/29 PCa sera 
3 Heterogeneous nuclear riboprotein HNRFF_HUMAN 5.1 9.4 46 53 132/30 PCa sera 
4 No protein identified - - - - - - PCa & healthy sera 
5 No protein identified - - - - - - PCa & healthy sera 
6 Alpha enolase ENOA_HUMAN 6.5 7.01 45 48 65/56 PCa sera 
7 Alpha enolase ENOA_HUMAN 6.7 7.01 45 48 63/56 PCa sera 
8 No protein identified - - - - - - PCa sera 
9 Alpha enolase ENOA_HUMAN 7.0 7.01 45 48 88/56 PCa sera 
10 WNT7A WNT7A_HUMAN 8.0 9.05 43 39 37/30 PCa sera 
11 ATP synthase subunit ATPK_HUMAN 8.5 - 52 11 60/56 PCa & healthy sera 
12 No protein identified - - - - - - PCa sera 
13 No protein identified - - - - - - PCa sera 
14 No protein identified - - - - - - PCa sera 
15 No protein identified - - - - - - PCa sera 
16 No protein identified - - - - - - PCa & healthy sera 
 
Identified TAAs from 2-DE immunoblots immunoreactive with PCa or healthy sera. Only 7 spots were identified out of 16 analysed by PMF using MALDI-TOF 
MS/MS. 65/56 = Mascot ion score of 65 where a score of >56 is considered significant. t; theoretical, e; experimental, pI; isoelectric point, MW; molecular weight.
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3.3.3.4 Identification of the 47 kDa protein as alpha enolase by 
MALDI-TOF MS 
 
16 proteins were shortlisted for MS identificaton from the PROTEOMEX screen in DU-
145, however, only 7 spots yielded any protein identication by MALDI-TOF MS (table 
3.4). Of these 7 proteins, three of them (spots 6, 7 and 9) separated at an estimated 
isoelectric point of 6.5, 6.7 and 7.0 and approximate molecular weight 47 kDa. All three 
proteins also showed strong reactivity with sera from PCa patients in comparison to 
controls (Figure 3.6 and Table 3.4) and were identified as the same protein, alpha enolase 
by PMF with significance (MOWSE score of 65, 63 and 88 for spots 6, 7 and 9 
respectively, where a MOWSE score of 56 is considered significant). 
 
In order to confirm the identification of alpha enolase by PMF, four peaks from sample 9 
were chosen from the peptides identified by PMF and subjected to sequence analysis by 
MALDI-TOF/TOF (table 3.5). Figure 3.8A shows the whole sequence of alpha enolase 
where bold letters indicate all four matched peptides by MALDI TOF MS/MS. B shows 
the sequence analysis for one of four sequenced peptides of alpha enolase, 
AAVPSGASTGIYEALELR, with a Mascot ion score of 114/30 (fig. 3.8C) where a score 
of >30 is significant, indicating identity or extensive homology to a known protein on the 
SwissProt database (p<0.05). 
 
Table 3.5:  Identification of alpha enolase peptides from DU-145 by MALDI-TOF 
  MS/MS 
Protein Observed 
m/z peak 
Mascot 
score 
SC 
(%) 
Peptide 
Alpha Enolase 1804.9656 144/30 4% R.AAVPSGASTGIYEALELR.D 
 1924.0011 72/30 3% K.LAMQEFMILPVGAANFR.E 
 1540.8016 102/31 3%   K.VVIGMDVAASEFFR.S 
 1908.0095 108/30 3%   K.LAMQEFMILPVGAANFR.E 
 
Four peaks identified as alpha enolase in DU-145 by PMF were subjected to MALDI-TOF 
MS/MS. The Mascot ion score for each peak is shown as well as the peptide it corresponds 
to. SC; protein sequence coverage. 114/30; MOWSE score of peptide is 114, where a 
score >30 is considered significant; underlined M indicates an oxidation of methionine. R 
or K. at the start of the peptide sequence represents tryptic cleavage sites for each peptide. 
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Figure 3.8:  Identification of alpha enolase a as potential TAA from the DU-145 cell 
line using MALDI-TOF MS/MS. 
The figure shows the full length sequence of human alpha enolase where peptides in bold 
indicate all four matched peptides by MALDI-TOF MS (A). Panel (B) shows one of four 
sequenced peptides of alpha enolase AAVPSGASTGIYEALELR with an m/z 1804.9583 
by MALDI-TOF MS/MS. Panel (C) shows the Mascot ion score of the peptide 
AAVPSGASTGIYEALELR after matching the SwissProt database. The sequenced 
peptide has a MOWSE score of 144 where a score >30 is significant, indicating identity or 
extensive homology to a known protein on the SwissProt database (p<0.05).  
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3.3.4  Confirmation of MALDI-TOF identification of alpha enolase 
  in the DU-145 PCa cell line 
 
Among the protein spots identified with high confidence by MALDI-TOF MS, this study 
focussed on alpha enolase as it was identified in more than one patient group and both PCa 
cell lines. However, before alpha enolase could be validated as a potential biomarker for 
PCa, it was important to confirm the MS identification of alpha enolase in PCa cell lines 
using other complementary techniques, and confirm the presence of a differential 
autoantibody response in the PCa and healthy sera samples analysed. Both studies were 
carried out using immunofluorescence, flow cytometry, western blotting, mass 
spectrometry and ELISA techniques. 
 
3.3.4.1 Confirmation of alpha enolase expression in DU-145 using 
immunofluorescence, flow cytometry and Western blotting 
 
To further demonstrate that alpha enolase is present in DU-145, the first experiments were 
carried out using immunofluorescence (method as described in section 3.2.3.1). In brief, 
DU-145 PCa cells were seeded and grown as a monolayer on round fluorescence 
compatible coverslips in 24 well plates. After a period of growth (about 48 hours), cells 
were examined to confirm the presence of alpha enolase by immunofluorescence using a 
commercially available specific monoclonal antibody raised against alpha enolase (clone 
L-27, Santa Cruz, UK) (figure 3.9A) or using a mouse IgG isotype control. Figure 3.9A 
shows intense cytoplasmic and nuclear staining for alpha enolase in DU-145 with some 
suggested staining observed around the outside of the cell (indicated by the red arrows on 
figure 3.9A). No staining was observed using the mouse IgG isotype control. 
 
The presence of alpha enolase in DU-145 was also verified using flow cytometry. In brief, 
DU-145 cells were counted, washed and permeabilised before incubation with the same 
anti-alpha enolase monoclonal antibody (clone L-27, Santa Cruz, UK). Expression of alpha 
enolase in DU-145 was demonstrated by a Beckman Coulter Gallios flow cytometer which 
showed a positive intracellular stain, indicated by a large number of cells shifted to the 
right of the overlay plot (figure 3.9B). In addition, no staining was observed in any of the 
controls - cells alone, secondary alone or mouse IgG isotype (figure 3.9B). In order to 
confirm that alpha enolase potentially exists around the outside of the cell as implied by 
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immunofluorescence (red arrows in figure 3.9A), DU-145 cells were stained using flow 
cytometry to determine cell surface alpha enolase expression. Multiple attempts 
demonstrated no alpha enolase cell surface expression in DU-145 (appendix VI). 
 
Finally, alpha enolase in DU-145 was verified using Western blotting. 20 µg of DU-145 
protein lysates were separated by 2-DE gels (3-10L IPG strips and 10% SDS PAGE) and 
transferred onto nitrocellulose membranes or stained with Coomassie blue as described in 
the discovery experiments (section 3.2.2.5). Membranes were probed with a monoclonal 
mouse-anti alpha enolase antibody at a 1:1000 dilution (clone L-27, Santa Cruz, UK) 
(figure 3.9C & D). Specific binding of the antibody was only observed at 49 kDa, and at a 
pH between 5 and 8. To further confirm the presence of alpha enolase in DU-145, a 
Coomassie stained replica gel was run alongside the analytical gel for spot picking. As 
with the discovery experiments, the membrane probed with the monoclonal mouse anti- 
alpha enolase antibody (figure 3.9C & D) was manually aligned to the stained gel (figure 
3.9E). Two spots representing positive alpha enolase expression by Western blotting were 
chosen from the immunoblots (circled in red in figure 3.9C&D) and excised from the 
stained replica gel before analysis by MALDI-TOF MS. 
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Figure 3.9: Verification of alpha enolase expression in DU-145 PCa cell line by 
immunofluorescence, flow cytometry and Western blotting. 
The presence of alpha enolase in DU-145 was determined by immunofluorescence staining 
using a specific monoclonal mouse anti-alpha enolase antibody, with membrane staining 
indicated by red arrows (A) and using flow cytometry (B). Alpha enolase expression was 
also determined by Western Blotting where DU-145 lysates were separated by 2-DE and 
immunoblotted with a monoclonal alpha enolase antibody (clone L-27, Santa Cruz, UK). 
Positive reactivity enclosed by the red circle on the blotted membrane (D) indicates the 
presence of alpha enolase protein in DU-145. Spots corresponding to alpha enolase were 
excised from the Coomassie stained replica gel (E) for the confirmation of alpha enolase in 
DU-145 by mass spectrometry. Objective magnification x 40. 
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3.3.4.2  Confirmation of alpha enolase expression in DU-145 using 
mass spectrometry 
 
Two spots at an estimated molecular weight of 49 kDa and a pI of 6.5 and 7.0 respectively 
showing positive expression of alpha enolase by Western blotting (figure 3.9C, D & E), 
were excised from a stained Coomassie gel and subjected to an overnight in-gel trypsin 
digest for TAA identification by MALDI-TOF MS (as described in section 2.2.9). Tryptic 
peptides were identified by PMF and used to search the SwissProt databases using the 
Mascot search engine (search criteria outlined in section 2.2.9.3.1). Identified proteins are 
summarised in table 3.6). Both spots were identified as the same protein, alpha enolase by 
PMF with a MOWSE score of 82 and 100 for spots 1 and 2 respectively (where a 
score >56 is considered significant). 
 
Table 3.6:  Verification of alpha enolase from DU-145 2-DE spots by MALDI-TOF 
 MS/MS 
Spot 
no. 
Protein name Accession t. Isoelectric 
point 
t. MW 
(Da) 
Mascot  
score 
1 Alpha enolase ENOA1_HUMAN 7.01 47,841 82/56 
2 Alpha enolase ENOA1_HUMAN 7.01 47,841 100/56 
 
Corresponding spots recognised by the monoclonal mouse anti-alpha enolase antibody were identified by 
MALDI-TOF by PMF or MS/MS of one or more of the peaks identified by PMF. 82/56 = Mascot score of 82 
where a score >56 is considered significant. t; theoretical. 
 
Nine peaks from one of the spots, (spot 2) were chosen from the PMF and subject to 
sequence analysis by MALDI-TOF/TOF. Figure 3.10A shows all nine peptides identified 
as alpha enolase using MALDI-TOF MS/MS, while figure 3.10B shows the whole 
sequence of alpha enolase where bold letters indicate all nine matched peptides by 
MALDI-TOF mass spectrometry. 
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Figure 3.10:  Verification of alpha enolase by MALDI-TOF mass spectrometry. 
Panel (A) shows the nine peaks identified as alpha enolase by PMF, which were then 
subjected to MALDI-TOF MS/MS. The Mascot ion score for each peak is shown as well 
as the peptides they correspond to. Panel (B) shows the full length protein sequence of 
alpha enolase where bold letters indicate all nine matched peptides by mass spectrometry. 
SC; protein sequence coverage. R or K. at the start of the peptide sequence represents 
tryptic cleavage sites for each peptide. 
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3.3.4.3  Confirmation of the presence of alpha enolase autoantibodies 
in pooled discovery sera 
 
To confirm that pooled PCa and healthy discovery sera contained autoantibodies to alpha 
enolase, a full-length commercially available recombinant alpha enolase protein was 
purchased from Fitzgerald (USA) to serve as a positive control. Recombinant alpha 
enolase was separated by 10% SDS PAGE and transferred onto nitrocellulose membranes 
before probing with pooled (discovery) sera from PCa and healthy subjects (i.e. same 
patient samples used in the DU-145 discovery/identification experiments).  
 
Various concentrations of recombinant alpha enolase (1000 ng, 100 ng, 50 ng, 25 ng & 10 
ng) were separated by SDS PAGE and immunoprobed with PCa or control sera (1:80 
dilution; same as the discovery experiments). Expression of alpha enolase was 
demonstrated at the expected 47 kDa molecular weight using a mouse anti-alpha enolase 
antibody probed against the recombinant protein, which served as a positive control (figure 
3.11). Figure 3.11A showed that pooled PCa sera was able to detect as little as 25 ng of 
recombinant alpha enolase, whereas pooled healthy sera could not detect beyond 1000 ng 
by Western blot analysis (figure 3.11A). No bands were observed when PCa or healthy 
sera were screened with various concentrations of BSA, which served as a negative control.  
 
A similar study was carried out using an ELISA assay to demonstrate that PCa and healthy 
sera contained differential titres of alpha enolase autoantibodies. A pre-optimised 
concentration of alpha enolase (100 ng/mL) was coated on each well of a 96 well plate 
overnight and incubated with various dilutions of pooled PCa or healthy (discovery) sera. 
Using a two way ANOVA, statistical significance (p=0.001) was observed at each dilution 
between PCa and control sera at p<0.05 (figure 3.11B). This study was also carried out in 
order to determine the optimum sera dilution required for subsequent verification and 
validation experiments by ELISA (chapter 5). Similar to figure 3.11A, figure 3.11B shows 
that PCa sera contain more autoantibodies to alpha enolase than healthy sera even at the 
same antigen concentration. Results from both studies indicate that pooled PCa (discovery) 
sera contain more autoantibodies against recombinant alpha enolase compared to healthy 
sera.  
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Figure 3.11: Detection of autoantibodies to various concentrations of recombinant 
alpha enolase and various dilutions of pooled PCa and healthy sera. 
Panel A shows recombinant alpha enolase protein titrated at various concentrations (10 – 
1000 ng) and loaded onto SDS PAGE gels to verify the presence of autoantibodies to 
recombinant alpha enolase in pooled patient or healthy (discovery) sera. Sera were used at 
the same dilution as those used in the discovery experiments. r; recombinant alpha enolase. 
Panel B shows the mean optical density of pooled PCa and healthy sera from the discovery 
sample set to 100 ng of recombinant alpha enolase. Statistical significance (p=0.001) was 
observed at each dilution between PCa and control sera at p<0.05. 
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3.3.4.4 Confirmation of the prevalence of alpha enolase sera 
autoreactivity in patients with PCa  
 
Section 3.3.4.3 demonstrated alpha enolase specific reactivity patterns to pooled PCa sera, 
indicating that autoantibodies to alpha enolase may serve as a potential PCa biomarker 
following additional validation. It was important to then determine the frequency of alpha 
enolase autoantibody occurrence in the patients studied. To do this, all patients that made 
up the discovery set were analysed using an ELISA assay. Serum from each patient – PCa 
(n=26) or healthy controls (n=3) (1:25 dilution) was added to 96 well plates coated with 
recombinant alpha enolase. Sera from individual PCa patients were compared against 
pooled healthy sera (n=3), due to insufficient volumes of healthy sera. Wells containing 
recombinant alpha enolase protein and incubated with a monoclonal anti-alpha enolase 
antibody served as a positive control, while wells containing secondary alone or 
recombinant protein alone served as a negative control. No increase in absorbance was 
observed in wells containing only recombinant alpha enolase or secondary antibody (data 
not shown).  
 
Figure 3.12 shows an increase in the average absorbance values of various PCa samples to 
recombinant alpha enolase, compared to pooled healthy controls, indicating a differential 
serum autoantibody titre to alpha enolase in the samples studied. Due to the limited volume 
of sample available, alpha enolase expression could only be studied in a pool of healthy 
control sera compared to individual PCa sera (n=26 patients). As a result, the conventional 
statistical test could not be performed between the two patients groups to determine 
whether there was a significant difference between both groups. Nevertheless, the average 
optical density of the pooled healthy control samples was 0.34 and 21 out of the 26 PCa 
patients studied (81%) had an average optical density >0.34 (mean optical density of 
healthy sera is indicated by a red dashed line in figure 3.12). Figure 3.12 also shows the 
average absorbance of all patients studied when arranged according to their Gleason grade, 
where there seemed to be no association between Gleason grade and alpha enolase 
autoantibody quantity. 
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Figure 3.12:  ELISA assay showing the mean optical density for PCa or pooled 
healthy sera towards recombinant alpha enolase.  
The graph shows the mean optical density (at 450 nm) of 26 PCa or pooled healthy sera 
towards 100 ng recombinant alpha enolase. Samples which made up the discovery set were 
utilised in this study - Gleason 7 (3+4) (n=11), Gleason 7 (4+3) (n=10), Gleason 8 (n=2) 
and Gleason 9 (n=3). Vertical error bars indicate standard deviation of the replicates (n=3) 
from each sample. Dashed red line indicates the average absorbance at 450 nm of healthy 
control sera. As healthy sera was only available in a small pool to compare with individual 
PCa samples, it was not possible to perform the conventional statistical test to determine 
the significance of autoantibody titres between PCa and healthy control groups.  
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3.4 DISCUSSION 
 
The current study aimed to identify TAAs and autoantibodies which can serve as 
biomarkers for PCa. To this end, a serological analysis of the proteome (PROTEOMEX), 
which combines 2-DE and Western blotting to detect autoantibodies in the sera of patients 
to TAAs in two classic PCa cell lines was utilised. Although PROTEOMEX is more 
usually carried out using tumour tissues, the lack of sufficient tissue material allowed PCa 
cell lines to be investigated as a source of biomarkers. 
3.4.1  TAA identification in the PC-3 cell line 
 
Initial screening in the PC-3 PCa cell line used a small subset of Gleason 7 (3+4), (4+3), 
benign and healthy controls samples to identify TAAs in PC-3. A sub-aim of the study was 
to identify biomarkers which could distinguish the aggressive from non-aggressive form of 
Gleason 7 PCa. Using PROTEOMEX, two intense spots reacted with sera from newly 
diagnosed PCa patients and not from healthy controls, suggesting that these proteins evoke 
a humoral immune response in PCa (figure 3.3). Using PMF and MALDI-TOF MS/MS 
(figure 3.5 and table 3.3), both spots were identified as the same protein, alpha enolase. 
Figure 3.3 also shows that both spots were more intense in Gleason 7 (4+3) compared to 
Gleason 7 (3+4) although the same amount of protein was loaded on both gels. This 
suggests that there may be a higher titre of autoantibodies to alpha enolase in the 
aggressive form of Gleason 7 PCa (Gleason 7 4+3) compared to the less aggressive form 
(Gleason 7 3+4). However, to further validate this finding, additional studies utilising an 
ELISA assay need to be carried out on a large cohort of patients with both Gleason 7 (4+3) 
and Gleason 7 (3+4) PCa to determine if there is a relationship between alpha enolase 
expression and PCa aggressiveness. 
 
Alpha enolase is one of the most abundantly expressed cytosolic proteins in many 
organisms (Diaz-Ramos et al., 2012). It is expressed by most cells, where its level of 
expression is dependent on the pathophysiological, developmental and metabolic cell state 
(McAlister and Holland, 1982). Enolase catalyses the dehydration of 2-phospho-D-
glycerate (2-PG) to phosphoenolpyruvate (PEP) in the 9th step of glycolysis (Tomaino et 
al., 2011). Many studies have reported the use of a similar immunoproteomic approach to 
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identify autoantibodies to alpha enolase. He et al (2007) identified autoantibodies to alpha 
enolase in 27.7% of non-small cell lung cancer (NSCLC) patients compared to 1.7% of 
healthy controls. Immunohistochemical tissue staining also found an increased alpha 
enolase expression in NSCLC tumour tissues, which was confirmed by flow cytometry 
showing alpha enolase expression on cancer cell surfaces. Using a proteomics approach, 
Tomaino et al (2011) also identified circulating autoantibodies to two acidic forms of 
phosphorylated alpha enolase in 62% of patients with pancreatic cancer compared to 4% of 
healthy controls. 
3.4.2  TAA identification in the DU-145 cell line 
 
The DU-145 study (section 3.3.3) utilised another classic PCa cell line to screen for PCa 
sera immunoreactivity. Due to sample volume limitations, the same set of samples used for 
the PC-3 screen was not used for the DU-145 screen. Furthermore, in comparison to other 
studies in the literature who have carried out TAA identification using PROTEOMEX, the 
number of immunoreactive spots yielded from the PC-3 study was low (2 spots in our 
study, compared to 25 spots on average in the literature). Thus, the number of patients 
utilised for screening was increased. The new discovery sample set consisted of PCa 
patients with a medium to high Gleason grade (Gleason 7, 8, 9); because it was 
hypothesised that sera from these patients would contain more TAAs and autoantibodies 
than those with lower grades, because they had more aggressive tumours. At this point in 
the study, no more healthy control male volunteers had been recruited for this investigation 
leaving the number of control sera from the PC-3 experiment the same as the one used to 
screen the DU-145 lysates (n=3). 
 
DU-145 immunoscreening revealed more immunoreactive spots than PC-3 (figure 3.6; 18 
immunoreactive spots in DU-145 compared to 2 spots in PC-3). In addition, PCa sera 
reacted exclusively and more intensely with twice the number of spots compared to healthy 
sera, suggesting increased autoantibody responses in PCa compared to healthy controls 
(figure 3.6).  The visualisation of spots in DU-145 occurred within a similar molecular 
weight region as PC-3 (40 – 90 kDa) range. Other studies using PROTEOMEX have also 
found this molecular weight region the most immunoreactive (Desmetz et al., 2008 and 
Forgber et al., 2009). 
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Although 18 spots were differentially expressed on immunoblots, only 16 could be 
matched to proteins on the replica gel due to difficulties in aligning immunoblots to mini-
gels. Out of the 16 spots analysed by MALDI-TOF MS, only 7 spots could be identified as 
5 different proteins (summarised in table 3.4). This could be due to insufficient protein in 
the sample, insufficient tryptic cleavage sites on the protein, sample contamination which 
masks peptide signals in mass spectrometry or protein sequences not being present in the 
MASCOT database searched. In terms of biological processes however, the TAAs 
identified belong to several groups; immune response, B-cell activation and cell surface 
binding (CH60 or HSP-60), cell-cell signalling (WNT7A), metabolic enzymes (alpha 
enolase) and energy metabolism (ATP synthase subunit). HSP-60 belongs to a family of 
chaperone proteins and has previously been shown to induce an immune response in 
hepatocellular carcinoma (Hong et al., 2015), colorectal cancer and ductal carcinoma in 
situ (Desmetez et al., 2008). Desmetz et al. (2008) also demonstrated that autoantibodies to 
HSP-60 could serve as a potential breast cancer biomarker, where 32% of patients with 
ductal carcinoma in situ (DCIS) had autoantibodies to HSP-60 compared to 4.3% of 
healthy controls. Furthermore, a significantly higher frequency of autoantibodies to HSP-
60 was found in high grade DCIS patients compared to patients with lower grade cancers. 
WNT7A part of the WNT signalling pathway, has been found to be over-expressed in the 
epithelium of serous ovarian carcinomas, but undetected in normal ovary, benign and 
endometrial carcinomas, suggesting its role as a TAA (Yoshioka et al., 2012). 
 
Out of several candidate TAAs identified, this study observed for the first time that alpha 
enolase was capable of inducing a specific sera reactivity in a subset of PCa patients, 
compared to healthy controls. Interestingly, although two sets of patient samples (and two 
separate cell lines) were utilised for TAA identification, both studies identified reactivity to 
alpha enolase in PCa, warranting further investigation into the potential utility of alpha 
enolase as a biomarker for PCa. It is also well documented that the overexpression of alpha 
enolase in various tumours and its ability to induce a humoral and/or cell mediated immune 
response in various cancers, allows it to be classified as a true TAA (Capello et al., 2011). 
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3.4.3  Tumour antigen confirmation and verification 
 
Although alpha enolase was identified with a high level of significance in PC-3 and DU-
145, it was important to demonstrate that its identification was not due to false discovery. 
Thus, verification experiments aimed to confirm results obtained by immunoblotting and 
MALDI-TOF mass spectrometry (sections 3.3.1 and 3.3.2), to demonstrate the presence of 
alpha enolase in DU-145 and a differential expression of serum autoantibodies to alpha 
enolase in the discovery cohort using immunofluorescence, flow cytometry, Western 
blotting and mass spectrometry. 
 
DU-145 cells were immunofluorescently screened with a monoclonal anti-alpha enolase 
antibody which demonstrated correct alpha enolase expression in the cytoplasm and some 
potential membrane expression (figure 3.9). Alpha enolase expression was also verified by 
flow cytometry, Western blotting and MALDI-TOF MS (figure 3.9 and 3.10); where 
extracellular staining flow cytometry staining failed to detect membranous alpha enolase 
(appendix VI). It is well documented that alpha enolase is expressed on the membrane of 
cells, where it acts as a plasminogen receptor in cancer cells (Lopez-Aemany et al., 1994), 
leukocytic cell lines (Lopez-Aemany et al., 2003) and monocytoid cells (Miles et al., 
1991). The expression of membranous alpha enolase is likely to be dependent on the 
activation status or pathophysiological conditions of the cells (Fontan et al., 2000 and Arza 
et al., 1997). However, this study failed to confirm membranous alpha enolase expression 
in DU-145, possibly due to cell surface proteins cleaved off during cell harvesting by 
Trypsin & Versene treatment. 
 
The presence of autoantibodies to alpha enolase in sera was also verified (section 3.3.4.3). 
Using the same pooled sera from the DU-145 discovery study, Western blotting and 
ELISA showed a differential expression of sera autoantibodies in PCa sera compared to 
controls (figure 3.11). When patients in the PCa pool were screened individually using an 
ELISA assay, a higher level of autoantibody response was detected in PCa patients 
compared to a pool of healthy controls (figure 3.12). Due to sample volume limitations, it 
was not possible to carry out a statistical test to determine if the observed differences in 
autoantibody responses were statistically significant. Studies to demonstrate significance 
were carried out in subsequent chapters (chapter 5). 
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Previous research has identified alpha enolase autoantibodies in PCa. Autoantibodies to 
alpha enolase were first demonstrated in one PCa patient by Adamus et al. (1996) and 
subsequently in another PCa patient by Weleber et al. (2005). Alpha enolase has also been 
identified as a TAA in chronic myeloid leukaemia (Zou et al., 2005), HER2+ breast cancer 
(Mojtahedi et al., 2011) non-malignant diseases such as rheumatoid arthritis (Saulot et al., 
2002) and 41% of asthma patients (Nahm et al., 2006).  
 
To our knowledge, this is the first report outlining the presence of alpha enolase 
autoantibodies in a subset of (Gleason 7, 8 and 9) PCa patients. However, the occurrence 
of alpha enolase autoantibodies in a large sample cohort needs to be experimentally 
determined in order to validate our findings, which constitutes part of the penultimate 
chapter (chapter 5). The identification of alpha enolase as a TAA and potential PCa 
biomarker in this study demonstrates the robustness of the methodology developed in 
identifying relevant TAAs for PCa.  
 CHAPTER 4: Alpha enolase in other biological samples 
148 
   
4. CHAPTER 4: EVALUATION OF ALPHA 
ENOLASE PROTEIN EXPRESSION IN OTHER 
BIOLOGICAL SAMPLES 
4.1  INTRODUCTION 
 
Early diagnosis and treatment of PCa increases the possibility of curing the disease by 
avoiding the progression and development of micro metastasis in localised tumours (Smith 
et al., 2003). PSA, the first line test for PCa detection currently lacks the sensitivity and 
specificity required for accurate cancer diagnosis, resulting in an increase in PCa incidence 
due to the widespread use of PSA screening (Stanford et al., 1999). This emphasises the 
need for the identification of more accurate markers which can detect the presence of 
prostate tumours but more importantly, distinguish indolent from aggressive diseases. 
 
Using MALDI-TOF mass spectrometry, the previous chapter identified antibody responses 
to alpha enolase in two metastatic PCa cell lines (PC-3 and DU-145; section 3.3.2 & 3.3.3), 
suggesting that alpha enolase may serve as a potential PCa biomarker following additional 
investigation. However, before studies could be carried out to validate its utility as a 
potential PCa biomarker, it was important to evaluate the expression of alpha enolase in 
more than one prostate relevant biological sample. This would further confirm studies 
reported in the literature regarding its expression pattern and justify its validation in other 
biological samples in the subsequent chapter. 
 
Discovered in 1934 by Lohmann and Meyerhoff, enolase (phosphopyruvate hydratase) is a 
homodimeric metalloenzyme which catalyses the dehydration of 2-phospho-D-glycerate 
(2-PG) to phosphoenolpyruvate (PEP) in the 9th step of the glycolytic pathway (Pancholi, 
2001). During gluconeogenesis, enolase also catalyses the reverse reaction in the anabolic 
pathway which hydrates phosphoenolpyruvate to 2-phospho-D-glycerate (World, 1971). 
Enolase is a metalloenzyme, requiring Mg2+ ions for its catalytic activity (Brewer, 1981 
and Brewer and Ellis, 1983). Three isoforms of the enzymes exist in mammals: α-enolase 
(ENO1), γ-enolase (ENO2) and β-enolase (ENO3), all encoded by three separate genes 
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ENO1, ENO2, ENO3, with high sequence identity. The isoform expression of enolases is 
tissue specific: ENO1 is found in most adult tissues while ENO2 is present in neurons and 
neuroendocrine tissues and ENO3 in muscle tissues (Craig et al., 1990, Feo et al., 1990 
and Rider and Taylor, 1975). 
 
Depending on its cellular location, alpha enolase plays a functional role in several 
physiological processes. Using an alternative start codon, the ENO1 gene can be translated 
into a 37 kDa protein, c-myc promoter binding protein (MBP-1). In the nucleus, MBP-1 
binds to the c-myc P2 promoter acting as a transcription repressor which leads to tumour 
suppression by its interaction with histone deacetylase (Feo et al., 2000). Furthermore, 
studies have shown the association of ENO1 with MBP-1 in the transcriptional regulation 
of the c-myc oncogene (Subramanian and Miller, 2000). In addition to its role in 
transcriptional regulation, alpha enolase acts as a stress protein, upregulated by the 
activation of hypoxia-inducible factor (HIF-1) and increasing the protection of cells by 
increasing anaerobic metabolism (Semenza et al., 1996 and Aaronson et al., 1995). 
 
In pancreatic, breast and lung cancers, alpha enolase has been identified on the surface of 
tumour cells (Capello et al., 2009, Seweryn et al., 2009 and He et al., 2007), while it is 
secreted by exosomes in melanoma and non-small cell lung cancer (Mears et al., 2004 and 
Yu et al., 2006).  Alpha enolase lacks a transmembrane domain; as a result, it is not clear 
how it translocates to the cell surface. However, it is well documented that the binding of 
alpha enolase to its plasminogen receptor leads to the activation of plasminogen to plasmin 
by tissue-type (tPA) or urokinase type (uPA) plasminogen activators, further contributing 
to physiological and pathophysiological processes such as embryogenesis and tissue 
remodelling, inflammatory responses, cell invasion and tissue metastasis (Felez 1998, 
Moscato et al., 2000; Lopez-Alemany et al., 2003 and Plow et al., 1995). 
 
Alpha enolase is overexpressed in many tumours (table 4.1), where it induces a humoral 
and/or cell mediated immune response, classifying it as a true TAA (Capello et al., 2011). 
Otto Warburg observed that cancer cells consume more glucose than their normal 
counterparts and thereby generate ATP by converting pyruvate to lactic acid, even in the 
presence of a normal supply of oxygen (Warburg, 1930 and Vander Heiden et al., 2009). 
This mechanism, termed the ‘Warburg effect’ is observed in many tumours where 
glycolytic enzymes are upregulated by hypoxia-inducible factor. As alpha enolase contains 
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a hypoxia responsive element, an upregulation of alpha enolase has been identified at both 
the mRNA and protein level in many cancers, as summarised in table 4.1.  
 
Table 4.1: Increased expression of alpha enolase in cancer 
Cancer Alpha enolase mRNA or protein expression 
Brain mRNA (Altenberg and Greulich, 2004) 
Breast mRNA (Tu et al., 2010), protein (Somiari et al., 2003, Malorni 
et al., 2006 and Kabbage et al., 2008) 
Cervix mRNA (Altenberg and Greulich, 2004), protein (Bae et al., 
2006 and Bae et al., 2005) 
Colon mRNA (Altenberg and Greulich, 2004), protein (Katayama et 
al., 2006 and Wong et al., 2008) 
Eye mRNA (Altenberg and Greulich, 2004) 
Gastric mRNA (Altenberg and Greulich, 2004), protein (Qi et al., 2005 
and Zhao et al., 2007) 
Head & neck mRNA (Tsai et al., 2010 ), protein (Govekar et al., 2009) 
Kidney mRNA (Altenberg and Greulich, 2004) 
Leukaemia protein (Lopez-Pedrera et al., 2006) 
Liver mRNA (Altenberg and Greulich, 2004, Hamaguchi et al., 
2008), protein (Takashima et al.,  2005) 
Lung mRNA (Altenberg and Greulich, 2004), protein (Li et al., 2004, 
Li et al., 2006, Huang et al., 2006, Rubporn et al., 2009, Chang  
et al., 2006) 
Muscle mRNA (Altenberg and Greulich, 2004) 
Ovary mRNA (Altenberg and Greulich, 2004), protein (Cao et al., 
2010) 
Pancreas mRNA (Altenberg and Greulich, 2004), protein (Shen et al., 
2004, Capello  et al., 2009, Mikuriya et al., 2007) 
Prostate mRNA (Altenberg and Greulich, 2004), protein (Rehman et al., 
2004) 
Skin mRNA (Suzuki et al, 2010 ) 
Testis mRNA (Altenberg and Greulich, 2004) 
 
The expression of alpha enolase at the mRNA or protein level reported in various cancers. 
Adapted from Capello et al. (2011). 
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4.1.1  Aims and objectives 
 
The aim of this chapter is to evaluate the expression of alpha enolase in various biological 
samples, in order to validate its potential utility as a PCa biomarker. This will be carried 
out by: 
1. Demonstrating and confirming the expression of alpha enolase in four available 
PCa cell lines – PC-3, LNCaP, OPCT-1 and DU-145 using immunofluorescence, 
flow cytometry and Western blotting. 
2. Demonstrating and confirming the expression of alpha enolase in the urine of PCa 
and healthy controls by Western blotting. 
3. Demonstrating and confirming the expression of alpha enolase in normal organ 
tissues, multiple tumour tissues and cancer adjacent normal tissues and a small 
cohort of PCa patient tissues using immunohistochemistry. 
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4.2  METHODS 
 
 
 
Figure 4.1:  Method outline for the identification/verification of alpha enolase  
  expression in  other biological samples. 
A flowchart summary of the methods used for the identification of alpha enolase 
expression in this chapter. 
 
4.2.1  Prostate cancer sera and urine 
 
Sera and urine samples from PCa patients were collected and banked at the Urology Centre, 
Nottingham City Hospital, Nottingham, UK. Samples were prepared and stored as outlined 
in section 2.2. 
4.2.2 PCa cell lines 
 
Four available PCa cell lines were purchased from ATCC and utilised in this study as a 
source of TAAs (PC-3, DU-145, LNCaP and OPCT-1). PC-3, DU-145 and LNCaP were 
purchased from ATCC while OPCT-1 was gifted from ONYVAX. PC-3 was grown in 
Ham’s F12 media supplemented with 1% sodium pyruvate, 1% non-essential amino acids 
and 10% foetal calf serum (FCS). DMEM was supplemented with 10% FCS and 1% L-
Glutamine for DU-145 cells, while RPMI-1640 media was supplemented with 5 ng/mL 
hydrocortisone, 5 ng/mL testosterone and 10% FCS for LNCaP cells. OPCT-1 was 
cultured in keratinocyte media supplemented in 2% FCS. The attributes of all PCa cell 
 CHAPTER 4: Alpha enolase in other biological samples 
153 
   
lines utilised in this chapter are outlined in table 3.1. Cell lines were maintained by serial in 
vitro passage as described in section 3.2.1.1. 
 
4.2.3  Immunofluorescence, flow cytometry, Western blotting 
 
The verification of TAAs by immunofluorescence, flow cytometry and Western blotting 
was carried out as described in 3.2.3.  TAAs were verified in all cell lines using the 
monoclonal mouse anti-alpha enolase antibody (clone L-27, Santa Cruz, UK). 
4.2.4  Immunohistochemistry staining of alpha enolase TMAs 
 
Tissue pre-staining: Tissue microarray slides (TMA) were purchased from US Biomax – 
slides BN243a, MC246 and T195B representative of normal organs, multiple cancer and 
prostate cancer tissues respectively (appendix III-V). Prior to immunohistochemical 
staining, paraffin wax on the TMA slides was melted at 60ºC for 10 min to remove the wax 
and unmask the antigen epitopes, in order to facilitate the staining procedure. Each slide 
was then allowed to cool on the bench at room temperature for 5 – 10 min before being 
placed on an Autostainer ST5010 XL (Leica, Milton Keynes, UK), which carried out 
automated deparaffinisation/hydration process as follows: 
 
• Slide immersed in a xylene bath (1) for 5 min 
• Slide immersed in a xylene bath (2) for 5 min 
• Slide immersed in a graded alcohol bath (1): (100%) ethanol for 2 min 
• Slide immersed  in a graded alcohol bath (1): (100%) ethanol for 2 min 
• Slide immersed in a graded alcohol bath: (70%) ethanol for 2 min 
• Slide immersed in dH2O for 5 min 
 
Slides were then placed into a bath containing citrate buffer for antigen retrieval (0.01 M 
citrate solution pH 6) and microwaved for 20 min at full power before carefully allowing 
to cool by dipping the slides into a bath of running tap water for 5 min. While slides were 
underwater, they were loaded onto sequenza immunostaining coverslips (Fisher Scientific, 
Loughbrough, UK) and inserted into sequenza immunostaining slide racks (Fisher 
Scientific, Loughbrough, UK). Each slide was then rinsed with a 1 x TBS solution which 
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was applied between the sequenza slide and its coverslip. This created a reservoir which 
allowed liquid to flow away from the bottom of the slide by capillary action. 
 
Tissue staining: Tissue staining was carried out using a Novolink Polymer Detection 
System kit (Leica, Milton Keynes, UK) which allows the co-visualisation of mouse and 
rabbit antibodies on a single slide. The staining protocol was carried out as per the 
manufacturer’s instructions. In brief, all staining solutions were applied in 100 µL volumes 
each time and then followed up with after two 5 min washes in TBS. A peroxidase block 
step was carried out using the peroxidase block solution for 5 min to reduce non-specific 
tissue staining due to endogenous peroxidase activity. The blocking buffer was washed as 
described before and a protein block was added for 5 min at room temperature and washed, 
to reduce non-specific background staining. After this, an optimised dilution (1:3000) of 
mouse monoclonal alpha enolase antibody (clone L-27, Santa Cruz, UK) was added to the 
sequenza reservoir. Antibody was left to bind for 60 min at room temperature followed by 
washing, and the addition of a post-primary block for 30 minutes which was washed as 
before. 
 
100 µL of a Novolink polymer was added and left to incubate for 5 min followed by a 
wash. DAB working solution was added for another 5 min, washed and counterstained 
with haematoxylin in a 6 min incubation step. Excess haematoxylin was rinsed off the slide 
using dH2O. Each slide was then removed from the sequenza reservoir and placed into the 
Autostainer as before, for a dehydration process which was carried out as follows: 
 
• Slide immersed in dH2O for 5 min 
• Slide immersed in a graded alcohol bath: (70%) ethanol for 2 min 
• Slide immersed in a graded alcohol bath (1): (100%) ethanol for 2 min 
• Slide immersed in a graded alcohol bath (2): (100%) ethanol for 2 min 
• Slide immersed in a xylene bath (1) for 5 min  
• Slide immersed in a xylene bath (2) for 5 min  
 
Coverslips were mounted onto each slide using DPX mounting medium.  
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4.3  RESULTS 
 
As depicted in figure 4.1, the identification of alpha enolase in other biological samples is 
subdivided into 3 sections: 
 
i. Alpha enolase expression in other PCa cell lines (section 4.3.1) 
ii. Alpha enolase expression in urine (section 4.3.2) 
iii. Alpha enolase expression in tissues (section 4.3.3). 
4.3.1   Alpha enolase expression in other PCa cell lines 
 
Although alpha enolase was identified in PC-3 and DU-145 PCa cell lines in the previous 
chapter (sections 3.3.1 and 3.3.2), its expression was only verified in DU-145 due to 
feasibility restraints (section 3.3.4). Thus, this chapter aimed to determine its expression in 
other available PCa cell lines. 
 
4.3.1.1 Alpha enolase protein expression in other PCa cell lines 
demonstrated by immunofluorescence 
 
Three available PCa cell lines (PC-3, LNCaP and OPCT-1) were examined for the 
expression of alpha enolase in PCa. As detailed in section 3.2.3.1, cells were grown on a 
monolayer and alpha enolase expression was determined using a mouse monoclonal anti-
alpha enolase antibody (clone L-27, Santa Cruz, UK). Figure 4.2 demonstrates a distinctive 
cytoplasmic expression in all 3 cell lines tested (DU-145 cells added for reference). 
Although these cell lines ranged from having moderate to high metastatic potential (table 
3.1), there was no obvious relationship in the level of alpha enolase expression and 
metastasis as demonstrated by immunofluorescence. It is worth noting, that although 
membranous expression was identified in DU-145 by immunofluorescence (indicated by 
red arrows in figure 4.2) no membranous expression was identified in any of the other PCa 
cell lines tested. These 4 cell lines have however provided a model system which alpha 
enolase expression could be investigated, for example to study its interacting partners. No 
expression was identified in isotype controls. 
 
 CHAPTER 4: Alpha enolase in other biological samples 
156 
   
 
Figure 4.2:  Alpha enolase expression in PCa cell lines by immunofluorescence.  
Immunofluorescence staining of all available PCa cell lines (DU-145, PC-3, LNCaP and 
OPCT-1) to assess alpha enolase protein expression. All cells were stained using a 
monoclonal mouse anti-alpha enolase antibody (clone L-27, Santa Cruz, UK). Cytoplasmic 
alpha enolase expression was identified in all PCa cell lines as shown by 
immunofluorescence. Red arrows indicate a possible expression of alpha enolase around 
the membrane of the cell in DU-145. Objective magnification x40. 
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4.3.1.2 Alpha enolase protein expression in other PCa cell lines 
demonstrated by flow cytometry  
 
As the previous chapter indicated that there was no cell surface alpha enolase expression in 
DU-145 (figures 3.9 and 4.2), the expression of intracellular alpha enolase was 
investigated in LNCaP, PC-3 and OPCT-1 using single colour flow cytometry against a 
monoclonal mouse anti-alpha enolase antibody (clone L-27, Santa Cruz, UK) and a goat 
anti-mouse secondary antibody conjugated to FITC. Using appropriate isotype controls, 
gated regions were defined in order to determine positivity. Figure 4.3 shows a histogram 
overlay of isotype control, secondary alone and cells alone compared to the test (PCa cells 
stained with alpha enolase antibody). Flow cytometry showed a right shift of cells positive 
for alpha enolase, compared to the controls (secondary alone, cells alone or isotype control) 
in PC-3, LNCaP and OPCT-1 (figure 4.3). DU-145 expression is also shown for 
comparison. Similar to results obtained with DU-145, no cell surface alpha enolase 
expression was observed in any of the PCa cell lines tested (appendix VI). 
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Figure 4.3:  Intracellular alpha enolase expression in all PCa cell lines 
demonstrated by flow cytometry.  
Flow cytometric data showing intracellular alpha enolase expression in 4 available PCa 
cell lines (DU-145, PC-3, LNCaP and OPCT-1). All cells were stained using a monoclonal 
mouse anti-alpha enolase antibody (clone L-27, Santa Cruz, UK) or a goat anti-mouse 
secondary antibody conjugated to FITC. Histogram overlay shows a shift to the right for 
positive cells compared to isotype, secondary and cells alone.  
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4.3.1.3 Alpha enolase protein expression in other PCa cell lines 
demonstrated by Western blotting 
 
In order to validate and confirm the expression of alpha enolase in all available PCa cell 
lines, Western blotting was performed on the cell lysates prepared from PC-3, LNCaP and 
OPCT-1. Cells lysates were separated on 10% SDS PAGE gels and transferred onto 
nitrocellulose membranes before immunoblotting with a monoclonal mouse anti-alpha 
enolase antibody (clone L-27, Santa Cruz, UK). Correct expression of alpha enolase was 
demonstrated by recombinant alpha enolase loaded into separate wells on Western blots 
(figure 4.4). Figure 4.4 shows the presence of an alpha enolase specific band at 47 kDa in 
PC-3, LNCaP, and OPCT-1. No bands were identified in BSA which served as a negative 
control (figure 4.4). 
 
 
Figure 4.4:   Alpha enolase expression in PCa cell lines demonstrated by Western 
 blotting. 
Western blot showing the expression of alpha enolase in 3 available PCa cell lines (LNCaP, 
OPCT-1 and PC-3). All cell lines were screened for alpha enolase expression using a 
monoclonal mouse anti-alpha enolase antibody (clone L-27, Santa Cruz, UK). A specific 
band at 47 kDa was identified in all cell lines, where correct alpha enolase expression was 
demonstrated by a recombinant alpha enolase protein. A fainter band was detected at 75 
kDa. No expression was detected in BSA (negative control). L; molecular weight ladder. 
 
4.3.2  Alpha enolase expression in urine 
 
To determine whether alpha enolase is secreted into the urine of the samples studied, PCa 
and healthy control samples that made up the discovery set were pooled into two main 
pools – a PCa (n=26 patients) and healthy pool (n=3 patients), due to the limited number of 
healthy control samples available. From each pool, the same amount of urinary proteins 
(50 µg) were separated on 10% SDS PAGE gels and run in duplicate before transferring 
onto nitrocellulose membranes for Western blot analyses. Transferred proteins were then 
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immunoprobed with a monoclonal mouse anti-alpha enolase antibody (clone L-27, Santa 
Cruz, UK) at a pre-optimised antibody dilution. 
 
Correct expression of alpha enolase was demonstrated at 47 kDa by comparison to 
recombinant alpha enolase, which was loaded into a separate well on Western blots (figure 
4.5). Figure 4.5 shows the presence of an intense band at 47 kDa in pooled PCa and 
healthy urine, where both bands were equally as intense. No bands were identified in BSA 
which served as a negative control (figure 4.5). It is also worth noting, that although alpha 
enolase is a 47 kDa protein, an intense band was observed with this monoclonal antibody 
at approximately 66 kDa in both PCa and healthy urine (figure 4.5). The band at 66 kDa 
was more intense in PCa urine compared to healthy controls, suggesting that there may be 
an increased expression of alpha enolase at 66 kDa in PCa (figure 4.5). To our knowledge, 
alpha enolase does not have a transcript variant at 66 kDa, which implies that this band 
may be due to a posttranslational modification or because it is bound to another (carrier) 
protein. 
 
 
Figure 4.5:  Alpha enolase expression in urine demonstrated by Western blotting.  
Urine samples which made up the discovery pool were pooled into two separate pools 
(PCa n=26, healthy control n=3). Urinary proteins were separated by SDS PAGE and run 
in duplicate before screening with a monoclonal mouse anti-alpha enolase antibody. A 
band at 47 kDa was observed in healthy and PCa urine samples similar to the positive 
control using a recombinant alpha enolase protein. Differential alpha enolase expression 
was identified in PCa urine compared to healthy controls at approximately 66 kDa. No 
expression was detected in BSA (negative control).  
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4.3.3  Alpha enolase expression in tissue  
 
Despite being useful tools to study the presence of alpha enolase, urine, PCa cell lines and 
serum autoantibody responses are not useful tools in demonstrating cellular protein 
localisation or protein abundance at the tissue level (Even-Desrumeaux et al., 2011 and 
Alvarez-Chaver et al., 2014). In addition, although our previous studies with cell lines 
have demonstrated the presence of alpha enolase in transformed PCa cell lines, it was 
necessary to show that this protein was also present in non-immortalised PCa tumour tissue, 
and not simply present in cell lines due to long term culture or as a result of 
immortalisation. Investigating alpha enolase in tissue, aimed to further evaluate the 
robustness of alpha enolase as a biomarker and confirm its subcellular localisation as 
shown by immunofluorescence. 
 
4.3.3.1  Alpha enolase expression in normal organ tissues 
 
To this end, commercially produced tissue microarrays (TMAs; purchased from US 
Biomax) from normal organ tissues (slide #BN234A) (patient details listed in appendix III) 
immunohistochemically stained for their alpha enolase protein expression using a 
monoclonal mouse-anti alpha enolase antibody (clone L-27, Santa Cruz, UK) alongside an 
isotype control. Before the study commenced, a series of optimisation experiments were 
performed on tissue core off-cuts collected from the Nottingham Prostate Research Group 
(NPRG) on formalin fixed paraffin embedded (FFPE) TMA blocks. Optimal conditions for 
alpha enolase tissue staining were determined to be citrate buffer for antigen retrieval, 
1:3000 dilution of a 1 mg/mL antibody stock solution, and antibody incubation for 1 h at 
room temperature.  
 
In collaboration with Nottingham University Hospitals, tissue scoring was carried out by 
Dr Desmond Powe (Histopathology Department at the Queens Medical Centre, 
Nottingham University Hospitals, Nottingham, UK) for the expression of alpha enolase in 
the stained tissue sections. In line with previous reports, alpha enolase expression was 
identified mostly in the cytoplasm and also in the nucleus in some cases. However, for this 
preliminary study, only alpha enolase cytoplasmic expression was scored, by designating 
alpha enolase tissue staining a value (score) between 0 – 3 (0 = negative; no staining, 1 = 
weak staining, 2 = moderate staining or 3 = strong staining), as depicted in figure 4.6.  
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Figure 4.6: Semi-quantitative scoring method used to determine the 
immunohistochemical alpha enolase protein expression in PCa.  
The figure illustrates the scoring method used for all TMA sections. Objective 
magnification: x20 and x40 inset. 
 
From this IHC staining, it was observed that there was a diffuse immunostaining pattern 
localised predominantly in the cytoplasm and the nucleus of all tissues stained (figure 4.6). 
Figure 4.7 shows the alpha enolase expression in multiple organ normal tissues. Out of all 
the tissues stained, 42% of the tissues showed no alpha enolase staining (cerebrum, cardiac 
muscle, lung, ovaries and prostate), 25% showed weak staining (pancreas, uterine cervix, 
skin), while 33% showed moderate staining for alpha enolase (liver, kidney, breast and 
colon). It is important to note that in figure 4.7, uterine cervix (E) is a cancer adjacent 
normal cervix tissue. Staining for each tissue was carried out in duplicate and 
representative figures for each normal tissue type are shown in figure 4.7. A summary of 
the TMA scores demonstrating alpha enolase expression in multiple organ normal tissues 
is summarised in table 4.2. 
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Figure 4.7:  Immunohistochemical staining showing alpha enolase protein expression 
in multiple organ normal tissues.  
Immunohistochemical staining demonstrates alpha enolase expression in normal cerebrum 
(A), cardiac muscle (B), lung (C), liver (D), cancer adjacent normal cervix tissue (E), colon 
(F), kidney (G), breast (H), ovary (I), pancreas (J), prostate (K) and skin (L). Duplicate 
cores stained per patient. Image shows a representative image from one of the duplicates. 
Objective magnification: x20.  
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Table 4.2: Alpha enolase protein expression in multiple organ normal tissues 
 
 
 
Tissues were purchased from US Biomax (Cat. BN243A), and stained in duplicate, where scores of each 
representative organ is shown. Cytoplasmic staining was performed by a pathologist using a numerical 
scoring system between 0 - 3 (0 = negative; no staining, 1 = weak staining, 2 = moderate staining or 3 = 
strong staining). Numbers in unshaded and shaded cells represent the score for each tissue using the score 
system. 
 
 
4.3.3.2 Alpha enolase expression in multiple cancers and adjacent 
normal tissue 
 
Alongside studying the alpha enolase expression in multiple organ normal tissues, it was 
also of interest to investigate the protein expression of alpha enolase in multiple cancers as 
well as corresponding adjacent normal tissues. As before, tissue cores were purchased from 
US Biomax which included tumours and adjacent normal tissues from 12 organs (slide 
#MC246, patient details listed in appendix IV). TMAs were stained using already 
optimised conditions for alpha enolase as before, and scored by the same pathologist. 
 
Figures 4.8 and 4.9 depict alpha enolase protein expression in multiple cancer tissues 
alongside adjacent normal tissues. Interestingly, an increased cytoplasmic alpha enolase 
expression was observed in 50% of cancers compared to their corresponding adjacent 
Tissue Score 0 1 2 3
Cerebrum 0 0
Cardiac 0 0
Lung 0 0
Liver 2 2
Uterine cervix 1 1
Colon 2 2
Kidney 2 2
Breast 2 2
Ovary 0 0
Pancreas 1 1
Prostate 0 0
Skin 1 1
Alpha enolase expression in multiple 
organ normal tissues
Stain intensity
 CHAPTER 4: Alpha enolase in other biological samples 
165 
   
normal tissues (lung, colon, ovary, oesophagus, skin and cerebrum; summarised in table 
4.2), while no change in expression was observed in 42% of cancers (prostate, uterine 
cervix, stomach, liver and kidney). A lower expression of alpha enolase in cancer 
compared to adjacent normal tissues was identified in breast cancer alone.  
 
It is important to note that the highest alpha enolase score in cancer occurred in melanoma, 
which had a score of 3 in cancer and 1 in the adjacent normal tissue. As before, a diffuse 
immunostaining pattern localised predominantly in the cytoplasm and the nucleus was 
observed in cancer adjacent normal and in tumour tissues. There was a remarkable staining 
difference observed in normal skin tissue which exhibited a weak reactivity (score 1; figure 
4.9J) compared to melanoma which exhibited an intense alpha enolase immunoreactivity 
(score 3; figure 4.9I). Alpha enolase tissue staining in cancer and adjacent normal tissues 
are summarised in table 4.3. A comparison between alpha enolase expression in normal 
organ tissues and cancer tissues in all organs studied are summarised in table 4.4.  
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Figure 4.8:  Immunohistochemical staining showing alpha enolase protein expression in multiple organ tumours with matched adjacent 
normal tissues I.  
Immunohistochemical staining demonstrates alpha enolase expression in prostatic adenocarcinoma (A), adjacent normal prostate tissue (B), 
squamous cell carcinoma of the lungs (C), adjacent normal lung tissue (D), colon adenocarcinoma (E), adjacent normal colon tissue; fibrous 
tissue and blood vessel (F), invasive ductal carcinoma (G), adjacent normal breast tissue (H), serous ovarian adenocarcinoma (I), adjacent 
normal ovary tissue (J), squamous cell carcinoma of the uterine cervix (K) and adjacent normal cervical canals tissue (L). Objective 
magnification: x20. 
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Figure 4.9:  Immunohistochemical staining showing alpha enolase protein expression in multiple organ tumours with matched 
adjacent normal tissues II. 
Immunohistochemical staining demonstrates alpha enolase expression in squamous cell carcinoma of the oesophagus (A), adjacent normal 
oesophagus tissue (B), stomach adenocarcinoma (C), adjacent normal stomach tissue (D), hepatocellular carcinoma (E), adjacent normal hepatic 
tissue (F), clear cell renal carcinoma (G), adjacent normal kidney tissue (H), malignant melanoma of the right heel (I), adjacent normal skin 
tissue (J), glioblastoma (K) and adjacent normal cerebrum tissue (L). Objective magnification: x20.  
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Table 4.3:  A summary of alpha enolase protein expression in multiple cancer tissues 
and adjacent normal tissues 
 
 
*Alpha enolase expression observed in various tumours alongside their corresponding adjacent healthy 
tissues. Tissues were purchased from US Biomax (Cat. MC246), and cytoplasmic staining was performed by 
a pathologist using a numerical scoring system between 0 - 3 (0 = negative; no staining, 1 = weak staining, 2 
= moderate staining or 3 = strong staining).* Numbers in unshaded and shaded cells represent the highest 
score for each tissue using the score system. Alpha enolase expression in adjacent normal tissues are shown 
in (A) and cancer tissues (B). Changes in protein expression for alpha enolase protein in cancer compared to 
control tissues is indicated in (C), where + = increased expression, 0 = no change, - = low expression in 
cancer relative to normal tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
A B C
Tissue Score 0 1 2 3 Tissue Score 0 1 2 3
Prostate 2 2 Prostate 2 2 0
Lung 0 0 Lung 2 2 +
Colon 0 0 Colon 2 2 +
Breast 2 2 Breast 0 0 -
Ovary 0 0 Ovary 2 2 +
Uterine cervix 0 0 Uterine cervix 1 1 0
Esophagus 0 0 Esophagus 2 2 +
Stomach 2 2 Stomach 2 2 0
Liver 2 2 Liver 1 1 0
Kidney 1 1 Kidney 1 1 0
Skin 1 1 Skin 3 3 +
Cerebrum 0 0 Cerebrum 2 2 +
Change in 
expression
Alpha enolase expression in adjacent 
normal  tissues
Alpha enolase expression in multiple 
cancer tissues
Stain intensity Stain intensity
* * 
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Table 4.4: Alpha enolase protein expression in multiple organ normal tissue and 
cancer tissues 
 
Alpha enolase stain intensities in multiple organ normal controls compared to multiple cancer tissues. Tissues 
were purchased from US Biomax (Cat. MC246) and BN243A) and cytoplasmic alpha enolase staining was 
performed by a pathologist using a numerical scoring system between 0 - 3 (0 = negative; no staining, 1 = 
weak staining, 2 = moderate staining or 3 = strong staining). Numbers in unshaded and shaded cells represent 
the score for each tissue using the score system. Alpha enolase expression in multiple organ normal controls 
is depicted in (A) while expression in multiple cancer tissues is shown in (B). Changes in expression in 
cancer compared to control tissues is indicated in (C), where + = increased expression, 0 = no change, - = 
low expression in cancer relative to normal tissues. 
 
 
 
4.3.3.3  Alpha enolase protein expression in prostate cancer 
 
Previous tissue staining with alpha enolase (section 4.3.3.2) demonstrated a differential 
protein expression in 7 out of 12 cancer tissues studied, with the highest cytoplasmic 
expression occurring in melanoma. From table 4.2 and 4.3, alpha enolase expression in 
normal prostate tissue has a score 0 while adjacent normal tissues and prostatic 
adenocarcinoma scored a value of 2 and 2 respectively. Although there was no change in 
cytoplasmic alpha enolase score in PCa and its adjacent normal tissues (score 2 and 2), 
there was a lower expression of alpha enolase in normal prostate (score 0), indicating that 
further investigation into the expression of alpha enolase in PCa needed to be carried out. 
Moreover, each cancer and adjacent normal tissue studied in section 4.3.3.2 was collected 
from a single patient, making it difficult to decipher the general pattern of alpha enolase 
A B C
Change in 
expression
Tissue Score 0 1 2 3 Tissue Score 0 1 2 3
Prostate 0 0 Prostate 2 2 +
Lung 0 0 Lung 2 2 +
Colon 2 2 Colon 2 2 0
Breast 2 2 Breast 0 0 -
Ovary 0 0 Ovary 2 2 +
Uterine cervix 1 1 Uterine cervix 1 1 0
Liver 2 2 Liver 1 1 -
Kidney 2 2 Kidney 1 1 -
Skin 1 1 Skin 3 3 +
Cerebrum 0 0 Cerebrum 2 2 +
Alpha enolase expression in multiple 
organ normal tissues
Alpha enolase expression in multiple 
cancer tissues
Stain intensity Stain intensity
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expression in PCa. In addition, our group has an interest in PCa research and identifying 
biomarkers for PCa. 
Thus, it was essential that more PCa patient tissues were studied to better understand alpha 
enolase expression in PCa.  
 
To this end, TMAs were purchased from US Biomax (slide #T195B) containing 9 cases -
patients from various Gleason grades and tumour stages (table 4.5 and appendix V). TMAs 
included tissue cores from two healthy males and a case of low grade malignant 
leiomyosarcoma which acted as a control (figure 4.10). Figure 4.10 shows the protein 
expression of alpha enolase in patients with various grades and stages of PCa where, as 
before, a diffuse immunostaining pattern localised predominantly in the cytoplasm and the 
nucleus was observed in all tissue sections (PCa and control tissues). Patient information 
and alpha enolase tissue scores are summarised in table 4.5. 
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Figure 4.10:   Immunohistochemical staining showing alpha enolase protein expression in multiple prostate cancer patients and normal 
prostate tissues.  
Immunohistochemical staining demonstrates alpha enolase expression in prostatic adenocarcinomas of a 64 year old male diagnosed at grade 1, 
stage I cancer (A), 73 year old male diagnosed at grade 2, stage II cancer (B), 73 year old male diagnosed at grade 2-3, stage IV cancer (C), 61 
year old male diagnosed at grade 1, stage IV cancer (D), 70 year old male diagnosed at grade 2, stage III cancer (E), 66 year old male diagnosed 
at grade 2-3, stage III cancer (F), 65 year old male diagnosed at grade 1-2, stage II cancer (G), 66 year old male diagnosed at grade 3, stage II 
cancer (H), 62 year old male diagnosed at grade 3, stage II cancer (I), 69 year old male diagnosed at low grade malignant leiomyosarcoma, stage 
Ia (J), normal prostate tissue of a 33 (K) and 43 year old male (L) respectively. Duplicate cores stained per patient. Image shows a representative 
image from one of the duplicates. Objective magnification: x20. 
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Table 4.5: A summary of patients studied for alpha enolase expression in PCa tissues  
 
Pos. Pathology diagnosis Age Grade Stage 
Gleason 
Grade 
Gleason 
Score TNM 
Alpha 
enolase 
IHC score 
A Adenocarcinoma 64 1 I 1 1+2 T1N0M0 2 
B Adenocarcinoma 73 1 II 3 3+3 T2N0M0 0 
C Adenocarcinoma 73 2-3 IV 4 4+4 T3N0M1 2 
D Adenocarcinoma 61 1 IV 2 3+2 T3N1M0 2 
E Adenocarcinoma 70 2 III 3 3+4 T3N0M0 2 
F Adenocarcinoma 66 2-3 III 4 3+4 T3aN0M0 3 
G Adenocarcinoma 65 1-2 II 2-3 2+3 T2N0M0 2 
H Adenocarcinoma 66 3 II 5 5+5 T2N0M0 2 
I Adenocarcinoma 62 3 II 3 5+4 T2N0M0 2 
J Low grade 
malignant 
leiomyosarcoma 
69 - Ia - - T1N0M0 
G1 
 
0 
K Normal prostate 
tissue 
33 - - - - - 0 
L Normal prostate 
tissue 
43 - - - - - 0 
 
Alpha enolase protein expression in multiple prostate cancer, low grade malignant leiomyosarcoma and 
normal prostate tissues. Tissues were purchased from US Biomax (Cat. T195B), and cytoplasmic staining 
was performed by a pathologist using a numerical scoring system between 0 - 3 (0 = negative; no staining, 1 
= weak staining, 2 = moderate staining or 3 = strong staining). The table shows the patient age, grade, stage, 
Gleason grade, Gleason sum, TNM status alongside alpha enolase tissue score for each patient studied. Pos = 
position; image reference on figure 4.10, IHC; immunohistochemistry score.  
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4.4  DISCUSSION 
 
The previous chapter identified alpha enolase as a potential TAA that elicits a differential 
humoral immune response in some PCa patients, compared to healthy controls (section 
3.3.2 and 3.3.3). Furthermore, its expression in the metastatic DU-145 PCa cell line was 
also verified (section 3.3.4). In order to demonstrate its suitability as a potential PCa 
biomarker, it was important to first determine its expression in other biological sample 
sources. Hence, this chapter aimed to demonstrate alpha enolase expression in other 
available PCa cell lines, urine and tissue. 
4.4.1  Alpha enolase expression in other PCa cell lines 
 
The expression of alpha enolase in other PCa cell lines was determined by 
immunofluorescence, flow cytometry and Western blotting (as these techniques had 
successfully verified alpha enolase in the previous chapter; section 3.3.4.1 and figure 3.9). 
Using immunofluorescence, figure 4.2 confirms the subcellular localisation of alpha 
enolase in PCa cell lines, showing a strong, diffuse cytoplasmic staining and a slightly 
weaker nuclear expression in PC-3, LNCaP and OPCT-1, similar to findings by Perconti et 
al. (2007). Furthermore, no membranous alpha enolase expression was identified in any of 
these three cell lines by immunofluorescence, unlike in DU-145 (red arrows in figure 4.2 
and figure 3.9). 
 
However, in order to confirm the possibility of a potential membranous localisation of 
alpha enolase in other PCa cell lines, each cell line was subject to cell surface staining 
using flow cytometry. Using this technique, no alpha enolase expression was observed in 
any cell line (appendix VI). Contrary to these findings, the membranous expression of 
alpha enolase has been well studied and reported in pancreatic (Capello et al., 2009), lung 
(Chang et al., 2006 and Hsiao et al., 2013) and non-small cell lung cancers (He et al., 
2007). However, it is well documented that the surface expression of alpha enolase 
depends on the physiological status of the cell (Fontan et al., 2000 and Arza et al., 1997), 
potentially explaining the lack of cell membrane expression in these cell lines. It is also 
important to highlight that methods of harvesting cells (e.g. trypsin and versene) for 
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staining by flow cytometry may cleave off cell surface markers, thereby explaining the 
lack of alpha enolase expression observed in this study.  
Flow cytometry, however, confirmed the intracellular expression of alpha enolase in PC-3, 
LNCaP and OPCT-1, showing a shift to the right in the histogram of all PCa cell lines 
screened (figure 4.3), while Western blotting confirmed the presence of a band at 47 kDa, 
similar to expression by recombinant alpha enolase. All three studies combined 
demonstrate that alpha enolase is present in all PCa cell lines tested.  
 
As all four cell lines have different characteristics, further studies could compare the 
expression of alpha enolase in all PCa cell lines in reference to a housekeeping protein 
such as β-actin using Western blotting, facilitating the normalisation of protein expression 
levels in each cell line. This would determine the expression levels of alpha enolase in 
metastatic (PC-3 and DU-145) compared to non-metastatic (OPCT-1) and hormone 
sensitive (LNCaP) PCa in order to generate a better understanding of alpha enolase 
expression in PCa. 
 
Furthermore, although it would have been of interest to compare the expression levels of 
alpha enolase in cell lines obtained from a healthy prostate with PCa cell lines, in order to 
determine if a differential expression exists in PCa, this was not feasible due to the lack of 
normal prostate cell lines available during the study. However, it is already well 
documented that alpha enolase protein and/or mRNA expression is increased in several 
tumours such as brain (Altenberg and Greulich, 2004), breast (Hennipman et al., 1987), 
head & neck (Tsai et al.,2010), liver (Takashima et al., 2005), lung (Rubporn et al., 2009),  
ovary (Cao et al., 2010), pancreas (Shen et al., 2004), prostate (Rehman et al., 2004) and 
skin cancers (Suzuki et al., 2010). A study investigating the expression levels of alpha 
enolase in cancer and normal prostate tissue was carried out subsequently in this chapter 
(section 4.3.3). 
4.4.2  Alpha enolase expression in urine 
 
The expression of urinary alpha enolase was also studied in the samples that made up the 
discovery cohort (samples detailed in table 2.11). Figure 4.5 shows a band at 47 
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 kDa at the same intensity in PCa and healthy urine. This finding is similar to Rehman et al. 
(2004) who identified alpha enolase as one of 6 commonly expressed urinary proteins on 
2-DE gel spots of PCa and benign samples after prostatic massage. 
 
Using this specific monoclonal anti-alpha enolase antibody, a differential protein 
expression was observed between PCa and healthy urine towards a protein at 66 kDa, 
although the molecular weight of alpha enolase is 47 kDa (figure 4.5). One of the reasons 
for this observed band could be the occurrence of post translational modifications (PTMs) 
in alpha enolase, or the presence of carrier proteins bound to alpha enolase. Interestingly, 
Tomaino et al. (2011) identified that phosphorylation of alpha enolase on serine 419 
induces the production of a specific autoantibody in patients with pancreatic ductal 
adenocarcinoma. Their study also found 95% diagnostic accuracy using autoantibodies 
produced towards phosphorylated alpha enolase and CA19.9 levels in both advanced and 
resectable pancreatic ductal adenocarcinoma. In addition, alpha enolase autoantibodies 
correlated with significantly better clinical outcome in patients treated with chemotherapy. 
The study by Tomaino et al. (2010) demonstrates the diagnostic value of PTMs associated 
with TAAs, in serving as potential biomarkers for cancer. 
 
Similar to Tomaino et al. (2011), it would have been beneficial to demonstrate (using data 
dependent acquisition in LTQ Orbitrap MS) whether any PTMs were present in the urine 
samples screened, and if these PTMs were responsible for eliciting the immune responses 
observed. It would have also been useful to determine which PTMs occurred the most after 
screening a cohort of PCa (compared to normal volunteer) urine samples; and to confirm 
whether alpha enolase PTMs have any diagnostic utility. However, these studies could not 
be performed due to limitations in the technology utilised in this study and due to time and 
feasibility constraints. 
 
A further limitation of this study is that pooled samples were utilised to determine alpha 
enolase urine expression (figure 4.5). As a result, it is not certain how many samples in the 
pool contain alpha enolase. It could have been only one sample that had alpha enolase or it 
could have been several or even all of the urine samples. Thus, the only way to definitively 
determine this would be to screen each sample that made up the pool individually. 
Although it would have been advantageous to screen patients individually, this was not 
carried out due to time and feasibility constraints. Further studies need to investigate the 
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expression of alpha enolase in the urine of patients with PCa compared to healthy controls 
(e.g. in an ELISA assay) in order to determine if a differential expression of alpha enolase 
exists in urine, facilitating its use as a potential PCa biomarker. 
4.4.3  Alpha enolase expression in tissue 
 
Although the expression of alpha enolase is well reviewed by Capello et al. (2011), alpha 
enolase tissue expression was carried out to confirm its expression in a range of normal 
organs, multiple cancers, and adjacent normal tissues. It also served as an avenue to 
confirm its subcellular localisation and optimise conditions to determine the expression of 
alpha enolase in a large PCa cohort which constitutes part of the next chapter – as our 
group has a focus on PCa biomarker discovery. 
 
Using immunohistochemistry, multiple normal organ tissues demonstrated negative to 
moderate staining for alpha enolase (figure 4.7 and table 4.2). Out of all 12 organs stained, 
42% (5 out of 12 organs) showed negative alpha enolase expression, while 25% (3 out of 
12) and 33% (4 out of 12) showed weak and moderate staining, respectively. Although 
each organ is derived from a single patient, making it difficult to draw definite conclusions 
from these results, this study shows a low to moderate expression of alpha enolase in 
normal tissues (table 4.2). In contrast, alpha enolase expression in multiple cancer tissues 
demonstrated a range of negative to strong staining, where out of 12 organs stained, 8% (1 
out of 12) showed negative alpha enolase expression, while 25% (3 out of 12), 58% (7 out 
of 12) and 8% showed weak, moderate and strong expression, respectively (table 4.2B). 
Table 4.3A also shows a similar expression pattern of alpha enolase in normal tissues and 
adjacent tissues (negative to moderate staining). These results imply a differential 
expression of alpha enolase between healthy tissues and cancer tissues, similar to findings 
in the literature and reviewed by Capello et al., (2001) and table 4.1. 
 
When the alpha enolase expression was compared between cancer and adjacent normal 
tissues, no changes were observed in 41% of the organs (prostate, uterine cervix, stomach, 
liver and kidney) (table 4.3). Furthermore, although each organ screened was derived from 
a single patient, it is interesting to note that a reduced expression of alpha enolase only 
occurred in invasive ductal carcinoma in breast cancer, out of all the tissues stained. This 
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finding is similar to work published by Shih et al. (2010) who found lower levels of 
autoantibodies to alpha enolase in patients with stage IV non-small cell lung cancer, small 
cell lung cancer and breast cancer compared with healthy controls. This study also showed 
an increased alpha enolase expression in lung, colon, ovary, oesophagus, skin and 
cerebrum, similar to work already published and reviewed by Capello et al. (2011). 
It is also important to note that, while no change in expression between adjacent normal 
tissue and PCa tissue was identified from this small TMA cohort, there was a difference in 
the expression pattern between normal prostate tissue and PCa/adjacent prostate tissue 
(table 4.4). This indicates that there may be a differential expression of alpha enolase in 
PCa; however, because of the small sample size used in this TMA, it is not possible to 
make any firm conclusions about the expression of alpha enolase in PCa. This work then 
led to the final phase of the study which assessed the expression of alpha enolase in a small 
sample set of PCa patients (n=9 PCa patients; table 4.4). From table 4.5, 7 out of 9 patients 
(78% of cases) demonstrated a moderate alpha enolase expression, while 1 out of 9 (11%) 
showed a negative and high expression of alpha enolase in PCa, respectively (table 4.5). 
No expression was observed in healthy prostate tissue and low grade malignant 
leiomyosarcoma (table 4.5). This study again points to a differential expression of alpha 
enolase in PCa, but as previously mentioned, due to the small number of patients utilised in 
this study, firm conclusions cannot be drawn as to the association between alpha enolase 
and PCa. 
 
The aim of this chapter was to demonstrate the expression of alpha enolase in different 
biological samples, in order to validate its potential utility as a PCa biomarker. Apart from 
PCa cell lines, where no healthy prostate cells were available to serve as a control, all other 
biological samples (urine and tissue) have shown a high expression of alpha enolase in PCa 
compared to healthy controls; further indicating that alpha enolase is a TAA of potential 
interest in PCa and its diagnostic value needs to be validated in a larger sample cohort. 
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5. CHAPTER 5: VALIDATION OF ALPHA 
ENOLASE AS A BIOMARKER FOR PROSTATE 
CANCER AND ITS CORRELATION WITH 
CLINICO-PATHOLOGICAL VARIABLES 
 
5.1   INTRODUCTION 
 
In the UK, PCa is the second leading cause of cancer-related deaths in men after lung 
cancer (Cancer Research UK, 2015b), and arises mainly from prostatic intraepithelial 
neoplasia (PIN). PIN is a precursor lesion that progresses to adenocarcinoma and 
eventually into metastatic disease (DeMarzo et al., 2003). In addition, PCa is 
asymptomatic until it becomes advanced or metastatic disease, thus, patient screening to 
aid early PCa diagnosis is mandatory (Smith et al., 2003). 
Chapter 3 (section 3.3.2 and 3.3.3) identified alpha enolase in two well-characterised PCa 
cell lines as potential TAAs in PCa. In addition, using the same set of patient sera, a 
differential autoantibody expression in alpha enolase was identified in a small subset of 
patients with PCa compared to healthy controls (3.3.4.4). This initial findings warranted 
the evaluation and verification of alpha enolase in PCa as a potential PCa biomarker, 
which constituted part of the previous chapter. From that study, a differential alpha enolase 
expression was identified almost exclusively in a small cohort of PCa patients compared to 
healthy controls in tissues (section 4.3.3.3) and urine (section 4.3.2). These initial studies 
were the first to demonstrate an increased alpha enolase expression in a small cohort of 
PCa patients compared to healthy controls and warranted the validation of alpha enolase as 
a potential biomarker in PCa.  
It is well documented that the existence of TAAs in cancer patients induce the production 
of IgG autoantibodies triggered by CD4+ T cells and B-cells. The release of these TAAs 
by shedding, secretion or cell lysis allow them to be taken up by antigen presenting cells 
where they are processed and presented by major histocompatibility complex (MHC) class 
I or MHC class II molecules. These antigenic fragments are primed for the activation of 
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CD8+ and CD4+ T cells respectively. Thus, MHC class II molecules present antigenic 
fragments to CD4+ T-cells, which via the secretion of cytokines, trigger the proliferation 
of B cells and the production of IgGs against the same TAAs (Sahin et al., 1997). The 
immune response generated against TAAs suggests that autoantibodies can be used as a 
diagnostic tool for the detection of many cancers (Mojtahedi et al., 2011).  
 
Alpha enolase is overexpressed in many cancers (table 4.1) has been reported to induce the 
production of autoantibodies in many cancers such as pancreatic (Tomaino et al, 2011), 
leukaemia (Cui et al., 2005 and Zou et al., 2005), melanoma (Suzuki et al.,2010 and 
Forgber et al., 2009), head and neck (Tsai et al., 2010, Shukla et al., 2007 and Shukla et al., 
2009), breast (Shih et al., 2010 and Ejma et al., 2008) and lung cancers (He et al., 2007, Li 
et al., 2006, Shih et al., 2010 and Chang et al., 2006, Jankowska et al., 2004, Nakanishi et 
al., 2006, Ueda, 2005 and Dot et al., 2005). In addition, many studies have demonstrated 
the diagnostic and prognostic utility of alpha enolase autoantibodies. For example, Tu et al 
(2010) identified that increased alpha enolase expression in breast cancer correlates with 
poor nodal status, tumour size, and a shorter disease free survival, while Shih et al., 2010 
identified a reduction in alpha enolase autoantibody expression in advanced stages of 
breast and lung cancer. In hepatocellular carcinoma, the increased expression of alpha 
enolase correlates positively with venous invasion and increased with tumour d-
differentiation (Takashima et al., 2005 and Hamaguchi et al., 2008), while patients with 
high alpha enolase autoantibody expression have a been shown to have significantly poorer 
clinical outcomes than patients with lower expression, including shorter overall and 
progression free survival in head and neck and non-small cell lung cancers (Tsai et al., 
2010 and Chang et al., 2006).  
 
Despite the utility of alpha enolase autoantibodies in cancer detection, no studies have 
investigated its expression in a cohort of PCa patients till date. As a result, no studies have 
determined whether or not there is any correlation between alpha enolase protein 
expression or autoantibody expression and clinical clinico-pathological variables. Thus, the 
primary objective of this chapter was to assess the expression profile of alpha enolase in 
tumour tissues of from a large cohort of patients with various grades and stages of PCa and 
to determine whether the alpha enolase expression correlates with important clinical 
variables. The second aim is to determine whether the autoantibody response to alpha 
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enolase in PCa patient sera correlates with any clinico-pathological variables in patients 
with various Gleason grades and stages of PCa. 
5.1.1  Aims and objectives  
 
 
The aim of this chapter is to investigate the diagnostic significance of alpha enolase in PCa. 
This will be carried out by: 
1. Screening a prostate TMA cohort from Nottingham University Hospitals to 
determine levels of alpha enolase protein expression using immunohistochemistry. 
2. Statistically determining whether alpha enolase expression correlates with any 
clinico-pathological variables. 
3. Demonstrating that autoantibodies to alpha enolase are differentially expressed in 
PCa compared to healthy controls/benign diseases using an ELISA technique 
4. Determining whether alpha enolase autoantibody expression correlates with 
important clinico-pathological variables in PCa. 
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5.2    METHODS 
 
5.2.1  Patient tissue and sera samples 
 
Tissue samples 
Tissue microarray analysis of alpha enolase expression was carried out at the department 
of Histopathology, Queens Medical Centre, Nottingham University Hospitals, NHS Trust, 
Nottingham, UK in collaboration with Dr Desmond Powe. Ethical approval for collection 
and use of pathology specimen was granted by the North West 7 Research Ethics 
Committee – Greater Manchester Central Research Ethics Committee number 
10/H1008/72. Samples were collected between 1999 and 2001 from a total of 235 
diagnosed patients at the Nottingham City Hospital, as part of a wider study carried out by 
the Nottingham Prostate Research Group (NPRG).  
 
From each patient, two 0.6 mm cores of TURP or radical prostatectomy tissue specimens 
were assembled using a Grand Master Arrayer (3DHitech Ltd, Hungary) to make tissue 
microarrays using formalin-fixed paraffin embedded benign and clinically confirmed PCa 
cores. Pathological variables such as age, histology, location of metastasis, PSA, Gleason 
score, time taken to metastasis and D’Amico risk were recorded. 
 
Sera samples 
Human sera was collected from patients at the Leicester General Hospital, Leicester, UK 
after ethical approval by the National Research Ethics Committee. Samples were collected 
from two separate patient cohorts – the LE sample series, consisting of patients who had a 
TRUS biopsy (ethical number NREC #09/H0401/92 and UHL 10858). This cohort was 
gathered under the title ‘A pilot study to identify gene fusions in prostate cancer’. The 
second sample cohort was collected under the title ‘Define the role of the Transperineal 
Template guided prostate biopsy’ (approval number NREC #11/EM/0312 and UHL 11068), 
making up the TP series. Males aged 51-89 years (for the LE cohort) or 50-84 years (for 
the TP cohort), referred by their GP for high PSA levels (>4 ng/mL) and/or having 
symptoms of PCa and attending the urology clinic under the supervision of Mr Masood 
Khan, were recruited after signed informed consent forms had been collected.  
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In addition, healthy control sera was obtained from volunteers at Nottingham Trent 
University (Ethical number 135) after informed consent forms had been signed and 
collected. As described in detail in section 2.2.1, samples were collected and processed 
using the protocol outlined in section 2.2.1 and stored at -80ºC, thawing only prior to 
processing. 
5.2.2  Immunohistochemical staining of alpha enolase 
 
TMA sections were immunostained as described in section 4.2.4. In brief, TMA sections 
cut at the Queens Medical Centre, were melted at 60ºC and deparaffinised and hydrated 
using an Autostainer. Slides were immersed twice in xylene baths and then in graded 
alcohol baths (100%, 100% and 70% ethanol) before a wash at 5 min. Antigen retrieval 
was carried out using a citrate buffer in a microwave and slides were rinsed and loaded 
onto sequenza reservoir. Tissue staining was carried out using the Novolink Polymer 
Detection System kit following the manufacturer’s instructions. First, a peroxidase block 
step was carried out, followed by washes and the addition of a protein block to eliminate 
excess background staining. An optimised dilution (1:3000) of mouse monoclonal alpha 
enolase antibody (clone L-27, Santa Cruz, UK) was added for 60 min followed by washing 
and the addition of a post-primary antibody, polymer, DAB stain and counterstain using 
haematoxylin. Excess haematoxylin was rinsed and slides were placed in the Autostainer 
for dehydration using dH2O and graded alcohol baths (70%, 100% and 100% ethanol) 
before two final immersions in a xylene bath. Coverslips were mounted onto each slide 
using DPX mounting medium. 
5.2.3  ELISA to detect alpha enolase autoantibody responses 
 
An ELISA assay was carried out to detect the presence of autoantibodies to alpha enolase 
in patients with PCa, and described in detail in section 3.2.3.3. In brief, 96 well plates were 
coated overnight with a recombinant alpha enolase protein (100 ng/mL) and washed. Each 
well was blocked to eliminate non-specific binding using a BSA blocking buffer before 3 
wash steps with TBST. Sera from PCa, benign, healthy controls or monoclonal mouse anti-
alpha enolase antibody (positive control) was allowed to bind for 90 min before a wash 
step and incubation with a rabbit anti-human IgG (for sera) or goat anti-mouse (alpha 
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enolase positive control) secondary antibody conjugated to HRP. Wells were washed and a 
TMB substrate was added, which was stopped with a sulphuric acid stop solution and an 
absorbance reading at 450 nm was taken. 
5.2.4   Statistical analysis 
 
Stained TMA sections were microscopically assessed by a pathologist (Dr Desmond Powe) 
and semi-quantitative tissue scoring was carried out using a scale ranging from 0 (no 
staining), 1 (weak staining), 2 (moderate staining) and 3 (strong staining). The association 
between alpha enolase expression and clinical variables are calculated using univariate chi-
square analysis and cumulative survival probabilities were modelled using Kaplan-Meier 
survival plots and a Cox regression hazards risk model (SPSS software version 20.0, SPSS 
Inc., USA). Statistical significance was considered as p≤0.05. 
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5.3    RESULTS 
 
The validation of alpha enolase as a potential PCa biomarker and its correlation with 
clinico-pathological variables is subdivided into 2 sections: 
 
i. Alpha enolase expression in NPRG prostate TMAs (section 5.3.1) 
ii. Alpha enolase sera autoantibody expression (section 5.3.2). 
5.3.1  Alpha enolase protein expression in NPRG prostate TMAs 
 
As this study was based on the identification of markers for PCa, a large TMA consisting 
of 235 patients, in collaboration with the NPRG at the Queen’s Medical Centre, 
Nottingham was utilised to verify alpha enolase expression. The same assay conditions 
used in the previous chapter were applied to this cohort (antibody dilution, incubation 
times outlined in section 4.2.4). This patient cohort consisted of 10 TMA FFPE blocks 
which were constructed using cores taken from patients with BPH and clinically confirmed 
PCa. As stated previously, a semi-quantitative scoring intensity scale ranging from 0 – 3 (0 
= no staining, 1 = weak; 2 = moderate; 3 = strong staining) was utilised for cytoplasmic 
expression of alpha enolase or 0-2 for nuclear expression of alpha enolase. The association 
between alpha enolase and clinical variables are modelled using Kaplan-Meier plots and 
the Cox regression hazards risk model was used to calculate univariate chi-square analysis. 
A statistical significance at p≤0.05 was utilised in each case. 
 
5.3.1.1 Cytoplasmic alpha enolase expression in PCa and benign 
prostatic disease 
 
As demonstrated in the previous figure 4.6, alpha enolase expression was observed mainly 
in the cytoplasm of the prostatic epithelia. Table 5.1 shows the frequency of cytoplasmic 
alpha enolase expression in PCa and benign tissues within the NPRG cohort (n=235 
patients). Of all cases that were negative for cytoplasmic alpha enolase (n=21), 71.4% of 
them occurred in PCa while 28.6% occurred in benign patients. However, of all cases with 
a positive alpha enolase expression (n=214), 58.9% occurred in PCa compared to 41.1% of 
benign controls patients (table 5.1).   
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Table 5.1: Frequency of cytoplasmic alpha enolase expression in NPRG cohort 
Pathology Frequency 
Negative 
(n=21) 
Positive 
(n=214) 
Total 
(n=235) 
0 1, 2 and 3  
Benign disease Number of cases 6 88 94 
 Percentage (%) 28.6 41.1 40.0 
Prostate cancer Number of cases 15 126 141 
 Percentage (%) 71.4 58.9 60.0 
Benign and PCa tissues were scored for cytoplasmic alpha enolase expression using a semi-
quantitative 3 point scoring system ranging from 0 – 3 (0 = negative expression, 1 = weak 
expression, 2 = moderate expression, 3 = strong expression). Negative or positive staining in 
benign or cancer patients is depicted in the table 5.1.  
 
Although from table 5.1, 41.1% of benign cases showed positive alpha enolase expression, 
further examination of positive staining distribution for each patient group showed that 
most of the benign tissues demonstrated weak (score 1; 54.5%) or moderate staining (score 
2; 19.1%) compared to cancer patients with 45.5% and 80.9% (table 5.2). Similarly, strong 
alpha enolase tissue expression (score 3) was observed in 78.6% of cancer patients 
compared to 21.4% in benign cases (table 5.2). Statistical significance (p=0.000003) was 
observed when weak cytoplasmic alpha enolase expression (staining intensity score 0 and 
1; 17%) was compared to strong expression (staining intensity score 2 and 3; 46.8%). 
These findings demonstrate that higher cytoplasmic alpha enolase expression is more 
frequent in PCa compared to benign prostatic tissue. 
 
Table 5.2: Cytoplasmic alpha enolase positive staining intensity distribution 
Pathology Frequency 
Positive intensity (stain score)  
1 
(n=132) 
2 
(n=68) 
3 
(n=14) 
Total 
(n=214) 
Benign disease Number of cases 72 13 3 88 
 Percentage (%) 54.5 19.1 21.4 41.1 
Prostate cancer Number of cases 60 55 11 126 
 Percentage (%) 45.5 80.9 78.6 58.9 
 
Benign and PCa tissues scored for cytoplasmic alpha enolase expression using a semi-quantitative 3 point 
scoring system ranging from 0 – 3 (0 = negative expression, 1 = weak expression, 2 = moderate 
expression, 3 = strong expression. The table shows the positive staining distribution for cancer or benign 
controls. 
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To determine whether cytoplasmic alpha enolase expression correlated with any clinico-
pathological variables in PCa (Gleason grade, D’Amico risk prediction, bone metastasis or 
survival), a dichotomous categorisation of cytoplasmic alpha enolase expression in PCa 
patients was performed using Kaplan Meier survival modelling in order to assess these 
score categories. The first categorisation used was negative cytoplasmic alpha enolase 
expression (stain intensity 0) vs. positive expression (stain intensity 1, 2 and 3). This was 
compared to a low (stain intensity 0 and 1) vs. high expression (stain intensity 2 and 3). 
Figure 5.1 shows the Kaplan Meier survival time analysis of negative vs. positive 
cytoplasmic alpha enolase expression compared to low vs. high cytoplasmic alpha enolase 
expression. 
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Figure 5.1:  Dichotomous categorisation of cytoplasmic alpha enolase expression 
modelled by Kaplan-Meier survival graphs.  
Immunohistochemical staining for cytoplasmic alpha enolase staining was carried out and 
scored using a 3 point scoring system ranging from 0 – 3 (0 = no expression, 1 = weak 
expression, 2 = moderate expression, 3 = strong expression). Survival analysis of clinically 
confirmed PCa patients for different categories is shown between 0-125 months. A shows 
analysis for negative (score 0; 0.0 on survival graph) vs. positive cytoplasmic staining 
(score 1, 2 and 3; 1.0 on survival graph) (p=0.759), while B shows low (score 0 and 1; 0.0 
on survival graph) vs. high alpha enolase expression (score 2 and 3; 1.0 on survival graph) 
(p=0.101). 
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Low vs. high cytoplasmic alpha enolase expression (staining score 0 and 1 vs. 2 and, 3; 
figure 5.1B) produced the best separation for predicting survival outcome in PCa (p=0.101). 
Figure 5.1B also shows that increased alpha enolase expression (staining intensity 2 or 3) 
is associated with an improved survival over 5 years, but this was not statistically 
significant. As a result, the low vs. high categorisation was applied to determine the 
association between alpha enolase expression and clinico-pathological variables in PCa. 
 
5.3.1.2  Asssociation between cytoplasmic alpha enolase expression 
and clinico-pathological features 
 
Next, the association between cytoplasmic alpha enolase expression in PCa samples and 
known clinic-pathological features were determined using a chi-square test (table 5.3). To 
summarise, cytoplasmic alpha enolase expression was not associated with Gleason grade 
(Gleason grade <7 vs. ≥7, p=0.464), initial PSA (p=0.992), D’Amico risk (p=0.831), 
proliferation (Ki67) (p=0.13), bone metastasis (p=0.295), or castrate treatment resistance 
(p=0.116) (figure 5.2 and table 5.3). Figure 5.2 shows a Kaplan-Meier survival graph for 
the association between cytoplasmic alpha enolase and survival, where no statistical 
significance was observed at p<0.05. There is some limited indication that patients with 
alpha enolase positive cancers are however more likely to live longer (p=0.101) (fig 5.2) 
and less likely to develop any metastasis (p=0.149) (table 5.3). However none of these 
findings are statistically significant at p<0.05 (table 5.3). 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: TAA validation 
 
189 
   
Table 5.3:   Association between cytoplasmic alpha enolase staining and clinico-
pathological variables in PCa 
Characteristics Frequency 
Negative Positive intensities p-value 
0 1 2 3 
Gleason grade 
Grade <7 
120 
11 12 
0.464 
Grade ≥7 50 47 
Initial PSA 
0 - 10 ng/mL 
119 
16 15 
0.992 10.1 - 20 ng/mL 10 10 
>20 ng/mL 35 33 
D'Amico risk 
prediction 
High 
125 
12 8 
0.831 Intermediate 48 43 
Low 6 8 
Proliferation 
(Ki67) 
0 - 10% 
71 
38 8 
0.13 
11 - 100% 10 15 
Bone metastasis 
No metastasis at 
presentation 
120 
48 52 
0.295 
Prostate associated 
bone metastasis at 
presentation 
12 7 
Bone metastasis 
due to other cancer 
causes 
1 0 
Any metastasis 
Negative 
99 
24 33 
0.149 
Positive 23 19 
Castrate 
treatment 
resistance 
 
50 25 25 0.116 
Survival Months 56 28 28 0.101 
 
The association between cytoplasmic apha  enolase expression and clinico-pathological variables. No 
statistical significance was found between cytoplasmic alpha enolase expression and clinical variables at 
p<0.05. 
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Figure 5.2:  Kaplan-Meier survival analysis from diagnosis to castrate resistance 
 using low vs. high cytoplasmic alpha enolase scoring intensities.  
Survival analysis of clinically confirmed PCa patients showing time from initial diagnosis 
(0 months) to castrate resistance. A numerical scoring method assigning 0.0=low alpha 
enolase expression vs. high expression (1.0) is shown. Results show no statistical 
significance p=0.116. 
 
 
5.3.1.3 Nuclear alpha enolase expression in PCa and benign 
prostatic diseases 
 
Although alpha enolase expression is more abundant in the cytoplasm (section 4.3.3.1), 
protein expression was also identified in the nucleus of the prostatic epithelia in benign and 
PCa tissues. For nuclear expression, score intensities ranging from 0-2 were utilised (0 = 
no staining, 1 = weak, 2 = strong staining), as a weaker staining pattern was observed 
compared to cytoplasmic staining. Table 5.4 shows the frequency of nuclear alpha enolase 
expression in PCa and benign tissues within this cohort, whereby of all the patients who 
showed negative alpha enolase nuclear expression (n=209), 56.9% of them were PCa 
patients compared to 43.1% of benign patients. Similarly, of all patients who had a positive 
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alpha enolase expression (n=29), 13.8% of positive staining was identified in benign 
diseases compared to 86.2% of PCa patients; demonstrating that high alpha enolase score 
intensities occur more frequently in PCa (table 5.4). 
Table 5.4: Frequency of nuclear alpha enolase expression in NPRG cohort 
 
 
 
 
 
 
 
 
Benign and PCa tissues scored for nuclear alpha enolase expression using a semi-
quantitative 2 point scoring system ranging from 0 – 2 (0 = negative expression, 1 = 
weak expression, 2 = strong expression). Negative or positive staining in benign or 
cancer patients is depicted in the table. 
 
Positive nuclear staining distribution showed that 90% of all the strong staining intensities 
(staining score 2) occurred in PCa compared to benign disease (10%) (table 5.5). A similar 
pattern was also observed with weakly stained tissues (staining score 1) with 84.2% for 
PCa and 15.8% for benign patients, further indicating that high alpha enolase score 
intensities occur more frequently in PCa. Statistical significance (p=0.003) was observed 
when weak nuclear alpha enolase expression (staining intensity score 0; 4.3%) was 
compared to strong expression (staining intensity score 1 and 2; 17.4%). These findings 
demonstrate that higher nuclear alpha enolase expression is more frequent in PCa 
compared to benign prostatic tissue. 
 
Table 5.5: Nuclear alpha enolase positive staining intensity distribution 
Pathology Frequency Positive intensity 
1 
(n=19) 
2 
(n=10) 
Total 
(n=29) 
Benign disease Number of cases 3 1 4 
 Percentage (%) 15.8 10 13.8 
Prostate cancer Number of cases 16 9 25 
 Percentage (%) 84.2 90 86.2 
 
Benign and PCa tissues scored for nuclear alpha enolase expression using a semi-
quantitative 2 point scoring system ranging from 0 – 2 (0 = negative expression, 1 = weak 
expression, 2 = strong expression). The table shows the positive staining distribution for 
cancer or benign tissues.  
Pathology Frequency 
Negative 
(n=209) 
Positive 
(n=29) 
Total 
(n=238) 
0 1 and 2  
Benign disease Number of cases 90 4 94 
 
Percentage (%) 43.1 13.8 39.5 
Prostate cancer Number of cases 119 25 144 
 
Percentage (%) 56.9 86.2 60.5 
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Similar to cytoplasmic expression, a dichotomous categorisation of nuclear alpha enolase 
expression in PCa was performed using Kaplan Meier survival modelling to determine 
whether nuclear alpha enolase expression correlated with any clinico-pathological 
variables. The first categorisation used was negative nuclear alpha enolase expression 
(stain intensity 0) vs positive expression (stain intensity 1 and 2), which was compared to a 
low (stain intensity 0 and 1) vs. high nuclear alpha enolase expression (stain intensity 2). 
Figure 5.3 shows the Kaplan Meier survival time analysis of negative vs. positive nuclear 
alpha enolase expression compared to low vs. high expression. 
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Figure 5.3:  Dichotomous categorisation of nuclear alpha enolase expression 
modelled by Kaplan-Meier survival graphs.  
Immunohistochemical staining for nuclear alpha enolase staining was carried out and 
scored using a  2 point scoring system ranging from 0 – 2 (0 = no expression, 1 = weak 
expression, 2 = strong expression). Survival analysis of clinically confirmed PCa patients 
for different categories are shown between 0-125 months. A shows analysis for negative 
(score 0; 0.0 on survival graph) vs. positive nuclear staining (score 1 and 2; 1.0 on survival 
graph) (p=0.205), while B shows low (score 0 and 1; 0.0 on survival graph) vs. high 
nuclear alpha enolase expression (score 2; 1.0 on survival graph) (p=0.194). 
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Although a low vs. high nuclear alpha enolase expression (figure 5.3B) produced the best 
separation for predicting survival outcome in PCa (p=0.194) compared to p=0.205 for 
negative vs. positive expression (figure 5.3A), there were not enough patients in the high 
stain intensity group (score 1.0 on the survival curve for figure 5.3B). As a result, the 
negative vs. positive intensity category (staining score 0 vs. 1 or 2; figure 5.3A) was 
applied to determine a correlation between nuclear alpha enolase staining and any clinico-
pathological variables in PCa.  
 
5.3.1.4  Asssociation between nuclear alpha enolase expression and 
clinico-pathological features  
 
The association between nuclear alpha enolase expression in PCa and known clinico-
pathological features (Gleason grade, D’Amico risk prediction, bone metastasis, survival 
and initial PSA) were also determined using a chi-square test. Similar to results obtained in 
the cytoplasmic expression, nuclear alpha enolase was not associated with Gleason grade 
(Gleason grade <8 vs. ≥8, p=0.36), initial PSA (p=0.645), D’Amico risk (p=0.79), 
proliferation (Ki67) (p=0.365), bone metastasis (p=0.642), metastasis (0.623), castrate 
treatment resistance (p=0.219) or survival (p=0.205) (table 5.6). Figure 5.4 shows a 
Kaplan-Meier survival graph for the association between nuclear alpha enolase and 
survival, where no statistical significance was observed at p<0.05.  
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Table 5.6:  Association between nuclear alpha enolase staining and clinico-
pathological variables in PCa 
Characteristics Frequency 
Negative Positive intensities p-value 
0 1 2 3 
Gleason grade 
Grade <8 
123 
39 9 
0.36 
Grade ≥8 64 11 
Initial PSA 
0 - 10 ng/mL 
122 
27 6 
0.645 10.1 - 20 ng/mL 19 2 
>20 ng/mL 56 12 
D'Amico risk 
prediction 
High 
128 
15 5 
0.79 Intermediate 77 16 
Low 12 3 
Proliferation 
(Ki67) 
0 - 10% 
96 
55 20 
0.365 
11 - 100% 14 7 
Bone metastasis 
No metastasis at 
presentation 
123 
97 7 
0.642 Prostate associated bone 
metastasis at 
presentation 
18 1 
Any metastasis 
Negative 
103 
56 4 
0.623 
Positive 40 3 
Castrate treatment 
resistance  51 41 10 0.219 
Survival Months 57 48 9 0.205 
 
The assocition between nuclear alpha enolase expression and clinico-pathological variables. No 
statistical significance was found between nuclear alpha enolase expression and any clinical variables at 
p<0.05. 
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Figure 5.4:  Kaplan-Meier survival analysis from diagnosis to castrate resistance 
 using negative vs. positive nuclear alpha enolase scoring intensities.  
Survival analysis of clinically confirmed PCa patients from initial diagnosis (0 months) to 
time to castrate resistance. A numerical scoring method assigning 0.0 = negative nuclear 
alpha enolase expression (stain intensity 0) vs. positive expression (1.0; stain intensity 1 
and 2)) is shown. Results show no statistical significance p=0.219. 
 
 
5.3.1.5 Membranous alpha enolase expression in PCa  
 
Immunohistochemical staining of the NPRG cohort revealed membranous alpha enolase 
expression in a small subset of patients (8 patients out of 235), and as a result, no statistical 
tests were performed on this small number of cases. Score intensities of 0 for no staining 
and 1 for positive staining was allocated to all tissues analysed. Membranous alpha enolase 
expression was only identified in PCa patients and not in benign cases. Table 5.7 shows the 
frequency of membranous alpha enolase staining, where no follow up clinical information 
was available for 3 out of 8 membrane positive patients. 
 
CHAPTER 5: TAA validation 
 
197 
   
Table 5.7: Membranous expression of alpha enolase in PCa 
Patient 
analysis no. 
Gleason 
Grade 
Any 
metastasis 
(Yes or No) 
Membrane 
expression 
(0 or 1) 
Cytoplasmic 
expression 
(0-3) 
Nuclear 
expression 
(0-2) 
      
48 9 No 1 2 1 
85 9 Yes 1 2 0 
97 Not available Not available 1 2 1 
105 5 No 1 3 0 
214 8 No 1 3 2 
233 Not available Not available 1 3 0 
241 Not available Not available 1 2 0 
365 6 No 1 1 0 
 
Membrane positive alpha enolase expression was identified in 8 patients out of 235. Cytoplasmic and 
nuclear expression score intensities ranging from 0-3 (cytoplasmic expression) or 0-2 (nuclear 
expression) in the same patients is also shown. 
 
In cases with available clinical information, alpha enolase membranous expression was 
identified in 3 out of 5 patients with high Gleason grade tumours (Gleason 8 & 9; 60% of 
cases) compared to 2 patients with low grade PCa (Gleason 5 and 6; 40% of cases) (table 
5.7). Furthermore, 1 out of 5 patients positive for alpha enolase membrane expression had 
metastatic PCa (20%) compared to 80% with no metastasis. Figure 5.5 shows membranous 
alpha enolase expression in 2 patients out of 5 with available clinical information. 
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Figure 5.5:  Membranous expression of alpha enolase in PCa.   
Membrane expression of alpha enolase was observed in 8 out of 235 patients by 
immunohistochemistry. A shows alpha enolase expression in a normal prostate, while B 
shows alpha enolase expression in one membrane positive (arrow) patient with Gleason 6 
PCa (patient no. 365). C shows alpha enolase expression in one patient with Gleason 9 
metastatic adenocarcinoma (patient no. 85); where intense expression is observed in the 
lumen (I) and positive membrane expression on the basal cells of the prostatic epithelium 
(II).  Objective magnification x 20 (A, normal prostate), x 40 (B & C). 
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5.3.2  Alpha enolase autoantibody expression in sera 
 
Autoantibodies to alpha enolase were detected in the sera of patients with PCa (section 
3.3.4.4 and figure 3.12). However, as not enough healthy control patients were used as a 
comparison, alpha enolase could not be validated as a potential biomarker for PCa. As a 
result, the aim of this study was to validate the frequencies of autoantibodies against alpha 
enolase using an ELISA assay against a full length recombinant alpha enolase protein. Sera 
from patients with various grades of PCa (n=69), various forms of benign diseases (n=26) 
including benign prostatic disease (n= 7), atypical glands suspicious of malignancy (n=10), 
high grade prostatic intraepithelial neoplasia (n=9) and healthy controls (n=25) were tested. 
 
5.3.2.1 Alpha enolase serum autoreactivity 
  
The mean OD ±1 SD for healthy sera (from 25 healthy patients) was 0.41±0.12. When 
‘mean OD 25 healthy control sera + 3 x SD’ was used as a cut-off point to determine 
positive reactivity (≥OD 0.77; dashed red line in figure 5.6), the prevalence of 
autoantibodies against alpha enolase occurred in 0% of healthy controls and 12% in benign 
patients (3 out of 26) - 22% in PIN patients (2 out of 9), 10% in patients with atypical 
glands suspicious of malignancy (1 out of 10) and 13% in benign tumours (1 out of 8 
patients). More significantly, alpha enolase expression also occurred in 22% in PCa 
patients (16 out of 70) (table 5.8 and figure 5.6). 
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Table 5.8: Frequency distribution of alpha enolase autoreactivity in sera 
Patient group Number of subjects 
No. (%) of subjects positive for 
anti-alpha-enolase autoantibody 
Healthy controls 25 0 (0%) 
Benign diseases 26 3 (12%) 
 High PIN 9 2 (22%) 
 Atypia 10 1 (10%) 
 Benign 7 0 (0%) 
Prostate cancer 69 16 (22%) 
 Gleason 6 25 5 (20%) 
 Gleason 7 (4+3) 11 3 (27%) 
 Gleason 7 (3+4) 18 2 (11%) 
 Gleason 8 2 1 (50%) 
 Gleason 9 13 5 (38%) 
 
Reactivity of anti-alpha enolase autoantibodies from healthy controls, patients with various 
forms of benign prostatic disease and PCa. 
 
Next, the study aimed to determine if there was any statistical significance between alpha 
enolase autoantibody expression in healthy controls (n=25) compared to benign (n=26) or 
PCa patients (n=69). Using a one way ANOVA, statistical significance was observed 
between healthy controls and PCa (p=0.0038) (figure 5.6). Statistical significance was not 
observed between healthy controls and benign diseases (p=0.1451) (figure 5.6) or between 
benign diseases and PCa (p=0.8867) at p<0.05. 
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Figure 5.6:  Alpha enolase sera autoantibody expression in healthy controls, 
 benign prostatic diseases and PCa.  
Mean optical density of ELISA for the detection of autoantibodies to alpha enolase in sera 
from healthy controls (n=25), benign prostatic diseases (n=26) and PCa patients (n=69). 
Vertical error bars indicate standard deviation, while middle dashed line indicates mean of 
each sample group. No statistical significance (ns) was observed between healthy controls 
and benign cases (p=0.1451), while statistical significance was observed between healthy 
control and PCa (p=0.0038) at p<0.05. The dashed red line indicates a positive alpha 
enolase cut off value (OD of 0.77), which is derived from mean OD healthy control sera + 
3SD. 
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5.3.2.2 The association between alpha enolase autoantibody 
expression and Gleason grade  
 
The correlation between the prevalence of autoantibodies against alpha enolase and 
Gleason grade in PCa was investigated. Table 5.8 outlines the frequency of alpha enolase 
autoantibody positivity in various Gleason grades for PCa, where positive reactivity (≥OD 
0.77; dashed red line in figure 5.7) was identified in 20% of Gleason 6 patients (5 out of 
25), 27% in Gleason 7 (4+3) (3 out of 11), 11% in Gleason 7 (3+4) (2 out of 18), 50% in 
Gleason 8 (1 out of 2) and 38% in Gleason 9 PCa patients (5 out of 13). Using a one way 
ANOVA, there was no statistical significance between the occurrence of autoantibodies 
against alpha enolase in healthy controls and Gleason grade 6 (0.0990), Gleason grade 7 
(3+4) (p=0.4334), Gleason 7 (4+3) (p=0.2852), or Gleason 8 (p=0.3892) (figure 5.7). 
Statistical significance was however observed between healthy controls and Gleason 9 PCa 
(p=0.0043) at p<0.05 (figure 5.7). 
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Figure 5.7:  Alpha enolase serum autoantibody expression in various grades of PCa 
  and healthy controls. 
Mean optical density of ELISA for the detection of autoantibodies to alpha enolase in sera 
from healthy controls (n=25), Gleason 6 (n=25) Gleason 7 (3+4) (n=18), Gleason 7 (4+3) 
(n=11), Gleason 8 (n=2) and Gleason 9 (n=13). Vertical error bars indicate standard 
deviation, while middle line indicates mean of each sample group. No statistical 
significance (ns) was observed between healthy controls and Gleason 6 (p=0.0990), 
Gleason grade 7 (3+4) (p=0.4334), Gleason 7 (4+3) (p=0.2852) or Gleason 8 patients 
(p=0.3892). Statistical significance was observed between healthy control and Gleason 6 
(p=0.0446) and healthy controls and Gleason 9 PCa (p=0.0043) at p<0.05. Dashed red line 
indicates a positive alpha enolase cut off value (OD of 0.77), which is derived from mean 
OD healthy control sera + 3SD. 
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5.3.2.3 The association between alpha enolase autoantibody 
expression and D’Amico risk classification 
 
The correlation between alpha enolase and D’Amico risk classification was also 
investigated. Using a one way ANOVA at p<0.05, statistical significance was not observed 
between healthy and low D’Amico risk (p=0.7927), but observed between healthy and 
intermediate D’Amico risk (p=0.0125) and healthy and high D’Amico risk classification 
(p=0.0059) (figure 5.8). No statistical significance was observed between low and 
intermediate D’Amico (p=0.1292) or intermediate and high D’Amico (p=0.7245). 
Statistical significance was however observed between low and high D’Amico (p=0.0262). 
 
 
Figure 5.8:  Alpha enolase autoantibody expression and D’Amico classification in 
PCa. 
ELISA mean optical density for the detection of autoantibodies to alpha enolase in sera 
samples from healthy controls and PCa patients from various D’Amico risk categories. 
Vertical error bars indicate standard deviation, while middle line indicates mean of each 
sample group. No statistical significance (ns) was observed between healthy controls and 
low D’Amico risk (p=0.0.7927), while statistical significance was observed between 
healthy control and intermediate risk (p=0.0125) and healthy controls and high D’Amico 
risk in PCa (p=0.0059) at p<0.05. The dashed red line indicates a positive alpha enolase 
cut off value (OD of 0.77), which is derived from mean OD healthy control sera + 3SD. 
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5.4   DISCUSSION 
 
 
The lack of specificity and sensitivity of PSA for the detection of PCa emphasises the need 
for early PCa detection. The previous chapter observed an increased expression of alpha 
enolase in urine and PCa tissue from a small sample cohort, compared to healthy controls 
(section 4.3.2 and 4.3.3). Thus, the aim of the present chapter was to utilise proteomic 
approaches such as immunohistochemistry and ELISA assays to validate the expression 
profile of alpha enolase protein and autoantibody responses in tumour tissues and sera 
from a larger sample cohort. Furthermore, the chapter aimed to determine whether alpha 
enolase protein or autoantibody expression correlates with important clinical variables. 
Due to the interest our group has in PCa and our access to a PCa TMA and sera, this study 
aimed to investigate the potential of alpha enolase as a biomarker for PCa. 
 
5.4.1  Alpha enolase expression in NPRG TMAs 
 
Similar to findings in the previous chapter (section 4.3.3.1) and reported by Perconti et al. 
(2007), alpha enolase expression was observed mainly in the cytoplasm of the patient 
tissues stained. Increased staining intensity occurred more frequently in PCa (121 patients) 
compared to benign diseases (88 patients) (table 5.1). A similar expression pattern was also 
observed when the positive intensity distribution was assessed, where the highest alpha 
enolase expression (staining intensity score 3) occurred more frequently in PCa (11 
patients) compared to benign controls (3 patients) (table 5.2). Similarly, a weak alpha 
enolase expression (staining intensity score 1) occurred more frequently in benign cases 
(72 patients) compared to PCa patients (60 patients) (table 5.2). 
 
When weak cytoplasmic alpha enolase expression (staining intensity score 0 and 1) was 
compared to strong expression (staining intensity 2 and 3), statistical significance was 
observed between PCa and benign diseases (p=0.000003). These results suggests that an 
increased cytoplasmic alpha enolase expression may be associated with PCa or malignancy, 
consistent with findings by Chu et al., (2011), who found that cytoplasmic alpha enolase 
was overexpressed by 18% of all canine mammary carcinomas studied, where alpha 
enolase overexpression correlated with oestrogen receptor positivity. A list of reported 
cancers showing increased alpha enolase mRNA and/or protein expression has been 
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reviewed by Capello et al., (2001) and can be found in table 4.1. Our results, combined 
with other studies showing an increased alpha enolase expression in a diverse range of 
tumours indicate that alpha enolase could serve as a potential diagnostic indicator for 
multiple cancers. 
 
A similar, but weaker pattern of staining intensity was observed with the nuclear alpha 
enolase expression.  Positive alpha enolase expression was observed more frequently in 
PCa (25 patients) compared to benign diseases (4 patients) (table 5.4). Furthermore, 
analysis of the distribution of positive staining demonstrated that more patients with PCa 
had an increased strong alpha enolase nuclear expression (9 patients) compared to patients 
with benign diseases (1 patient). As before, when weak alpha enolase expression (staining 
intensity score 0) was compared to strong expression (staining intensity score 1 and 2), 
statistical significance was observed (p=0.003). These findings complement the 
cytoplasmic alpha enolase expression pattern; reemphasising that higher nuclear alpha 
enolase expression is more frequent in PCa compared to benign prostatic tissue. This 
suggests that alpha enolase may be associated with PCa or malignancy.  
 
The novel finding of this study was that statistically significant alpha enolase cytoplasmic 
and nuclear overexpression (demonstrated by immunohistochemistry) occurs in patients 
with PCa, compared to benign controls. These results indicate that alpha enolase levels 
increases in PCa and suggest that its expression should be evaluated as a potential 
biomarker for PCa.  
 
5.4.2    The association beteween alpha enolase expression and 
clinico-pathological variables in PCa 
 
The findings from this study showed no statistical significance between cytoplasmic or 
nuclear alpha enolase and any clinico-pathological variables in PCa such as Gleason grade, 
initial PSA, D’Amico risk, proliferation, bone metastasis, castrate treatment resistance, 
survival or metastasis (table 5.3 and table 5.6). On close inspection of cytoplasmic alpha 
enolase expression, some of the clinico-pathological variables analysed yielded p values 
that neared significance – proliferation (p=0.13), metastasis (p=0.149), castrate treatment 
resistance (p=0.116) and survival (p=0.101) (figure 4.2).  
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Furthermore, Kaplan-Meier survival analysis (figure 5.2) showed that although there was 
no statistical significance between castrate treatment resistance and alpha enolase 
cytoplasmic expression, patients with cytoplasmic alpha enolase positive tumours may be 
more likely to live longer (p=0.101), although this finding was not statistically significant. 
It is evident from the Kaplan-Meier survival graphs (especially the graph analysing the 
association between time to castrate treatment resistance, survival probability and nuclear 
alpha enolase expression; figure 5.4) that there are insufficient data points in each category, 
making it difficult to draw firm conclusions from the data. As a result, in order to fully 
validate the association between alpha enolase and clinico-pathological variables in PCa, it 
would be advantageous to screen another PCa TMA with a larger number of patients to get 
a definite association between alpha enolase expression and clinico-pathological variables 
in PCa.  
 
To our knowledge, this is the first report evaluating the association between alpha enolase 
expression in PCa and important clinico-pathological variables. Although this study has 
not identified any significant associations between any clinico-pathological variables and 
alpha enolase cytoplasmic or nuclear expression, our study has identified some interesting 
findings that need to be repeated in a larger sample cohort. 
 
5.4.3   The expression of membranous alpha enolase in PCa 
 
Immunohistochemical staining of the NPRG PCa TMA revealed that out of 235 patients 
screened, only 8 patients demonstrated membranous alpha enolase expression (table 5.7). 
This highlights the possible frequency of alpha enolase membrane expression in PCa. 
However, the expression of alpha enolase in normal cells is well accepted and reviewed by 
Capello et al., (2010), where it is reported to act as a plasminogen receptor on the surface 
of many prokaryotic and eukaryotic cells. Hsiao et al., (2013) reported that surface alpha 
enolase promotes extracellular matrix degradation and tumour metastasis in lung cancer 
cells while Song et al., (2014) reported similar findings in glioma. To our knowledge, this 
is the first study reporting the expression of membranous alpha enolase in PCa, albeit in a 
small number of cases. The presence of membranous alpha enolase in a small subset of 
PCa patients suggests that alpha enolase may be a potential target for antibody dependent 
cytotoxicity (ADCC).  
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Due to the small number of patients positive for alpha enolase expression and the limited 
follow up clinical information available for the patients screened, no correlation could be 
made between the presence of membranous alpha enolase and the staining intensity of 
cytoplasmic or nuclear alpha enolase. In addition, no correlation could be made between 
Gleason grade, stage or D’Amico risk classification in this study. However, this study 
identified intense staining around the cell membrane of one patient with Gleason 6 PCa 
(figure 5.5B) and in the lumen of another patient with metastatic Gleason 9 PCa (figure 
5.5C). 
 
It is interesting that in the only patient with tumour metastasis, a strong alpha enolase 
expression was identified in the lumen of the prostatic epithelia (figure 5.5C). This 
suggests that alpha enolase may be secreted by the secretory columnar cells of the prostatic 
epithelia (in this patient). Also of interest is the fact that these cells also secrete PSA, the 
current diagnostic biomarker for PCa (Cramer et al., 2007). Although this finding was 
demonstrated in one patient, it would be interesting to determine whether urinary alpha 
enolase correlates with tissue alpha enolase expression, as urine is a less-invasive 
biomarker source for PCa. As demonstrated from the previous chapter, alpha enolase is 
normally present in urine (section 4.3.2), but studies investigating its expression in urine 
from a cohort of PCa/benign or healthy controls have not been carried out. Using a large 
sample cohort, it would be advantageous to screen patients with various grades of PCa for 
urinary alpha enolase expression, in order to determine whether alpha enolase urine 
expression can be utilised as a diagnostic or prognostic PCa biomarker. 
 
5.4.4   Alpha enolase autoantibody expression in sera 
 
Findings from the previous chapter (section 3.3.4.3 and 3.3.4.4) demonstrated that a 
differential alpha enolase autoantibody expression occurred in a small subset of patients 
with PCa. However, due to the small number of patients studied and the limited sample 
volumes available for comparison with healthy sera, the appropriate statistical test was not 
carried out. The aim of this follow up study was to evaluate the expression of a differential 
autoantibody expression in a larger PCa, benign and healthy sera cohort. 
 
Using a cutoff of 0.77 (mean OD 25 healthy control sera + 3 x SD), positivity was defined 
as any OD value above 0.77.  The results show that there was a higher occurrence of 
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positive autoantibody expression in PCa (16 patients) compared to benign disease (3 
patients) or healthy controls (0 patients) (table 5.8). In addition, when PIN samples are 
eliminated (PIN is thought to be the precursor to PCa, Cramer et al., 2007), alpha enolase 
autoantibody expression was only identified in 1 out of 17 patients with benign disease (5% 
of cases), compared to a 22% occurrence in PCa. The difference in autoantibody 
expression between healthy controls and PCa was statistically significant (p=0.0038), 
while no statistical significance was observed between healthy controls and benign 
diseases (p=0.1451) or benign diseases and PCa (0.8867) (figure 5.6). 
 
These findings further demonstrate the high expression of alpha enolase autoantibodies in 
PCa. To our knowledge, this is the first report on the frequency of alpha enolase 
autoantibody occurrence in PCa; and indicates that alpha enolase autoantibodies may 
potentially be added to a panel of diagnostic biomarkers for PCa after additional validation. 
Other studies have supported these findings; Peng et al., (2013) found a high incidence of 
autoantibody expression in liver cancer (14.3%; 12/84 cases) compared to healthy sera 
(4.1%; 3/74), while Shih et al., (2010) found a significantly decreased expression of alpha 
enolase autoantibodies in stage IV non-small cell lung cancer, small cell lung cancer and 
breast cancer patients. These studies suggest that differential expression of alpha enolase in 
cancers may serve as a potentially useful biomarker to stage and monitor cancer patients in 
the future. 
 
5.4.5    The association between alpha enolase autoantibody 
expression and Gleason grade 
 
When the correlation between alpha enolase autoantibody expression and Gleason grade 
was investigated, this study found no statistical significance between healthy controls and 
Gleason grade 6 (0.0990), Gleason grade 7 (3+4) (p=0.4334), Gleason 7 (4+3) (p=0.2852), 
or Gleason 8 (p=0.3892) (figure 5.7). Statistical significance was however observed 
between healthy controls and Gleason 9 PCa (p=0.0043) at p<0.05 (figure 5.7). This 
suggests that alpha enolase autoantibody expression may correlate with more advanced 
PCa. As stated previously, these findings are similar to Shih et al., (2010) who identified 
that the titre status of alpha enolase autoantibodies are highly associated with late stage of 
lung and breast cancer patients compared to healthy controls. 
 
CHAPTER 5: TAA validation 
 
210 
   
Although statistical significance was observed between healthy controls and Gleason 9 
PCa (p=0.0043), there were not enough patients in this study diagnosed with Gleason 8 
PCa (n=2 patients, compared to n=11 in Gleason 7, 4+3), to determine if a similar 
correlation could have been present in Gleason 8 compared to healthy controls, or if alpha 
enolase expression correlates with Gleason grade when more patients in each category. As 
a result, future studies could investigate the expression of autoantibodies to alpha enolase 
in more samples, ensuring that a minimum of 70 patients are in each category.  
 
5.4.6    The association between alpha enolase autoantibody 
expression and D’Amico risk classification 
 
The D’Amico risk classification stratifies patients into low, intermediate or high risk of 
biochemical recurrence after radical prostatectomy (Hernandez et al., 2007). This chapter 
also investigated the association between D’Amico risk classification and sera 
autoantibody alpha enolase expression (section 5.3.2.3). Figure 5.8 shows that alpha 
enolase autoantibody expression correlates with D’Amico risk classification, where no 
statistical significance was observed between healthy controls and low D’Amico risk 
(p=0.7927) but between healthy controls and intermediate (p=0.0125) and high D’Amico 
risk (0.0059). These results suggest that autoantibodies to alpha enolase may be used as a 
prognostic indicator to determine PCa recurrence or treatment response. It further suggests 
that autoantibodies to alpha enolase may be added to a panel of prognostic PCa biomarkers 
for better patient management. To our knowledge, this is the first report on the association 
between alpha enolase autoantibody expression in sera and D’Amico risk classification. 
 
To summarise, the aim of this chapter was to identify the association between alpha 
enolase protein and autoantibody expression in PCa and see whether there was any 
association between its expression and important clinico-pathological variables in PCa. 
This study has identified a high expression of cytoplasmic and nuclear alpha enolase 
protein in PCa compared to benign disease however there was no correlation to any 
important clinico-pathological variables, perhaps due to the limited number of samples 
screened in the NPRG TMA cohort. Our study is the first to report these findings in PCa, 
where statistical significance has been observed between autoantibodies to alpha enolase 
and PCa, Gleason 9 PCa and D’Amico risk classification. Although the NPRG TMA study 
showed no diagnostic/prognostic potential for alpha enolase, the high expression of 
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autoantibodies in sera and potential membranous expression in a small cohort of patients 
make alpha enolase an interesting candidate to study in a larger sample cohort to give 
validity to these results. 
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6 CHAPTER 6: SUMMARY OF DISCUSSION 
6.1   INTRODUCTION 
 
PCa is the most common cancer in men above 65 years (Drewa and Styczynski, 2008). 
Studies at autopsy have found that by 30-39 years of age, approximately 29% of men have 
microscopic evidence of disease, increasing to approximately 65% by age 70 (Sakr et al., 
1994). Approximately 41,700 new cases of PCa are diagnosed every year, where it is 
expected that 1 in 8 men will be diagnosed with PCa in their lifetime (Cancer Research UK, 
2015b). Unfortunately, this figure is expected to rise, due to the lack of specificity and 
sensitivity of PCa screening and detection methods (Madu and Lu, 2010). 
 
PCa risk is associated with age. Research has shown that only 1% of diagnoses occurred in 
patients under 50 (Cancer Research UK, 2015b), while patients of Caribbean and African 
origin have a greater risk of developing PCa (1 in 4 lifetime relative risk) (Prostate Cancer 
UK, 2015), and those with a family history (with more than one affected 1st degree relative) 
have 3.5 times relative risk of developing PCa (Johns and Houlston, 2003).  
 
The nature of PCa is such that many patients with early stages of the disease are 
asymptomatic, while symptoms of locally advanced PCa (e.g. nocturia, terminal dribbling, 
increased urinary frequency and poor stream) may be difficult to differentiate from patients 
with BPH, as these lower urinary tract symptoms are common to both conditions (GP 
online, 2014). Furthermore, PCa screening and diagnosis relies on a PSA blood test 
alongside an invasive and subjective DRE and TRUS guided biopsy (Roth-Kauffmann, 
2011). However, despite the utility of these tests, PCa diagnosis is associated with 
overdiagnosis, overtreatment, false positive results (PSA tests), bleeding, subjectivity 
(DRE), infection, and pain associated with biopsy (Cochrane, 2013). This causes 
unnecessary patient distress and increased clinical costs; which warrants the need for more 
sensitive and specific biomarkers to differentiate between PCa and other non-malignant 
conditions. 
 
It is well documented that antibodies present in cancer sera towards TAAs may provide 
insights into the interrelationship between the immune system and cancer (Chen et al., 
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1996, Rattner et al., 1997 and Gure et al., 2000). It may also provide a new understanding 
into, and guide the development of new treatment strategies for cancer and identify new 
biomarkers for the diagnosis and prognosis of cancer (Kellner et al., 2002, Usener et al., 
2003, Neumann et al., 2004, Ehlken et al., 2004 and Zippelius et al., 2007). As a result, the 
identification of these TAAs and autoantibodies has become the subject of much research.  
 
One of the proteome based techniques to identify TAAs and autoantibodies is known as 
PROTEOMEX, which involves screening patient sera with the proteomes of tumour cell 
lysates separated by 2-DE electrophoresis and subsequent TAA identification with mass 
spectrometry (Kellner et al., 2002). PROTEOMEX has successfully been utilised in the 
identification of many TAAs for various cancers such as HSP-60 and RS/DJ-1 in breast 
cancer (Hamrita et al., 2008, Desmetz et al., 2008 and Le Naour et al., 2011), cytokeratin 8 
and thioredoxin in renal cell carcinoma (Kellner et al., 2002 and Lichtenfels et al., 2003), 
eukaryotic elongation factor, alpha enolase, aldolase, glyceraldehyde-3-phosphate 
dehydrogenase and heterogeneous nuclear ribonucleoproteins A2B1 and galectin-3 in 
melanoma (Suzuki et al., 2010 and Forgber et al., 2009) and alpha enolase in pancreatic 
adenocarcinoma (Tomaino et al., 2007). Despite the utility of this method, no studies have 
utilised the PROTEOMEX technique for the identification of TAAs in PCa. Thus, the aim 
of this research was to identify TAAs and autoantibodies for PCa using the PROTEOMEX 
technique in combination with mass spectrometry. 
6.2 Urine contains prostate relevant TAAs that can be isolated 
and identified using the PROTEOMEX technique 
 
Urine is an excellent source for biomarker discovery for PCa due to the proximity of the 
bladder to the prostate gland (Hessels and Schalken, 2013). In patients who have PCa, the 
gentle massage of both sides of the prostate gland during DRE, stimulates the release of 
prostatic fluids and detached epithelial cells (expressed prostate secretions) into the urethra 
(Duijvesz et al., 2011). As a result, urine obtained after DRE in patients with PCa may 
contain prostatic secretions and cells originating from the prostate tumour, which could 
serve as early PCa biomarkers (Downes et al., 2006). Although the samples utilised from 
this study were not obtained from DRE massaged urine, chapter 2 aimed to determine if 
TAAs could be identified from non-massaged urine which could serve as PCa biomarkers. 
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In the pilot study, urine samples from PCa patients were separated by SDS PAGE, where 
differential bands were observed (between 37 – 75 kDa) in immunoblots screened with 
pooled allogenic PCa or healthy sera (figure 2.7) suggesting the specificity of the immune 
response for PCa. When the frequency and specificity patterns in autoreactivity were 
evaluated, section 2.3.2.1 shows that apart from one band that was common to all patient 
groups (50 kDa, figure 2.8), different autoreactivity patterns occurred in each PCa patient 
(2 bands in PC01, 4 bands in PC02, 2 bands in PC03), further emphasising the need to 
screen each patient individually, after a pooled PROTEOMEX study, similar to findings by 
Forgber et al., (2009). Furthermore, this study demonstrated two bands common to two 
PCa patients – PC02 and PC03 (at 43 and 40 kDa). The band at 43 kDa was excised from a 
Coomassie stained replica gel and identified by LC MALDI TOF/TOF as 25 significant 
proteins (table 2.9), the most significant of which was a well-known PCa biomarker, 
prostatic acid phosphatase identified using 14 peptides (table 2.10). Although this study 
verified prostatic acid phosphatase expression by Western blotting, consistent with 
findings by (Gutman, et al., 1936), the study highlighted the need to carry out more 
fractionation before TAA identification by PROTEOMEX. 
 
The next study (section 2.3.3) demonstrated that 2-DE in combination with MALDI 
TOF/TOF is a more suitable technique for TAA identification using PROTEOMEX, as a 
larger number of spots were observed from the immunoblot compared to the SDS PAGE 
screen (figure 2.11). Zinc-alpha-2 glycoprotein, alpha-1-acid glycoprotein, and serum 
albumin were identified from gel spots (table 2.12), and interestingly these same proteins 
were also identified from the previous study, although majority of the proteins identified 
from this study were serum albumin. From the immunoblot, zinc-alpha-2 glycoprotein 
demonstrated intense differential expression in PCa compared to healthy controls, 
consistent with findings by Gagnon et al., (1990) and Hassan et al., (2007), suggesting that 
zinc-alpha-2 glycoprotein may serve as a potential PCa biomarker. 
 
The final study aimed to determine if a combined OFFGEL and SDS PAGE approach 
could be utilised as a separation and screening method for PROTEOMEX prior to TAA 
identification by ESI MS. As before, a differential expression between PCa and healthy 
controls was identified in two bands (figure 2.15). Protein identification from one band 
identified serum albumin, zinc-alpha-2 glycoprotein and prostatic acid phosphatase (band 
#4; table 2.17). This study demonstrated that the best method for TAA identification was 
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2-DE in combination with MALDI TOF/TOF, where spots of interest yield one or two 
proteins, making it easy to narrow down proteins responsible for the immune response, 
similar to findings by Forgber et al., (2007). It also highlighted, most importantly that urine 
contains prostate relevant TAAs that can be isolated and identified using the 
PROTEOMEX method. 
6.3 Tumour cell lines provide a suitable source of TAAs for 
identifying autoantibodies associated with PCa 
 
The lack of available tumour tissue lysates led to the investigation of immortalised PCa 
cell lines as an alternative source of TAAs for PROTOEMEX studies. Although 
immortalised cell lines have been used as a TAA source in renal cell carcinoma (Kellner et 
al., 2002 and Lichtenfels et al., 2003), breast cancer (Hamrita et al., 2008, Desmetz et al., 
2008 and Le Naour et al., 2011), pancreatic adenocarcinoma (Tomaino et al., 2007) and 
melanoma (Suzuki et al., 2010 and Forgber et al., 2009), till date no studies have 
demonstrated the use of immortalised PCa cell lines for TAA identification using 
PROTEOMEX. Thus, the aim of this study was to use PROTEOMEX to identify TAAs 
and autoantibodies in two well-characterised PCa cell lines, which may serve as 
biomarkers for PCa. 
 
Initial studies in the PC-3 cell line showed a differential autoantibody response between 
PCa, benign and healthy controls, where within PCa patients, more intense autoreactivity 
was observed in Gleason 7 (4+3) compared to Gleason 7 (3+4), suggesting that a higher 
alpha enolase autoantibody titre may occur in patients with a more aggressive form of PCa 
(figure 3.3). Interestingly, this finding was also observed in a small number of cases in the 
subsequent chapters (figure 5.7), although this finding was not statistically significant. As a 
result, further studies need to investigate the relationship between alpha enolase 
autoantibody expression and aggressive PCa in order to validate these findings. 
 
In DU-145, patients from various grades and stages of PCa were utilised due to insufficient 
spot yielded from the PC-3 study. DU-145 immunoreactivity produced more spots (18 
spots, where only 16 of them could be matched on the replica gel. The identified spots 
represent proteins responsible for the immune response (HSP-60), metabolic enzymes 
(alpha enolase), energy metabolism (ATP synthase subunit) and cell signalling (WNT7A). 
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This study identified for the first time that autoantibodies to alpha enolase are differentially 
expressed in PCa sera compared to healthy controls, warranting the need to carry out 
further studies investigating the possibility of alpha enolase as a potential biomarker for 
PCa. 
 
Due to the possibility of false identification in biomarker studies, it was paramount that the 
TAA and autoantibody response was verified in the discovery sample cohort. As a result, 
the aim of the next section (section 3.3.4) was to confirm the alpha enolase protein 
identification in DU-145 alongside the presence of a differential alpha enolase 
autoantibody response in the discovery sample cohort of PCa patients compared to healthy 
sera. Studies confirming alpha enolase expression in PC-3 were carried out in the 
subsequent chapter (section 4.3.1). Using immunofluorescence, intracellular staining by 
flow cytometry, Western blotting and MALDI TOF MS, the presence of alpha enolase in 
DU-145 was verified (section 3.3.4). Although there was a suggested staining observed 
around the cell in DU-145 using immunofluorescence (figure 3.9), extracellular staining 
using flow cytometry failed to confirm any alpha enolase cell surface expression (appendix 
VI). The final study confirmed a differential alpha enolase autoantibody expression in 
pooled and individual samples that made up the discovery cohort. 
 
Taken together, both studies show that although alpha enolase is normally present in cells 
(Diaz-Ramos et al., 2012) and PCa cell lines, a differential autoantibody expression exists 
in sera, similar to findings in non-small cell lung cancer (He et al., 2007) and pancreatic 
cancer (Tomaino et al., 2011). This suggests that autoantibodies to alpha enolase can 
possibly be exploited as a potential PCa biomarker following additional investigation, 
which forms part of the penultimate chapter (section 5.3.2). Most importantly, chapter 3 
demonstrated the utility of immortalised PCa cell lines as a suitable source of TAAs for 
identifying autoantibodies associated with PCa. 
6.4 A differential alpha enolase expression in PCa occurs in other 
biological samples 
 
In order to validate its potential utility as a PCa biomarker, it was important to evaluate 
alpha enolase expression in more than one biological sample. In so doing, the potential of 
alpha enolase as a PCa biomarker for invasive (serum, tissue) or non-invasive (urine) 
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biological samples can be assessed. To this end, alpha enolase expression in other PCa cell 
lines, urine and tissue were determined using immunofluorescence, flow cytometry, 
Western blotting and immunohistochemistry. 
 
Chapter 4 identified alpha enolase expression in all PCa cell lines studied - PC-3, OPCT-1 
and LNCaP by immunofluorescence, flow cytometry and Western blotting (figure 3.9). 
Furthermore, extracellular staining failed to demonstrate the presence of membranous 
alpha enolase in PCa cell lines, contrary to findings by Capello et al. (2009), Chang et al. 
(2006) and He et al. (2007) who identified membranous alpha in pancreatic, lung and small 
cell lung cancers respectively.  
 
The next study evaluated alpha enolase expression in urine using Western blotting. 
Although urinary alpha enolase has previously been reported in one study investigating 
urine samples obtained after prostatic massage (Rahman et al., 2004), this is the first study 
to demonstrate the presence of urinary alpha enolase in non-massaged urine in patients 
with PCa. Alpha enolase was identified at 47 kDa in healthy controls and PCa patients, 
while a higher (differential) expression was observed in PCa at approximately 66 kDa, 
possibly due to posttranslational modifications in alpha enolase, as observed in pancreatic 
adenocarcinoma by Tomaino et al. (2011).  
 
Alpha enolase tissue expression was carried out to confirm its expression in a range of 
normal, tumour and adjacent normal tissue samples. From this study, a cytoplasmic and 
nuclear alpha enolase expression was observed in all TMAs screened, although higher 
cytoplasmic expression occurred in most cancers, compared to controls (section 4.3.3.1 
and 4.3.3.2); similar to work reviewed by Capello et al. (2001). A reduced alpha enolase 
expression was only identified in breast cancer, contrary to reports by Tu et al. (2010), who 
found that increased mRNA expression occurred in patients with breast cancer, where 
increased expression correlated with tamoxifen resistance, suggesting that alpha enolase 
expression may correlate to therapeutic outcome in breast cancer. 
 
Due to our interest in PCa, the expression of alpha enolase in a small cohort of patients (9 
patients) was investigated in this chapter. The results indicate an increased alpha enolase 
expression in 8 out of 9 patients studied (score intensity >0, where score intensity 0 was 
observed for normal prostate; table 4.4A). This study combined with all other findings 
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warrant the investigation of the utility of alpha enolase as a potential PCa biomarker. This 
chapter demonstrated that differential expression of alpha enolase occurs in tissue and 
urine (at 66 kDa), two main sample sources for PCa biomarkers, indicating that more 
studies need to be carried out in a larger sample cohort to evaluate the possibility of alpha 
enolase as a diagnostic PCa biomarker. 
6.5 High alpha enolase tissue expression occurs in PCa but does 
not correlate with any important clinico-pathological 
variables 
 
The 3rd and 4th chapters identified alpha enolase as a potential PCa biomarker worth 
investigation. In order to validate the utility of alpha enolase as a PCa biomarker, it was 
important to carry out studies in a larger sample cohort in order to determine whether 
statistical significance could be attributed to the preliminary findings. The aim of chapter 5 
was to screen a prostate TMA cohort for alpha enolase expression and determine if it 
correlates with any important clinico-pathological variables in PCa. 
 
Increased alpha enolase cytoplasmic and nuclear expression occurred more frequently in 
PCa compared to benign diseases, while weaker alpha enolase expression occurred more 
frequently in benign diseases. When weak cytoplasmic alpha enolase expression was 
compared with stronger expression, statistical significance was observed between PCa and 
benign diseases (p=0.000003), suggesting an increased expression occurs in malignancy. 
These findings are similar to Chu et al. (2011). A similar association was also observed 
with nuclear staining (p=0.003). These findings suggest that alpha enolase may serve as a 
potential PCa diagnostic biomarker, being able to differentiate PCa from benign disease. 
 
Chapter 5 failed to identify any association between cytoplasmic and nuclear alpha enolase 
and any important clinico-pathological variables in PCa, although in most cases, there were 
not enough patients in each dataset to make any firm conclusions about the possible 
associations between alpha enolase expression and clinico-pathological variables in PCa. 
Interestingly, it was observed that patients with cytoplasmic alpha enolase positive tumours 
may live longer (p=0.101), than those without. However, these findings were not 
significant but should be repeated in a larger sample cohort. 
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In tissue, alpha enolase was identified in 8 out of 235 patients screened, where it also 
occurred in the lumen of one patient with metastatic Gleason 9 PCa. Due to the low 
numbers of patients positive for alpha enolase membrane expression, no statistical test 
could be performed. This study however highlighted the association between cytoplasmic, 
membrane alpha enolase and clinico-pathological variables for the first time in PCa. 
6.6 High serum alpha enolase autoantibody expression occurs in 
PCa and correlates with D’Amico risk classification 
 
The 3rd and 4th chapters identified a differential autoantibody response to alpha enolase as a 
potential PCa biomarker in a small sample cohort. In order to validate these findings, alpha 
enolase autoantibody responses were screened in a larger sample cohort of patients with 
various stages and grades of PCa compared to benign and healthy controls. 
 
Using a cutoff defined by the mean OD of healthy sera, a higher occurrence of 
autoantibodies to alpha enolase occurred in PCa (16 patients) compared to benign (3 
patients) or healthy controls (0 patients), similar to work by Peng et al. (2013) who found a 
high incidence of autoantibody expression in liver cancer. The study also found statistical 
significance between the autoantibody expressions in healthy controls compared to PCa 
patients (0.0038). Our study is the first to identify a high expression of alpha enolase 
autoantibodies in PCa patients, suggesting that differential alpha enolase autoantibody 
expression may be added to a panel of diagnostic biomarker for PCa. 
 
Our study also identified a significant difference between alpha enolase expression in 
healthy controls compared to Gleason grade 9 PCa, suggesting that there may be an 
association between autoantibody expression and advanced PCa. Similarly, this study 
reported for the first time a correlation between alpha enolase autoantibody expression and 
D’Amico risk classification (section 5.3.2.3). This implies that autoantibodies to alpha 
enolase may not only serve as a diagnostic biomarker for PCa, but also a means of 
identifying patients with a high risk of biochemical recurrence in PCa after radical 
prostatectomy. 
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7 CHAPTER 7: CONCLUSIONS & FUTURE WORK 
7.1   CONCLUSIONS 
 
Early detection of PCa is essential for patient management, thus patient screening to aid 
early PCa diagnosis is mandatory (Smith et al., 2003). Using PROTEOMEX in 
combination with various mass spectrometry methods, this study identified prostate 
relevant TAAs (prostatic acid phosphatase, zinc-alpha-2 glycoprotein and serum albumin 
in urine, alpha enolase in PCa cell lines) and autoantibodies (alpha enolase) in various 
biological samples that have shown some differential expression in PCa compared to 
benign or healthy controls, suggesting that these identified biomarkers may have some 
diagnostic utility in PCa detection, staging and monitoring. Although the study failed to 
identify an association between alpha enolase tissue expression and any clinic-pathological 
variables in PCa, the study has yielded some interesting results that should be validated in 
a larger sample cohort. 
7.2   FUTURE WORK 
 
This study has paved the way for future projects to identify and verify/validate potential 
TAAs and biomarkers for PCa, using the already optimised PROTEOMEX method utilised 
throughout this study. Furthermore, this project has also enabled the identification of 
TAAs/autoantibodies in various biological samples with a view to demonstrating which 
sample source would serve as a better biomarker for PCa. Future work should most 
importantly demonstrate the diagnostic utility of alpha enolase as a biomarker in other 
sample sources alongside aim to identify new potential biomarkers for PCa. 
7.2.1  Immunodepletion of urinary proteins for the identification of 
TAAs and biomarkers for PCa 
 
One of the limitations from this study was that crude urinary lysates were utilised for 
biomarker discovery studies. It is well known that the presence of high abundant proteins 
in urine (e.g. albumin, IgG) mask lower abundant proteins which may serve as potential 
cancer biomarkers. Future work with urine samples could immunodeplete the top 20 most 
abundant urine proteins from PCa and healthy patient samples (e.g. using a Sigma 
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ProteoPrep 20 immunodepletion kit) to reduce sample complexity and improve the chances 
of finding potential PCa biomarkers. This kit will deplete the top 20 proteins which are: 
albumin, IgG, transferrin, fibrinogen, IgA, alpha-2-macroglobulin, IgM, alpha-1-
antitrypsin, complement C3, haptoglobulin, apolipoprotein A3, apolipoprotein A2, 
apolipoprotein B, acid-1-glycoprotein, ceruloplasmin, complement C4, complement C1q, 
IgD, prealbumin and plasminogen. Depletion of these 20 proteins removes 95% of the 
human plasma protein mass (as assayed in human serum). This kit has never been applied 
in the removal of abundant proteins in urine, which is a novelty of this approach for 
biomarker discovery. Depletion of these samples will reduce the complexity of before their 
analysis by 2-DE or OFFGEL in combination with PROTEOMEX.  
7.2.2  Validation of identified biomarkers to investigate their 
diagnostic/prognostic value in PCa  
 
Although some verification and validation (in a small cohort) was carried out in this study, 
all identified biomarkers (prostatic acid phosphatase, zinc alpha 2 glycoprotein, serum 
albumin and alpha enolase – protein and autoantibody responses) should be validated in a 
large sample cohort (minimum of 2,000 patients), in order to make firm conclusions about 
the potential of these candidates as PCa biomarkers. In such studies, each marker should be 
combined with PSA to determine whether a combination of both or a panel of these 
identified markers could increase the sensitivity and/or specificity of PCa detection. 
 
This study showed a differential expression of alpha enolase in urine. Studies could 
investigate the expression of urinary alpha enolase in a large cohort of patients, perhaps 
using an ELISA assay. In addition the possible post translational modification of urinary 
alpha enolase in PCa should also be investigated in order to determine if alpha enolase 
PTMs can serve as a PCa biomarker, similar to findings by Tomaino et al. (2011). 
7.2.3  Subcellular fractionation of PCa cell lines for TAA and 
biomarker identification  
 
Tumour cell lysates from PCa cell lines can be subcellular fractionated into nuclear, 
cytoplasmic and membranous fractions in order to enrich TAA for biomarker discovery. 
Each enriched fraction could be separated by 2-DE before immunoprobing with a cohort of 
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PCa (n=20) vs. healthy sera (n=20). In order not to mask individual immunoreactivity to 
TAA, five patients from each sample set could be pooled to make 4 sample pools for PCa 
and healthy controls respectively. Each pool will be used to screen the nuclear, 
cytoplasmic and membranous fractions to identify TAA for subsequent mass spectrometry 
identification. 
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APPENDIX I 
 
I Laboratory consumables and equipment 
II Laboratory reagents 
 
All chemicals and reagents were stored according to manufacturer’s instructions and used 
within their expiry date. 
 
Culture media      Supplier 
 
Dulbecco’s Modified Eagle Media (DMEM)   Lonza 
Eagle’s Minimal Essential Media (EMEM)   Lonza 
Ham’s F12       Lonza 
Keratinocyte Serum Free Media (KSFM)   Gibco 
RPMI 1640 media      Lonza 
F-12 Kaighn’s       Gibco 
 
Supplements to cell structure    Supplier 
 
Fetal calf serum (FCS)     Perbio Thermo Fisher 
Glucose       Lonza 
Hepes        Lonza 
Hydrocortisone      Sigma Aldrich 
L-glutamine       Lonza 
Non-essential amino acids (NEAA’s)   Lonza 
Sodium pyruvate      Lonza 
Testosterone       Sigma Aldrich 
 
Other cell culture reagents      Supplier 
 
Dimethyl Sulpoxide Hybri-Max (DMSO)   Lonza 
Dulbecco’s phosphate buffer saline (dPBS)   Lonza 
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Trypan blue 0.4% (v/v)     Sigma Aldrich 
Trypsin/Versene (T&V)     Lonza 
 
Chemical reagents      Supplier 
 
Acetic acid       Fisher Scientific 
Acetone (for HPLC)      Fluka Analytical 
Acetonitrile        Sigma Aldrich 
Ammonium bicarbonate     Sigma Aldrich 
Ammonium persulphate (APS)    Geneflow National Diagnostics 
Acrylamide (30%)      Geneflow National Diagnostics 
Bovine serum albumin (BSA)    Calbiochem 
Bovine serum albumin (BSA) (for protein assay standards) Pierce 
Bromophenol blue       Promega 
Coomassie brilliant blue      PhiBio Systems 
Deionising resin      Bio RAD 
Dithiothreitol (DTT)      Apollo Scientific 
Ethanol       Fisher Scientific 
Glycerol        Sigma Aldrich 
Hydrochloric acid (HCI)     Fisher Scientific 
Iodoacetamide       Sigma Aldrich 
Isopropanol       Fisher Scientific 
Isoton        Beckman Coulter 
Liquid nitrogen      BOC 
Marvel skimmed milk powder    Premier Brands 
Methanol       Fisher Scientific 
N, N, N’, N’-tetramethyl-ethylenediamine (TEMED)  Geneflow National 
Diagnostics 
NANOpure diamond distilled water    Barnstead 
Nitrocellulose membrane     Gilson Anachem 
Octyl 𝛽𝛽-D-glucopyranoside (OGP) Apollo Scientific 
Paraformaldehyde Sigma Aldrich 
Ponceau S solution Sigma Aldrich   
Precept tablets Johnson and Johnson 
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Precision plus protein WesternC standards Bio-RAD 
Propan-2-ol Fisher Scientific 
Protein assay BCA solution Bio-RAD 
Protogel running buffer Geneflow National Diagnostics 
Protogel stacking buffer Geneflow National Diagnostics 
RapidStep ECL reagent Calbiochem 
ReadyPrep overlay agarose Bio-RAD 
Sodium chloride (NaCl) Fisher Scientific 
Sodium dodecyl sulphate (SDS) Sigma Aldrich 
StrepTactin HRP Bio-RAD 
Sulphuric acid Fisher Scientific 
Teepol Johnson and Johnson 
Tris hydrochloride  Sigma Aldrich 
Trizma base Sigma Aldrich 
Tween-20 Sigma Aldrich 
Ultrapure 10X Tris-Glycine (transfer buffer) Geneflow National Diagnostics 
Ultrapure 10X Tris-Glycine/SDS (running buffer) Geneflow National Diagnostics 
Urea Melford 
VectaShield (with DAPI)  Vector Labs 
 
Proteomics reagents Supplier 
 
2-DE sample rehydration buffer Bio-RAD 
AG 501-X8 Resin, biotech, Grade, 20-50 mesh (100g) Bio-RAD 
C18ZipTip Millipore 
CHCA (a-Cyano-4-hydrocinnamic acid) Bruker Daltonics 
Dichloromethane (HPLC grade) Fisher Scientific 
Formic acid (HPLC grade) Fluka Analytical  
Methanol (HPLC grade) Fisher Scientific 
Mineral oil (for 2-DE) Bio-RAD 
Peptide calibrant standard II  Bruker Daltonics  
Readystrip IPG Strips (pH 3-10), 7cm Bio-RAD 
Recombinant alpha enolase protein Fitzgerald 
Trifluoroacetic acid (TFA) Fisher Scientific 
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Trypsin gold (MS grade) Promega 
Vivaspin 20 columns Sartorious Stedim Biotech 
 
Immunochemical reagents Supplier 
 
Primary antibody 
Mouse anti-human alpha enolase (L-27) Santa Cruz 
 
Secondary antibodies 
Rabbit anti-human IgG (HRP) Dako 
Goat anti-mouse IgG (HRP) Dako 
Goat anti-mouse IgG (Alexa flour 488) Life Technologies 
 
III  Buffers and stains 
 
Buffers were prepared as follows: 
 
Buffers and stains used for tissue culture 
 
Trypan blue for cell counting: 01% (v/v) trypan blue solution 
 DPBS 
 
Buffers and stains for cell lysis and Western blotting 
• Cell lysis buffer: 9.5 M urea 
 2% DTT 
 1% OGP 
 
• Sample reducing buffer: 10mL 0.5 M Tris HCl 6.8 (stacking gel buffer) 
 2.0 g SDS 
 6.4 mL Glycerol 
 0.05 g Bromophenol blue 
 Adjusted to 20 mL with ddH2O 
 
• Ammonium persulphate: 0.1 mg Ammonium persulphate 
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 1 mL ddH2O 
 
• Running buffer: 100 mL Geneflow 10X Tris/Glycine/SDS solution 
 900 mL dH2O 
 
• Transfer buffer: 100mL Geneflow 10X Tris/Glycine 
 900mL dH2O 
 
• TBS 0.1% Tween-20: 12.1 g Trizma base 
 87.6 g NaCl 
 Adjust to pH 7.5 
 
• 3% marvel TBS 0.1% 0.3 g Marvel milk powder 
Tween-20 (blocking buffer): 10 mL TBS 0.1% Tween-20 
 
• Coomassie blue stain: 1.5 g Coomassie blue 
 25 mL acetic acid 
 250 mL methanol  
 Adjust to 500 mL with dH2O 
 
• Coomassie blue destain: 500 mL methanol 
 50 mL acetic acid 
 Adjusted to 1 L with dH2O 
 
Buffers used for crude subcellular fractionation 
 
• Subcellular fractionation buffer 150 mM Tris-HCI 
 0.05% Tween-20 
 Adjust to pH 7.4 
Buffers used for 2-DE 
 
• 8.5M Urea stock solution: 127.6 g Urea 
 250 mL ddH2O 
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 5 g deionising resin 
 Filter through Whatmann no.1 filter paper 
 
• Equilibration buffer II: 177 mL 8.5 M urea (deionsed) 
 5.0 g SDS 
 50 mL Glycerol 
 8.25 mL Tris-HCl (1.5 M) pH 8.8 
 Adjust to 250 mL with ddH2O 
 
Buffers used for immunofluorescence 
 
• 4% paraformaldehyde: 4% (w/v) paraformaldehyde 
 1 x DPBS 
 
• 10% BSA TBS 0.1% 0.3 g Bovine serum albumin powder 
Tween-20 (blocking buffer): 10 mL TBS 0.1% Tween-20 
 
Buffers for ELISA 
 
• Coating buffer: 15 mM Na2CO3 
 30 Mm NaHCO3 
 0.2% Azide 
 Adjust to pH 9.6 
 
• Wash buffer (TTBS): 50 mM Tris HCl (pH 7.4) 
 150 mM NaCl 
 0.05% Tween-20 
 
• Dilution buffer: 2% BSA in TTBS 
 
• Blocking buffer: 4% BSA in TTBS 
 
• Stop solution: H2SO4 
Buffer for flow cytometry 
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• FACS buffer: 0.5% (w/v) BSA 
 0.02% (W/V) NaN3 
 1 x PBS 
 
• Wash buffer: 1% (w/v) BSA in 1X dPBS 
 
Kits     Supplier 
 
3100 OFFGEL Low Res Kit, pH 3-10    Agilent 
Bradford protein assay kit    Bio-RAD 
Mini format 1-D electrophoresis systems   Bio-RAD 
 
IV Equipment 
 
Laboratory consumables – glassware, plastics and sharps 
 
All pyrex glassware used was washed using teepol, rinsed twice in distilled water before 
autoclaving. 
 
Item        Supplier  
   
0.2 µL filter tips      Starlabs   
20 mL universal tubes     Starlabs  
384 MALDI ground steel target plate    Bruker 
Bijou tubes (7 mL)      Starlabs 
Cell scraper       Helena Biosciences 
Coverslips       Scientific Laboratory Supplies 
Cryovials (1.2 mL)      Helena Biosciences 
Disposable scalpel       Swann-Morton 
Eppendorf tubes (0.5 mL, 1.5 mL)    Sarstedt  
Falcon tubes (15 mL, 50 mL)     Sarstedt 
Filter paper (for gel blotting)     Fisher Scientific 
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Filter tips (10 µL, 200 µL, 1 mL)    Sarstedt 
Flat bottom culture dishes) 24 and 96-well)   Sarstedt 
Flow cytometry (FACS tubes)    Elkay 
Light microscope      Nikon/Olympus 
Measuring cylinders (10 mL, 100 mL, 500 mL, 1 L, 2 L) Sarstedt  
MTP AnchorChip target plates    Bruker 
Nitrocellulose membranes     Gilson Anachem 
Plastic Pasteur pipettes     Sarstedt 
Scalpel       Swann Morton 
Serological pipettes (5 mL, 10 mL, 25 mL)   Sarstedt  
Tissue culture flasks (T25, T75 and T175 cm3)  Sarstedt 
 
Laboratory equipment  
 
Equipment        Supplier 
 
-20ºC Freezer       Lec 
37ºC Incubator; CO2 water jacked    Forma 
4ºC Refrigerator centrifuge     Eppendorf/Sanyo 
4ºC Refrigerator      Lec 
-80ºC Freezer       Revco/Sanyo 
Autoclave       Rodwell 
Benchtop vortex mixer     Scientific industries 
CCD camera        Nikon 
Centrifuge       Sanyo 
Class II safety cabinets     Walker 
Distilled water system     Barnstead 
Electrophoresis running gel tanks    Bio-RAD 
Electrophoresis transfer tanks     Geneflow  
Flow cytometer      Beckman Coulter 
Gallios flow cytometer     Beckman Coulter 
Haemocytometer (counting chamber)   Weber 
Leica TCS SP5 confocal microscope    Leica  
Liquid chromatography (LC)     Bruker Daltonics 
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MALDI-TOF/TOF mass spectrometer   Bruker Daltonics 
Microwave        Scientific Laboratory Supplies 
Multichannel pipette      Starlabs 
Nanodrop ND-1000 micro-spectrophotometer  Nanodrop Technologies 
Nanopure diamond water reservoir    Barnstead 
Nikon eclipse Ts100 light microscope   Nikon 
Olympus BX51 fluorescence microscope   Olympus 
Orbital shaker       Stuart  
pH meter        Bio-RAD 
Plate reader       Tecan 
Power supply for electrophoresis    Bio-RAD 
Protean IEF Cell       Bio-RAD 
Sonicator        VWR 
Spectrophotometer      Tecan Ultra 
UNO-Thermoblock      Biometra 
Wet transfer apparatus     Geneflow National Diagnostics 
 
Software       Company 
 
Biotools       Bruker 
ClinPro Tools       Bruker 
FlexAnalysis       Bruker 
FlexControl       Bruker 
Kaluza        Beckman Coulter 
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APPENDIX II 
 
Proof of principle of the OFFGEL SDS PAGE methodology in DU-145 PCa cell line 
 
 
5 mg of protein from the DU-145 PCa cell line was lysed before fractionation by OFFGEL 
electrophoresis (pH 3-10, low resolution IPG strip). OFFGEL fractions were separated 
using a 10% SDS PAGE gel and probed with a monoclonal mouse anti-alpha enolase 
antibody (1:1000 dilution; L-27, SantaCruz, UK). Strong expression of alpha enolase at 47 
kDa was observed in fractions 8, 9, 10 and 11, while a moderate expression was identified 
in fraction 7, and weak expression in fraction 12. Moderate alpha enolase expression was 
also identified in fraction 7 at 66 kDa, while weak expression was identified in fractions 8, 
9 and 10. 
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APPENDIX III 
 
TMA datasheet purchased from US BIOMAX: Slide #BN243a 
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APPENDIX IV 
 
TMA datasheet purchased from US BIOMAX: Slide #MC246 
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APPENDIX V 
 
TMA datasheet purchased from US BIOMAX: Slide #T195b 
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APPENDIX VI 
 
 
Appendix VI: Extracellular alpha enolase expression in all PCa cell lines 
demonstrated by flow cytometry 
 
Flow cytometric data showing alpha enolase expression in 4 available PCa cell lines (DU-
145, PC-3, LNCaP and OPCT-1). All cells were stained using a monoclonal mouse anti-
human alpha enolase antibody (clone L-27, Santa Cruz, UK) or a goat anti-mouse 
secondary antibody conjugated to FITC. Histogram overlay shows no right shift in alpha 
enolase expression for DU-145, PC-3, LNCaP or OPCT-1 cell lines compared to the 
isotype or secondary controls, indicating that these PCa cell lines are negative for alpha 
enolase membrane expression. 
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